rosiglitazone has been researched along with Diabetes Mellitus, Adult-Onset in 1188 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (1.35) | 18.2507 |
| 2000's | 775 (65.24) | 29.6817 |
| 2010's | 370 (31.14) | 24.3611 |
| 2020's | 27 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC; Cawthorne, MA; Cottam, GP; Duff, PT; Haigh, D; Hindley, RM; Lister, CA; Smith, SA; Thurlby, PL | 1 |
| Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL | 1 |
| Adams, AD; Berger, JP; Doebber, TW; Hu, Z; Jones, AB; MacNaul, KL; Moller, DE; Santini, C; Yuen, W | 1 |
| Berger, JP; Bergman, JP; Boueres, JK; Doebber, TW; Gratale, DF; Han, W; Heck, JV; Koyama, H; Leung, K; MacNaul, KL; Metzger, EJ; Miller, DJ; Moller, DE; Sahoo, SP; Tolman, RL | 1 |
| Berger, JP; Bergman, JP; Desai, RC; Doebber, TW; Gratale, DF; Han, W; Heck, JV; Leung, K; MacNaul, KL; Metzger, EJ; Moller, DE; Sahoo, SP | 1 |
| Burris, TP; Chen, X; Combs, DW; Demarest, KT; Dudash, J; Osborne, MC; Rybczynski, PJ; Yang, M; Zeck, RE | 1 |
| Agrawal, AK; Berger, JP; Boueres, JK; Chao, YS; Desai, RC; Doebber, TW; Franklin, R; Heck, JV; Ippolito, MC; Jones, AB; Kelly, LJ; Koyama, H; MacNaul, KL; Miller, DJ; Moller, DE; Sahoo, SP; Wang, PR; Wright, SD; Wu, MS; Zhou, G | 1 |
| Chung, SS; Hu, W; Ko, BC; Li, Z; Liao, C; Lu, XP; Ning, ZQ; Pan, D; Shan, S; Shi, L; Tong, EH; Wong, VK; Yin, Z; Zhou, J | 1 |
| Henke, BR | 1 |
| Agejas, J; Alt, CA; Ardecky, R; Briere, DA; Brooks, DA; Brozinick, JT; Dolores Martín-Ortega, M; Ferritto, R; Fraser, JD; González, R; Hawkins, E; Lamas, C; López de Uralde, B; Martín, JA; Misener, EA; Montrose-Rafizadeh, C; Parra, F; Prieto, L; Reifel-Miller, A; Rhodes, GA; Rizzo, JR; Robey, RL; Rojo, I; Torrado, A; Warshawsky, AM; Wendel, SR; Zhang, TY | 1 |
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Berger, JP; Doebber, TW; Forrest, MJ; Jones, AB; Liu, K; Macnaul, KL; Moller, DE; Xu, L; Zhou, G | 1 |
| Becker, JW; Berger, JP; Chao, YS; Doebber, TW; Dropinski, JF; Elbrecht, A; Forrest, M; Heck, JV; Jones, AB; MacNaul, KL; McKeever, BM; Moller, DE; Shi, GQ; Wang, P; Xu, S; Zhou, G | 1 |
| Broderick, CL; Canada, E; Etgen, GJ; Gonzalez, I; Lamar, J; Mantlo, N; Montrose-Rafizadeh, C; Oldham, BA; Osborne, JJ; Shi, Q; Winneroski, LL; Xie, C; Xu, Y; York, J; Yumibe, N; Zink, R | 1 |
| Broderick, CL; Canada, EJ; Clutinger, CK; Etgen, GJ; Irwin, LA; Laurila, ME; Mantlo, N; Montrose-Rafizadeh, C; Oldham, BA; Shi, Q; Wang, M; Warshawsky, AM; Winneroski, LL; Xie, C; Xu, Y; York, JS; Yumibe, NP; Zink, RW | 1 |
| Bemis, JE; Boss, O; Carney, DP; Choy, W; Disch, JS; Elliott, PJ; Gagne, DJ; Galonek, H; Iffland, A; Israelian, K; Jin, L; Jirousek, MR; Lambert, PD; Lavu, S; Lynch, AV; Medvedik, O; Milne, JC; Ng, PY; Nunes, JJ; Olefsky, JM; Perni, RB; Schenk, S; Sinclair, DA; Smith, JJ; Vu, CB; Westphal, CH; Xie, R; Yang, H | 1 |
| Lee, IK; Lee, JH; Yun, BS | 1 |
| Ahn, BN; Bae, MH; Chong, W; Han, T; Kim, E; Kim, EJ; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, CS; Shim, HJ; Shin, CY; Shin, YA; Son, MH | 1 |
| Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Washburn, WN | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Audinot-Bouchez, V; Boutin, JA; Caignard, DH; Dacquet, C; Guillard, J; Hennuyer, N; Ktorza, A; Parmenon, C; Staels, B; Viaud-Massuard, MC | 1 |
| Acton, JJ; Akiyama, TE; Berger, JP; Chang, CH; Colwell, L; Debenham, S; Doebber, T; Einstein, M; Liu, K; McCann, ME; Meinke, PT; Moller, DE; Muise, ES; Tan, Y; Thompson, JR; Wong, KK; Wood, HB; Wu, M; Xu, L | 1 |
| Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
| Audinot, V; Ayral, E; Boutin, JA; Caignard, DH; Caijo, F; Dacquet, C; Girard, AL; Grée, R; Ktorza, A; Liutkus, M; Mosset, P; Renard, P | 1 |
| Isogai, S; Iwago, M; Kitamura, Y; Kiyota, K; Kohno, Y; Murakami, K; Okada, K; Seto, S; Shinozaki, T | 1 |
| Akiyama, TE; Berger, JP; Castriota, G; Chang, CH; Chen, Y; Doebber, TW; Einstein, M; Lau, F; Li, Y; Liu, K; Liu, W; McCann, ME; McKeever, B; McNamara, L; Meinke, PT; Mosley, RT; Wang, C; Wood, HB; Wu, M; Zhou, G | 1 |
| Aay, N; Aoyama, R; Arcalas, A; Bentzien, F; Cancilla, B; Chan, V; Du, H; Finn, P; Galan, A; Hanel, A; Harrison, A; Kearney, P; Koltun, ES; Lamb, P; Larson, CJ; Mohan, R; Nachtigall, J; Nuss, J; Ogilvie, K; Plonowski, A; Qian, F; Richards, S; Rosen, J; Tam, D; Wang, T; Won, KA; Yakes, M; Zhang, J; Zhang, W | 1 |
| Araki, K; Arita, T; Fukuzaki, T; Furukawa, A; Hayashi, S; Honda, T; Kuroha, M; Matsui, Y; Mori, M; Nakamura, K; Ohsumi, J; Satoh, S; Suzuki, O; Tanaka, J; Wakabayashi, K; Wakimoto, S | 1 |
| Haq, W; Katti, SB; Raza, S; Srivastava, AK; Srivastava, DS; Srivastava, SP | 1 |
| Campos, JL; da Silva, FM; dos Santos, JC; Figueira, AC; Mafud, AC; Nascimento, AS; Polikarpov, I | 1 |
| Fan, L; Li, Z; Ma, X; Tang, L; Wang, J; Wu, H; Xiao, W; Zhong, G | 1 |
| Ferreira, D; Han, JH; Jang, TS; Kang, C; Kulkarni, R; Myung, CS; Na, M; Oh, J; Zhou, W | 1 |
| Gregersen, S; Hermansen, K; Jeppesen, PB; Mellbye, FB | 1 |
| Angioni, C; Blöcher, R; Boß, M; Brüggerhoff, A; Brüne, B; Diehl, O; Geisslinger, G; Göbel, T; Grundmann, M; Hartmann, M; Heering, J; Kahnt, AS; Kaiser, A; Kostenis, E; Lamers, C; Merk, D; Proschak, E; Schader, T; Schubert-Zsilavecz, M; Steinhilber, D; Weizel, L; Wittmann, SK; Wurglics, M | 1 |
| Balaban, S; Cairns, R; Gao, Q; Grewal, T; Groundwater, PW; Hanh, J; Hibbs, DE; Hoy, AJ; Lai, F; Liao, VW; Lin, HY; Ong, JA; Sjöström, H; Váradi, L; Wood, P | 1 |
| Darwish, KM; Gomaa, MS; Helal, MA; Mostafa, S; Salama, I | 1 |
| Belin, RM; Brooks, DA; Cannady, EA; Cardona, GR; Chen, K; Chen, Q; Chen, Y; Coffey, DS; Deeg, MA; Eessalu, TE; Ficorilli, JV; Haas, JV; Hamdouchi, C; Johnson, JT; Kahl, SD; Lineswala, JP; Ma, X; Maiti, P; Marcelo, MC; Montrose-Rafizadeh, C; Otto, KA; Patel Lewis, A; Piper, JL; Pratt, EJ; Reifel Miller, A; Sweetana, SA; Wilbur, KL; Yumibe, NP; Zink, RW | 1 |
| Bell, A; Clapper, W; Gunnet, J; Haug, P; Hua, H; Huebert, N; Jenkinson, C; Koudriakova, T; Leonard, J; Murray, WV; Suckow, A; Sui, Z; Wall, M; Wang, Y; Winters, MP; Yan, W | 1 |
| Aursnes, M; Hansen, TV; Holen, T; Nebb, HI; Paulsen, SM; Sæther, T; Tungen, JE; Vik, A | 1 |
| Deng, F; Li, Y; Li, Z; Zhang, D; Zhang, L; Zhou, Z | 1 |
| Huang, Z; Li, Y; Liu, J; Ma, W; Miranda, KM; Peng, S; Tian, J; Zhang, Y | 1 |
| Chin, J; Choi, H; Choung, W; Hong, E; Jang, SM; Jang, TH; Jung, HJ; Jung, K; Kim, KH; Kim, SH; Kim, WS; Lee, BR; Lee, G; Lim, JS; Myung, J; Nam, EH; Park, M; Yang, D | 1 |
| Brunetti, L; Cerchia, C; Genovese, M; Gilardi, F; Laghezza, A; Lavecchia, A; Leuci, R; Loiodice, F; Paoli, P; Piemontese, L; Santi, A; Sblano, S; Thomas, A; Tortorella, P | 1 |
| Du, X; Guo, S; Jiang, C; Li, X; Liu, J; Ma, Y; Mei, S; Sun, N; Tang, K; Wang, X; Zhao, D | 1 |
| Dankert, J; Leclerc, K; Leucht, P; Mehta, D; Yim, N | 1 |
| Xiang, G; Yue, L; Zhang, J; Zhu, G | 1 |
| Boschero, AC; da Silva, NS; de Lima, TI; Guimarães, DSPSF; Kurauti, MA; Marmentini, C; Soares, GM; Teófilo, FBS | 1 |
| Gu, H; Xu, J; Zheng, F | 1 |
| Ali, R; Allison, BA; Baker, C; Jonas, DE; LeBlanc, ES; Middleton, JC; Riley, S; Vander Schaaf, EB; Voisin, CE | 1 |
| Byran, G; Krishnamurthy, PT; Ks, N; Li, Y | 1 |
| Ciaccio, M; Giglio, RV; Ilias, I; Janez, A; Pantea Stoian, A; Papanas, N; Patti, AM; Rizvi, AA; Rizzo, M; Sahebkar, A | 1 |
| Chen, Y; Feng, L; Huang, C; Jin, L; Li, Y; Li, YM; Lu, S; Song, K; Xue, H; Zhang, J; Zhao, Y; Zheng, Z | 1 |
| Chen, C; Chen, X; Huang, J; Jose, PA; Ni, Y; Ren, H; Shao, M; Su, Q; Wang, Y; Yan, H; Yang, J; Zhang, F; Zhong, J | 1 |
| Tseng, CH | 5 |
| Liu, JH; Liu, YY; Ruan, HJ; Song, CR; Sui, YL; Zhao, C; Zhu, JZ | 1 |
| Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N | 1 |
| Lebovitz, HE | 2 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Arslanian, S; Chan, CL; Chernausek, SD; El Ghormli, L; Gandica, RG; Gubitosi-Klug, R; Haymond, MH; Levitsky, LL; Siska, M; Willi, SM | 1 |
| Aquilante, CL; Bilker, WB; Bloomgarden, ZT; Brensinger, CM; Dawwas, GK; Deo, R; Dhopeshwarkar, N; Flory, JH; Gagne, JJ; Hennessy, S; Kimmel, SE; Leonard, CE; Soprano, SE | 1 |
| Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM | 1 |
| Chandran, A; Drews, K; El Ghormli, L; Sylvetsky, AC; Talegawkar, SA; Welsh, JA | 1 |
| Mourad, AAE; Mourad, MAE | 1 |
| Gong, L; Jin, H; Li, Y; Quan, Y; Tang, Q; Yang, J; Zou, Z | 1 |
| Cortez, I; Dineley, KT; Hernandez, CM | 1 |
| Calzone, R; Cugno, C; Halade, GV; Kizhakayil, D; Rahman, MM; Rahman, SM | 1 |
| Kelsey, MM; Pyle, L | 1 |
| Chen, MT; Gao, DD; Huang, JS; Li, YX; Wang, HY | 1 |
| Cantini, G; Cosmi, L; Crescioli, C; Filardi, T; Lenzi, A; Luconi, M; Morano, S; Sottili, M | 1 |
| Accili, D; Ishida, E; Kim-Muller, JY | 1 |
| Allen, KM; Coughlan, KA; Mahmood, FN; Ruderman, NB; Saha, AK; Valentine, RJ | 1 |
| Atsumi, GI; Imai, R; Ishibashi, K; Nakatani, E; Ohkura, N; Sekiguchi, M; Sugawara, K; Takahama, R; Takeda, Y | 1 |
| Azhar, S; Bittner, S; Han, L; Kraemer, FB; Shen, WJ | 1 |
| Areosa Sastre, A; González-Colaço Harmand, M; Martínez, G; Vernooij, RW | 1 |
| Andersson, AD; Enerbäck, S; Eriksson, O; Faxius, L; Gomez, MF; Guiducci, L; Hällsten, K; Heglind, M; Iozzo, P; Kauhanen, SP; Koffert, JP; Mikkola, K; Nuutila, P; Parkkola, R; Pham, T; Saraste, A; Silvola, JMU; Virta, J; Virtanen, KA | 1 |
| Kolesnik, E; Resl, M; Sourij, H; von Lewinski, D; Wallner, M | 1 |
| Choe, C; Ciaraldi, TP; Farr, O; Henry, RR; Hwang, WM; Kang, MC; Kim, SS; Kim, YB; Lim, DM; Mantzoros, C; Park, KS; Seo, JA | 1 |
| Bundhun, PK; Huang, F; Janoo, G; Teeluck, AR | 1 |
| Baker, HE; Breyer, MD; Cramer, MS; Harlan, SM; Heinz-Taheny, KM; Heuer, JG; Jaqua, DL; Qi, Z; Shiyanova, TL; Sullivan, JM; Wei, T | 1 |
| Jeong, SY; Kang, S; Kim, DS; Park, S | 1 |
| Cao, L; Ji, L; Li, H; Mao, K; Sha, L; Tang, X; Wei, J; Wei, N; Wu, J; Xie, W; Yang, S; Yang, Z; Zhu, L | 1 |
| Bacha, F; Bjornstad, P; El Ghormli, L; Gidding, SS; Levitsky, LL; Levitt Katz, LE; Lima, JAC; Lynch, J; Tryggestad, JB; Weinstock, RS | 1 |
| Mahboob, T; Tabassum, A | 1 |
| Arsenault, BJ; Bertrand, OF; Brassard, P; Costerousse, O; Després, JP; Laberge, AS; Piché, ME; Poirier, P | 1 |
| Beck-Nielsen, H; Brøsen, K; Christensen, MH; Frost, M; Gram, J; Jørgensen, NR; Stage, TB | 1 |
| Arslanian, SA; Braffett, BH; Caprio, S; Geffner, ME; Kelsey, MM; Levitsky, LL; McKay, SV; Shah, R; Sprague, JE | 1 |
| Liu, X; Xu, W; Zeng, L | 1 |
| Mahboob, T; Tabassum, A; Yasmeen, K; Zaidi, SNF | 1 |
| Cheng, D; Gao, H; Li, W | 1 |
| Chen, SJ; Cheng, YC; Chiang, MC; Huang, RN; Lin, CH; Nicol, CJB; Yen, CH | 1 |
| Babaei, R; Bayindir-Buchhalter, I; Billeter, AT; Gronych, J; Heikenwalder, M; Herzig, S; Hrabe de Angelis, M; Ketscher, L; Krunic, D; Lerch, S; Lichter, P; Müller-Stich, BP; Ruas, JL; Schuster, M; Sijmonsma, T; Spielmann, N; Vegiopoulos, A; Wolff, G | 1 |
| Chang, CH; Chen, PC; Chuang, LM; Dong, YH; Ko, WC; Wang, JL; Wu, LC | 1 |
| Al-Jabri, B; Bajaj, HS; Verma, S | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Bandyopadhyay, S; Chattopadhyay, N; Gayen, JR; Gupta, AP; Gupta, K; Kamthan, M; Kushwaha, R; Mishra, J; Vishwakarma, J | 1 |
| Duan, Y; Fu, X; Gao, H; Liu, Y; Xie, C; Xie, H; Yuan, H; Zhou, M | 1 |
| Cole, AL; Dusetzina, SB; Hickson, RP | 1 |
| Dierickx, P; Guan, D; Hu, C; Hu, W; Jia, W; Jiang, C; Lazar, MA; Loos, RJF; Moscati, A; Nadkarni, GN; Soccio, RE; Steger, DJ; Zhang, R | 1 |
| Alcorn, JF; Forno, E; Gopal, R; Grousd, JA; Marinelli, MA; McHugh, KJ; Mendy, A; Patel, S; Rich, HE; Richwalls, LJ; Seger, PJ | 1 |
| Craig, A; Issberner, J; Parvez, F | 1 |
| Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH | 1 |
| Beck-Nielsen, H; Brøsen, K; Christensen, MM; Feddersen, S; Stage, TB | 1 |
| Bilezikian, JP; Cobitz, AR; Eastell, R; Fitzpatrick, LA; Josse, RG; Kravitz, BG; Lewiecki, EM; Miller, CG; Nino, AJ; Northcutt, AR; Paul, G; Wooddell, M | 1 |
| Nemanich, S; Rani, S; Shoghi, K | 1 |
| Rimbach, G; Schrader, E; Wein, S; Wolffram, S | 1 |
| Bahn, G; Koska, J; Reaven, PD; Saremi, A; Yamashita, S | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Gada, E; Gore, MO; Khera, A; McGuire, DK; Owens, AW; Rohatgi, A; See, R | 1 |
| Cheung, RY; Goodwin, SH | 1 |
| Cetinkalp, S; Ertek, S | 1 |
| Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
| Bailbé, D; Epstein, O; Gorbunov, E; Philippe, E; Portha, B; Tarasov, S | 1 |
| Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW | 1 |
| Boyko, EJ; Floyd, JS; Forsberg, CW; Moore, K; Riley, K; Smith, NL; Wheeler, S | 1 |
| Atamer, A; Atamer, Y; Can, AS; Hekimoğlu, A; Ilhan, N; Koçyiğit, Y; Yenice, N | 1 |
| Gerstein, HC | 1 |
| Bach, RG; Brooks, MM; Donner, TW; Frye, RL; Garber, A; Genuth, S; Kelsey, SF; Kennedy, L; Lombardero, M; Monrad, ES; Pop-Busui, R | 2 |
| Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D | 1 |
| Mitka, M | 2 |
| Bigelow, R; Burns, S; Dickerson, S; Hafley, G; Home, PD; Komajda, M; Lopes, RD; Mahaffey, KW; McMurray, J; Newby, LK; Tourt-Uhlig, S; White, J | 1 |
| Chen, L; Cheng, Q; Evans-Molina, C; Lam, KS; Leung, PS; So, WY; Xu, A | 1 |
| Chow, WS; Lam, KS; Shiu, SW; Tan, KC; Wong, Y; Xiao, SM | 1 |
| Amisten, S; Lundquist, I; Meidute Abaraviciene, S; Muhammed, SJ; Salehi, A | 1 |
| Bravard, A; Disse, E; Laville, M; Rieusset, J; Tchernof, A; Veilleux, A; Vidal, H | 1 |
| Choi, JM; Jin, SM; Kim, JH; Kim, KW; Lee, S; Oh, BJ; Park, CY; Park, SW; Yang, SJ | 1 |
| Al-Daghri, NM; Al-Othman, A; Al-Saleh, Y; Alkharfy, KM; Alokail, MS; Chrousos, GP; Kumar, S; Moharram, O; Sabico, SB | 1 |
| Al Shaar, L; Azar, S; Bashshur, ZF; El-Mollayess, GM; Salti, HI | 1 |
| Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G | 1 |
| Hiatt, WR; Kaul, S; Smith, RJ | 1 |
| Chen, PC; Chen, RC; Hsu, CY; Lu, CJ; Muo, CH; Sun, Y | 1 |
| Chang, SS; Hu, HY | 1 |
| Ezhumalai, M; Pugalendi, KV; Radhiga, T | 1 |
| Argraves, WS; Cangemi, C; Christensen, MM; Gram, J; Grodum, E; Henriksen, JE; Rasmussen, LM; Skov, V; Sørensen, D | 1 |
| Anthony, J; Bhumra, SK; Deka, N; Kelkar, A; Marita, AR; Mutt, S; Mutt, SJ; Ranjith, V; Sharma, S; Sivaramakrishnan, H; Wilankar, C | 1 |
| Danhof, M; DeJongh, J; Scott, G; Stringer, F | 1 |
| Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M | 1 |
| McCarthy, M | 1 |
| Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A | 1 |
| DiNicolantonio, JJ; Meier, P | 1 |
| Nissen, SE | 4 |
| Patel, SS; Udayabanu, M | 1 |
| Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR | 1 |
| Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A | 1 |
| Fukui, M; Hinoi, E; Ito, Y; Kitao, T; Kubo, M; Shirahase, H; Yoneda, Y | 1 |
| Balakrishnan, P; Bass, E; Bennett, WL; Bolen, S; Clark, JM; Gribble, MO; Kao, WH; Maruthur, NM; Sahu, A; Wilson, LM | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
| Narasimhan, S; Weinstock, RS | 1 |
| La Caze, A; Niyomnaitham, S; Page, A; Smith, AJ; Whitfield, K | 1 |
| Moreno, E; Negrín, MA; Vázquez-Polo, FJ | 1 |
| Emmett, N; Leander, M; Li, L; Wang, G; Zhang, Y; Zhao, X | 1 |
| Chevalier, S; Farsijani, S | 1 |
| Alméras, N; Anand, SS; Dagenais, GR; Després, JP; Gerstein, HC; Hunt, DL; Jung, H; Punthakee, Z; Sharma, AM; Yusuf, S | 1 |
| Agarwal, S; Bilezikian, JP; Fitzpatrick, LA; Manavalan, JS; McMahon, DJ; Nino, A; Rubin, MR | 1 |
| Češka, R; Doležalová, R; Krupičková, Z; Marinov, I; Štulc, T; Svobodová, H | 1 |
| Bouillet, B; Brindisi, MC; Duvillard, L; Monier, S; Perségol, L; Petit, JM; Vergès, B | 1 |
| Anusree, SS; Das, AA; Nisha, VM; Priyanka, A; Raghu, KG | 1 |
| Ahad, A; Ahsan, H; Mujeeb, M; Siddiqui, WA | 1 |
| Breunig, IM; McPherson, ML; Shaya, FT; Snitker, S | 1 |
| Meierhofer, D; Sauer, S; Weidner, C | 1 |
| Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z | 1 |
| Abdel-Rahman, E; Ahuja, M; Amin, AT; Amin, RH; Bagasrawala, I; Dhanasekaran, M; Kariharan, T; Nanayakkara, G; Parameshwaran, K; Suppiramaniam, V | 1 |
| Curtis, PS; Home, PD; Jones, NP | 1 |
| Dangi-Garimella, S | 1 |
| Adams, SH; Akiyama, T; Carstens, E; Dunn, TN; Kim, JB; Knotts, TA; Lee, HW; Sears, DD; Smith, SR | 1 |
| Ciaraldi, TP; Samad, F; Wang, J | 1 |
| Abraira, C; Bahn, G; Duckworth, W; Emanuele, N; Florez, H; Hayward, R; Marks, J; Moritz, T; Reaven, PD; Reda, D; Warren, S | 1 |
| Dong, W; Ji, Z; Ma, L; Shao, Z; Sheng, S; Wang, R; Zhang, J; Zhang, X; Zhao, Z | 1 |
| Hsu, JC; Lu, CY; Ross-Degnan, D; Wagner, AK; Zhang, F | 1 |
| Abadie, KV; Bader, DA; Bajaj, M; Chan, L; Hamilton, MP; Hartig, SM; Long, W; Mancini, MA; McGuire, SE; Moore, DD; Motamed, M; Mueller, M; Trauner, M; Wagner, M; York, B | 1 |
| Ambrosius, WT; Banerji, MA; Bauer, DC; Bonds, DE; Chen, H; Cohen, RM; Hamilton, BP; Isakova, T; Josse, RG; Margolis, KL; Schnall, AM; Schwartz, AV; Sellmeyer, DE; Shibli-Rahhal, A; Simmons, DL; Sood, A; Vittinghoff, E; Williamson, JD | 1 |
| Han, JS; Park, MH | 1 |
| Ho, HY; Jian, JY; Lin, CH; Shih, CC; Wu, JB | 1 |
| Hasegawa-Moriyama, M; Inada, E; Kanmura, Y; Kurimoto, T; Saito, T; Yamada, T | 1 |
| Li, D; Liu, K; Wang, T; Xu, R; Zhao, D; Zhu, Z | 1 |
| Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Gore, MO; Grinsfelder, DB; Khera, A; McGuire, DK; Neeland, IJ; Pandey, A; Salahuddin, UI; See, R | 1 |
| Shuster, JJ; Walker, MA | 1 |
| Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C | 1 |
| Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM | 1 |
| Bao, Y; Chen, M; Hu, C; Jia, W; Jiang, F; Peng, D; Wang, J; Wang, S; Wang, T; Yan, J; Zhang, R | 1 |
| Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH | 1 |
| Bilezikian, JP; Bogado, CC; Cobitz, AR; Fitzpatrick, LA; Lewiecki, EM; Miller, CG; Nino, AJ; Northcutt, AR; Paul, G; Wooddell, MJ; Yu, HJ | 1 |
| Pugalendi, KV; Radhiga, T; Sundaresan, A | 1 |
| Figueiras, A; Herdeiro, MT; Roque, F; Silva, T; Soares, S | 1 |
| Carr, F; Dawed, AY; Donnelly, L; Leese, G; Palmer, CN; Pearson, ER; Tavendale, R; Zhou, K | 1 |
| Chen, YT; Liu, YM; Ou, HT; Wu, JS | 1 |
| Gandica, R; Zeitler, P | 1 |
| Alméras, N; Bertrand, OF; Brassard, P; Costerousse, O; Després, JP; Grenier, A; Poirier, EP | 1 |
| Balaz, M; Modica, S; Neubauer, H; Profant, M; Simon, E; Stefanicka, P; Straub, LG; Sun, W; Ukropcova, B; Ukropec, J; Varga, L; Wolfrum, C | 1 |
| He, K; Li, W; Qian, XH; Qu, H; Wang, H; Zhang, S | 1 |
| Sharma, SK; Verma, SH | 1 |
| Aslanidis, C; Buechler, C; Eisinger, K; Haberl, EM; Krautbauer, S; Neumann, M; Pohl, R; Rein-Fischboeck, L; Schacherer, D; Weiss, TS; Zimny, S | 1 |
| Borch-Johnsen, K; Fischer, KE; Hostenkamp, G | 1 |
| Holzhauer, B | 1 |
| Brunt, JJ; Cai, EP; Krishnamurthy, M; Luk, CT; Schroer, SA; Shi, SY; Sivasubramaniyam, T; Winer, DA; Woo, M | 1 |
| Halkin, H; Katzir, I; Loebstein, R; Lomnicky, Y; Vasterman-Landes, J | 1 |
| Colette, C; Monnier, L; Owens, DR | 1 |
| Channer, KS; Jones, TH; Kapoor, D | 1 |
| Aiello, LP; Child, A; Folkman, J; Shen, LQ; Weber, GM | 1 |
| Hamilton, JK; Hanley, AJ; Retnakaran, R; Shen, S; Vuksan, V; Zinman, B | 1 |
| Kostenbauder, HB | 1 |
| Farah, R; Lapin, O; Shurtz-Swirski, R | 1 |
| Huang, W; Huang, XZ; Yu, RM; Zhu, HL | 1 |
| Choi, MS; Jeon, SM; Jeong, YJ; Kim, DJ; Kim, HJ; Kwon, JH; Lee, MK; Moon, KD; Park, YB | 1 |
| Cobitz, A; Heise, M; Koch, G; Louridas, B; McMorn, S; Semigran, M; Sowell, M; Zambanini, A | 1 |
| Ajjan, RA; Grant, PJ | 1 |
| Beysen, C; Boyle, PJ; Decaris, M; Fong, A; Hellerstein, MK; Murphy, EJ; Nagaraja, H; Riiff, T | 1 |
| Beare, N; Broadbent, DM; Kumar, N; Liazos, E | 1 |
| Austin, PC; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Hirschberg, DL; Huang, M; Li, Z; Nestorova, G; Quertermous, T; Tsao, P; Wagner, R; Wilson, KD; Wu, JC; Yock, PG; Yue, P | 1 |
| Lehmann, DF; Lohray, BB | 1 |
| Califf, RM; Kramer, JM | 1 |
| Ahn, CW; Cha, BS; Choi, SE; Han, SJ; Hur, KY; Kang, ES; Kang, Y; Kim, HJ; Kim, SH; Lee, HC; Yun, CO | 1 |
| Hu, M; Luo, Y; Tian, H; Wu, W; Zhang, H; Zhou, X | 1 |
| Diamond, GA; Kaul, S | 4 |
| Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| Furberg, CD; Singh, S | 1 |
| Devchand, PR; Hamdy, O; Horton, ES; Nehra, V; Orasanu, G; Plutzky, J; Ziouzenkova, O | 1 |
| Kintscher, U | 1 |
| Kumar, H; Mishra, M; Tripathi, K; Vijay, SK | 1 |
| Loke, YK; Singh, S | 1 |
| Mannucci, E; Marchionni, N; Monami, M | 2 |
| Felson, S; Fisher, E; Schwartzbard, A; Zinn, A | 1 |
| Carter, L; Odom, J; Williamson, B | 1 |
| Bergman, J; Borra, R; Hällsten, K; Iozzo, P; Komu, M; Lautamäki, R; Nuutila, P; Parkkola, R; Sijens, PE | 1 |
| Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL | 2 |
| Luan, FL; Nguyen, K | 1 |
| Braga, MB; Gupta, M; Verma, S | 1 |
| Cai, T; Cremieux, PY; Pfeffer, MA; Piankov, N; Tian, L; Wei, LJ | 1 |
| Forst, T; Löbig, M; Marx, N; Pfützner, A; Seidel, D; Walcher, D | 1 |
| Diamant, M; Scheffer, PG; Schumm-Draeger, PM; Siegmund, T; von Bibra, H | 1 |
| Tanne, JH | 2 |
| Waksman, JC | 1 |
| Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Lipscombe, LL | 1 |
| Furberg, CD; Loke, YK; Singh, S | 2 |
| Cho, N; Momose, Y | 1 |
| Abraira, C; Davis, SN; Duckworth, W; Emanuele, N; Goldman, S; Hayward, R; Henderson, WG; Huang, GD; Marks, J; McCarren, M; Moritz, T; Reaven, PD; Reda, D; Vitek, ME; Warren, SR; Zieve, FJ | 1 |
| Capek, P; Ceska, R; Doležalová, R; Kasalová, Z; Marinov, I; Stulc, T; Svobodová, H | 1 |
| Balabolkin, MI; Klebanova, EM; Kreminskaia, VM; Kuzin, AG; Mamaeva, GG; Tel'nova, ME | 1 |
| Behar, A; Charnaux, N; Cohen-Boulakia, F; Cosson, E; Dabiré, H; Léger, G; Lestrade, R; Tarhzaoui, K; Valensi, P | 1 |
| Abdullah, SM; Ayers, CR; McGavock, JM; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS | 1 |
| Cohen, P | 1 |
| Contreras, R; Fong, DS | 1 |
| Bruskina, O; Byrne, RM; Cagliero, E; Crimins, J; Daher, M; Finn, AV; Gold, HK; Hendricks, M; John, MC; Kastrati, A; Nadelson, J; Oh, JS; Palacios, I; Schömig, A | 1 |
| Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS | 1 |
| Bakris, GL; Kalaitzidis, RG; Sarafidis, PA | 1 |
| Albaladejo Otón, MD; Calle Luna, JG; Granero Fernández, E; Hernández Martínez, AM; Martínez Hernández, P; Parra Pallarés, S | 1 |
| Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA | 1 |
| Abbasi, F; Lima, NK; Reaven, GM | 1 |
| Krentz, A | 1 |
| Ametov, AS; Kandalintseva, OA | 1 |
| Divine, G; Habib, ZA; Havstad, SL; Krajenta, R; Lanfear, DE; Pladevall, M; Tang, J; Tzogias, L; Wells, K; Williams, LK | 1 |
| Gallen, IW; Lumb, AN | 1 |
| Alfonso-Cristancho, R; Blonde, L; Conner, C; Hammer, M; Sullivan, SD | 1 |
| Bloomgarden, ZT | 1 |
| Blackburn, DF; Eurich, DT; Johnson, JA; Lamb, DA; Leung, AA; Majumdar, SR; McAlister, FA | 1 |
| Ambery, P; Cobitz, AR | 1 |
| Ambery, P; Pandya, B | 1 |
| Bebakar, WM; Brändle, M; Colagiuri, S; Kamaruddin, NA; Le Thi, TD; Marre, M; Shaw, J; Strand, J; Zdravkovic, M | 1 |
| Di Bari, M; Gensini, GF; Gori, F; Lamanna, C; Mannucci, E; Marchionni, N; Monami, M | 1 |
| Cappetta, D; Capuano, A; Carnuccio, R; Domenici, L; Donniacuo, M; Filippelli, A; Pieri, L; Rinaldi, B; Romagnoli, P; Rossi, F | 1 |
| Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S | 1 |
| Bashir, M; Iqbal, M; Khan, R; Malik, SA | 1 |
| Debiais, F | 1 |
| Nesto, RW; Zarich, SW | 1 |
| Fanning, EL; Menditto, LA; Weissman, PN | 1 |
| Anastasilakis, AD; Goulis, DG; Toulis, KA | 1 |
| Conway, JR; MacNair, D; Marble, RJ; Patasi, B | 1 |
| Scheen, AJ | 5 |
| Maldonado-Lutomirsky, M; Niggli, M; Rosenstock, J | 1 |
| Bajirovic, V; Byun, J; Kellogg, A; Oral, E; Pennathur, S; Pop-Busui, R; Raffel, D; Stevens, MJ; Vivekanandan-Giri, A | 1 |
| Andres, J; Biedasek, K; Bobbert, T; Clemenz, M; Kintscher, U; Mai, K; Meinus, S; Möhlig, M; Pfeiffer, AF; Reinecke, F; Sabath, M; Spranger, J; Spuler, S; Weicht, J; Weickert, MO | 1 |
| Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
| Chawla, S; Chogtu, B; Gupta, U; Singh, NP | 1 |
| Luan, FL | 1 |
| George, J; Hannah, S; Lang, CC | 1 |
| Barnett, AH | 1 |
| Smahelová, A | 1 |
| Kang, JH; Park, HO; Yun, SI | 1 |
| Chae, YN; Choi, SH; Kim, HS; Kim, JG; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, SK; Shin, CY; Shin, YA; Son, MH | 1 |
| Sinclair, A; Viljoen, A | 1 |
| Lewin, A; Lyness, W; Raskin, P; Reinhardt, R | 1 |
| Simon, D | 1 |
| Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F | 1 |
| Retnakaran, R; Zinman, B | 1 |
| Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 2 |
| Kamal, MA; Qu, X; Seale, JP; Tan, Y | 1 |
| Hanefeld, M | 3 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Carpinteri, R; Doga, M; Giustina, A; Mancini, T; Mazziotti, G; Simetovic, N; Vescovi, PP | 1 |
| Li, K; Li, L; Liu, H; Yang, G; Yang, M; Zong, H | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kim, DH; Kim, SK; Lee, HC; Lee, JH; Park, SE | 1 |
| Armor, B; Burt, R; Townsend, S | 1 |
| Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM | 1 |
| Gore, MO; McGuire, DK | 1 |
| Abdel-Gaber, SA; Ashour, OM; Fouad, AA; Morsy, MA | 1 |
| Hobbs, FD; Taylor, C | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW | 1 |
| Hesselink, MK; Jorgensen, JA; Lenaers, E; Mensink, M; Minnaard, R; Schaart, G; Schrauwen, P | 1 |
| Alexander, CM; Chapell, R; Gould, AL | 1 |
| Choe, C; Christiansen, L; Ciaraldi, TP; Henry, RR; Kung, J; Mudaliar, S; Phillips, SA | 1 |
| Barbehenn, E; Floyd, JS; Lurie, P; Wolfe, SM | 1 |
| Chan, CF; Crowe, LA; Johnston, DG; Keenan, NG; Pennell, DJ; Varghese, A; Yee, MS | 1 |
| Brackenridge, AL; Hovorka, R; Jackson, N; Jefferson, W; Russell-Jones, D; Shojaee-Moradie, F; Stolinski, M; Umpleby, AM | 1 |
| Cobitz, AR; Kolatkar, NS; Koro, CE; Osei, SY; Stender, M | 1 |
| Brath, H; Ludvik, B; Toplak, H; Wascher, T | 1 |
| Huang, Q; Liu, HL; Liu, ZQ; Sun, H; Wu, J; Yang, M; Yin, JY; Zhou, HH | 1 |
| Bassett, K; Carleton, B; Carney, G; Dormuth, CR; Wright, JM | 1 |
| Akarca, U; Akyildiz, M; Batur, Y; Cetinkalp, S; Omer, Z; Yilmaz, C; Yilmaz, F | 1 |
| Baran, I; Budak, F; Duran, C; Ersoy, C; Erturk, E; Fazlioglu, M; Gul, OO; Imamoglu, S; Kaderli, A; Kiyici, S; Sigirli, D; Tuncel, E | 1 |
| Austin, PC; Gomes, T; Hux, JE; Juurlink, DN; Lipscombe, LL; Mamdani, MM | 1 |
| de Vries, CS; Russell-Jones, DL | 1 |
| Fisher, M | 1 |
| Ersoy, C; Guclu, M; Gul, CB; Imamoglu, S; Kiyici, S; Oral, AY; Oz Gul, O; Tuncel, E; Ulukaya, E; Yilmaz, Y | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| Ihm, SH; Kang, JG; Kim, SW; Lee, WY; Oh, KW; Park, CY; Park, H; Park, SW; Rhee, EJ; Won, JC; Yoo, HJ | 1 |
| Ahn, YB; Baek, KH; Kang, MI; Kim, MK; Ko, SH; Lee, KW; Song, KH; Yoon, KH | 1 |
| Braga, MF; Leiter, LA | 1 |
| McGill, JB | 1 |
| Alméras, N; Angel, J; Batalla, N; Bertrand, OF; Costerousse, O; De Larochellière, R; Després, JP; Dzavik, V; Natarajan, M; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L; Title, L | 1 |
| Derosa, G; Maffioli, P; Tinelli, C | 1 |
| Cheng, L; Han, X; Shi, Y | 1 |
| Yki-Järvinen, H | 1 |
| Douglas, IJ; Evans, SJ; Pocock, S; Smeeth, L | 1 |
| Jiang, JD; Kong, WJ; Pan, HN; Song, DQ; Wang, SK; Wang, YM; Wang, ZZ; Wei, J; Wu, JD; Xue, R; Zhang, H; Zhao, W; Zhou, ZX | 1 |
| Finck, BN; Gropler, RJ; Herrero, P; Schechtman, KB; Sharp, T; Shoghi, KI; Welch, MJ | 1 |
| Dixit, A; Pandey, P | 1 |
| Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Yu, D; Zinman, B | 1 |
| Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Sailer, N; Tsanikidis, H; Vitta, I; Vrabas, I | 1 |
| Blüher, M; Catalán, V; Fernández-Real, JM; Frühbeck, G; Gómez-Ambrosi, J; Martínez-Barricarte, R; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodríguez de Cordoba, S; Sabater, M | 1 |
| Beiderbeck, AB; Sakaguchi, M | 1 |
| Allen, E; Chen, R; Hollander, P; Li, J | 1 |
| Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B | 1 |
| Chang, MK; Clément, MV; Hewitt, RE; Kumar, AP; Lim, KS; Pervaiz, S; Quake, AL; Salto-Tellez, M; Singh, R; Zhou, T | 1 |
| Baek, SH; Chang, K; Ihm, SH; Kim, HY; Kim, JH; Seung, KB; Youn, HJ | 1 |
| Depaoli, AM; Higgins, LS | 1 |
| Alevizos, M; Angelopoulou, N; Athanasiadou, Z; Iliadis, F; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Sailer, N; Vitta, I; Vrabas, IS | 1 |
| Jazet, IM; Meinders, AE | 2 |
| Eliasson, B; Gustafson, B; Smith, U | 1 |
| Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR | 1 |
| Gerstein, HC; Hanley, AJ; Sheridan, P; Yusuf, S; Zinman, B | 1 |
| Bob, F; Bozdog, G; Dragos Jianu, C; Dumitrascu, V; Gadalean, F; Giju, S; Gluhovschi, C; Gluhovschi, G; Ianculescu, C; Marian, R; Petrica, L; Petrica, M; Ursoniu, S; Velciov, S; Vlad, A | 1 |
| Agrawal, A | 1 |
| Chu, SH; Chun, SH; Li, AH | 1 |
| DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C | 1 |
| Guagnini, AP; Hautenauven, F; Lekeu Hinostroza, JP; Nyssen, V | 1 |
| Ahn, CW; Cha, BS; Cho, M; Kim, KR; Lee, EJ; Lee, HC; Lim, SK; Nam, JS; Nam, JY; Park, JS; Yoo, JS | 1 |
| Clevidence, DE; Juckett, MB; Lucarelli, MJ | 1 |
| Berberoglu, Z; Demirag, NG; Yazici, AC | 1 |
| Bolger, AF; Eckel, RH; Giugliano, RP; Herrington, D; Kaul, S | 2 |
| Krumholz, HM | 1 |
| Chandrashekhar, Y; Finn, AV; Narula, J | 1 |
| Cannon, CP; Fitzgerald, PJ; García-García, HM; Gerstein, HC; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Nesto, RW; Ratner, RE; Serruys, PW; van Es, GA | 1 |
| Chang, YH; Hong, SI; Hong, YJ; Im, M; Kim, M; Lee, DY; Lee, JK; Lee, YY | 1 |
| Caveda, E; Rodriguez, A; Simó, R | 1 |
| DeAngelis, CD; Fontanarosa, PB | 1 |
| Abdullah, SM; Ayers, CR; Fordan, S; Ghayee, HK; Gruntmanis, U; McGuire, DK; See, R | 1 |
| Abbasi, F; Lamendola, C; Reaven, GM | 1 |
| Arondekar, B; Darkow, TE; Harley, C; Thayer, S | 1 |
| Moynihan, R | 1 |
| Iheanacho, I | 1 |
| Açar, G; Akçakoyun, M; Esen, AM; Esen, O; Kahveci, G; Karaahmet, T; Kargin, R; Kirma, C; Pala, S; Tigen, K | 1 |
| Abbatecola, AM; Cacciapuoti, F; Canonico, R; Cioffi, M; DiCioccio, L; Lattanzio, F; Mansi, L; Molinari, AM; Paolisso, G; Rambaldi, P | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Jelic-Ivanovic, Z; Koulouris, S; Manolis, AS; Mikhailidis, DP; Pastromas, S; Rini, GB; Rizzo, M; Sakellariou, D; Spasojevic-Kalimanovska, V; Vekic, J; Zeljkovic, A | 1 |
| Guo, X; Karathanasis, SK; Kassab, GS; Lu, X; Onyia, JE; Peterson, RG; Zimmerman, KM | 1 |
| Dushinat, M; Friedman, N; Halkin, H; Katzir, I; Kokia, E; Kurnik, D; Loebstein, R; Lomnicky, Y; Silverman, B; Vesterman-Landes, J | 1 |
| Dai, XP; Huang, Q; Liu, ZQ; Yin, JY; Zhang, KH; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Rennings, AJ; Smits, P; Stewart, MW; Tack, CJ | 1 |
| Slaoui, M | 1 |
| Eggertson, L | 2 |
| Agra, R; Albuquerque, JL; Arahata, C; Arruda, MJ; Canadas, V; Gusmão, A; Montenegro, L; Pontes, L; Silva, LM; Vilar, CF; Vilar, L | 1 |
| Wadman, M | 1 |
| Beck-Nielsen, H; Home, PD; Jones, NP; Kahn, SE; Noronha, D; Viberti, G | 1 |
| Farkouh, ME; Fuster, V | 2 |
| Chaudhuri, A; Dandona, P; Ghanim, H | 1 |
| Bilik, D; Brown, MB; Crosson, JC; Herman, WH; Hsiao, VC; Karter, AJ; Lasser, NL; Mangione, CM; Marrero, DG; McEwen, LN; Selby, JV; Tseng, CW | 1 |
| Juurlink, DN | 1 |
| Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C | 1 |
| Aubert, RE; Chen, W; Haffner, SM; Herrera, V; Pendergrass, M | 1 |
| Alméras, N; Angel, J; Batalla, N; Bertrand, OF; Costerousse, O; De Larochellière, R; Després, JP; Dzavik, V; Natarajan, M; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L; Title, LM | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Drazner, MH; Khera, A; McGavock, J; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS | 1 |
| Gerstein, HC; Hanley, AJ; Harris, SB; Neuman, J; Qi, Y; Raboud, J; Retnakaran, RR; Zinman, B | 1 |
| Buchanan, TA; Xiang, AH | 1 |
| Chan, LY; Cheng, AS; Lai, KN; Lan, HY; Leung, JC; Tang, SC | 1 |
| Anand, S; Bailey, SD; Diaz, R; Do, R; Engert, JC; Gerstein, HC; Keavney, B; Mohan, V; Montpetit, A; Xie, C; Yusuf, S | 1 |
| Asao, K; Bilik, D; Brown, MB; Crosson, JC; Duru, OK; Ferrara, A; Herman, WH; Hsiao, VC; Karter, AJ; Kim, C; Lee, PG; Marrero, DG; McEwen, LN; Pomeroy, NE; Selby, JV; Subramanian, U | 1 |
| Chang, CH; Chang, SL; Cheng, JT; Lee, YC; Lin, JG; Pai, HC; Tzeng, CY | 1 |
| Roehr, B | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Almdal, T; Boushel, R; Dela, F; Hansen, CN; Haugaard, SB; Madsbad, S; Ploug, T; Prats, C; Rabøl, R | 1 |
| Ledford, H | 1 |
| Choi, JE; Choi, JM; Kim, DH; Kim, SW; Lee, WJ; Park, JS; Yoon, SY | 1 |
| Rosen, CJ | 2 |
| Li, Y; Tong, N; Zhang, X | 1 |
| Lecka-Czernik, B | 1 |
| Krumholz, H; Lehman, R; Yudkin, JS | 1 |
| Freemantle, N | 1 |
| Cohen, D | 1 |
| Swanson, A; Watrin, K; Wilder, L | 1 |
| Chen, L; Wu, Z; Zhao, XM | 1 |
| Auwerx, J; Bernad, J; Burcelin, R; Coste, A; Galès, A; Lefèvre, L; Olagnier, D; Perez, L; Pipy, B; Valentin, A | 1 |
| Bloomgarden, Z; Handelsman, Y | 1 |
| Fu, X; Han, Y; He, X; Heng, CK; Huang, C; Li, N; Shi, X; Wu, Y; Zhao, Y | 1 |
| Beck-Nielsen, H; Christiansen, C; Gjessing, H; Gram, J; Grodum, E; Hangaard, J; Hansen, HM; Hansen, TB; Henriksen, JE; Juhl, H; Vestergaard, V; Yderstræde, K | 1 |
| Johansen, K | 3 |
| Hamburg, M; Sharfstein, JM; Woodcock, J | 1 |
| Bravard, A; Disse, E; Laville, M; Lefai, E; Meugnier, E; Peretti, N; Pesenti, S; Rabasa-Lhoret, R; Rieusset, J; Vidal, H; Vouillarmet, J | 1 |
| Anand, S; Boyko, EJ; Gerstein, HC; Mohan, V; Shaw, JE; Sheridan, P; Yusuf, S | 1 |
| Bowker, SL; Johnson, JA | 1 |
| Bruin, JE; Gerstein, HC; Holloway, AC; Hyslop, JR; Petrik, JJ; Raha, S; Tarnopolsky, MA | 1 |
| Riddle, MC | 1 |
| Corrada, E; Ferrante, G; Presbitero, P; Zavalloni, D | 1 |
| Malaga, G; Miranda, JJ | 1 |
| Casazza, G; Ceriani, E; Costantino, G; Podda, GM | 1 |
| Chilton, RJ; Schernthaner, G | 1 |
| Gautier, JF; Lesven, S; Maréchaud, R | 1 |
| Al-Jebawi, AF | 1 |
| Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N; Tsanikidis, H; Vitta, I | 1 |
| Gerstein, HC; Hettinga, BP; Holloway, AC | 1 |
| Bashir, M; Idrees, M; Khan, RU; Malik, SA; Rahman, IU | 1 |
| Dhanjil, S; Godsland, IF; Johnston, DG; Pavitt, DV; Richmond, W; Yee, MS | 1 |
| Alexander, GC; Jackevicius, CA; Krumholz, HM; Montori, VM; Shah, ND; Tu, K | 1 |
| Almeida, RL; Almeida, TS; Fedrizzi, D; Fedrizzi, P | 1 |
| Chen, Y; Chu, H; Huang, Y; Nie, L; Sun, W | 1 |
| Kahn, BB; McGraw, TE | 1 |
| Chang, B; Chen, L; Dong, L; Li, M; Li, XY; Lian, FM; Liu, WK; Qin, PJ; Tong, XL; Wang, J; Yu, B; Zhang, JH; Zhen, Z | 1 |
| Cross, JT; Gardner, JS; Garrison, LP; Veenstra, DL | 1 |
| Bao, Y; Hu, C; Jia, W; Jiang, F; Lu, J; Qin, W; Tang, S; Wang, C; Xiang, K; Yu, W; Zhang, R | 1 |
| Ahmed, AF; El-Moselhy, MA; El-Sisi, SF; Sharkawi, SS; Taye, A | 1 |
| Louisa, M; Setiabudy, R; Takeuchi, M | 1 |
| Baek, MC; Hwang, HH; Kim, JG; Lee, JE; Lee, W; Moon, PG; Ryu, SH | 1 |
| Conner, C; Hammer, M; Lee, WC | 1 |
| Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW | 1 |
| Tolman, KG | 1 |
| Ledford, CJ | 1 |
| Kwok, CS; Loke, YK; Singh, S | 1 |
| Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B | 2 |
| Erem, C; Fidan, E; Karahan, C; Kocak, M; Onder Ersoz, H; Yilmaz, H; Yilmaz, M | 1 |
| Hurren, KM; Jaber, LA; Taylor, TN | 1 |
| Rabøl, R | 1 |
| Curtis, B; Hall, GC; McMahon, AD; Smith, HT | 1 |
| Baillot-Rudoni, S; Bouillet, B; Brindisi, MC; Duvillard, L; Petit, JM; Poussier, A; Radu, L; Vergès, B | 1 |
| Koch, A | 1 |
| Bandyopadhyay, G; Fan, W; Gayen, JR; Li, P; Lu, M; Mahata, SK; Nalbandian, S; Olefsky, JM; Sarruf, DA; Schwartz, MW; Sharma, S; Talukdar, S; Webster, NJ | 1 |
| Abdullah, WZ; Ibrahim, S; Mustaffa, N; Yusof, Z | 1 |
| Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY | 1 |
| Egidi, G; Popert, U | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Abdullah, SM; Armstead, SI; Ayers, CR; de Lemos, JA; Gore, MO; Khera, A; McGavock, J; McGuire, DK; Narang, N; See, R; Snell, PG; Stream, A | 1 |
| Allen, E; Chen, R; Frederich, R; Hollander, PL; Li, J | 1 |
| Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; MacDonald, MR; McMurray, JJ; Petrie, MC; Pocock, SJ | 1 |
| Bechlioulis, A; Kanioglou, C; Kazakos, N; Kostoula, A; Makriyiannis, D; Michalis, LK; Naka, KK; Papafaklis, MI; Papathanassiou, K; Pappas, K; Tsatsoulis, A; Vezyraki, P | 1 |
| Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P | 1 |
| Heckbert, SR; Schambelan, M; Winterstein, AG | 1 |
| Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N | 1 |
| Traynor, K | 1 |
| Ahmed, D; Pillai, KK; Sharma, M | 1 |
| Al-Daghri, N; Chittari, MV; Creely, SJ; da Silva, NF; Evans, M; Harte, AL; Khanolkar, M; Kumar, S; Kusminski, CM; Levick, PL; McGee, KC; McTernan, PG; Patel, V; Tripathi, G | 1 |
| Kim, CM; Lee, DH; McGuire, M; Suh, DC | 1 |
| Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B | 1 |
| Kahn, SE; Utzschneider, KM | 1 |
| Gram, J; Henriksen, JE; Juhl, HF; Nybo, M; Olesen, M; Preil, SR; Rasmussen, LM; Yderstraede, K | 1 |
| Abdalla, DS; Boscá, L; César, FA; Faine, LA; Galdino, SL; Heras, BL; Hernandes, MZ; Lima, MC; Pitta, IR; Rudnicki, M; Souza, ES | 1 |
| Baevsky, T; Dresner, J; Feldman, L; Kaiserman, I; Shani, M; Vinker, S | 1 |
| Mullard, A | 1 |
| Jungbauer, A; Liebner, F; Zoechling, A | 1 |
| Li, L; Liu, H; Yang, G; Yang, M; Zhang, L | 1 |
| Fernández-Real, JM; Moreno-Navarrete, JM; Ortega, F; Peral, B; Pérez-Pérez, R; Ricart, W; Sabater, M; Serrano, M; Tinahones, F | 1 |
| Chen, L; Fu, JY; Han, J; Li, J; Pan, L; Tian, JY; Ye, F; Zhang, XL | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Derosa, G | 1 |
| He, X; Jiang, Q; Jiang, W; Li, Z; Liu, Z; Lu, X; Shao, H; Si, S; Xu, Y; Yang, Y; Zhang, H; Zhao, B; Zheng, Z | 1 |
| Bhalla, K; Choi, JH; Dewi, R; Girnun, GD; Hwang, BJ; Mclenithan, J; Ou, L; Pozharski, E; Stock, J; Twaddel, W | 1 |
| Kamal, MA; Qu, X; Seale, JP; Sun, LQ; Tan, Y; Wang, X | 1 |
| Fan, MS; Huang, CG; Li, ZX; Sun, ZL; Tang, YH | 1 |
| Gadzhanova, S; Gillies, M; Roughead, E; Zuo, Y | 1 |
| Afzal, R; Bosch, J; Dagenais, G; Diaz, R; Gerstein, H; Holman, R; Probstfield, J; Punthakee, Z; Ramachandran, A; Riddle, M; Rydén, LE; Yusuf, S; Zinman, B | 1 |
| Bao, Y; Jia, W; Lu, J; Zhou, J; Zhou, M | 1 |
| Amin, F; Idrees, M; Jan, NU; Khan, MI; Khan, RU; Salman, M; ur Rahman, I | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Drazner, MH; Gore, MO; McGavock, J; McGuire, DK; See, R; Szczepaniak, LS | 1 |
| Chaudhuri, A; Dandona, P; DiGenio, A; Hollander, P; Ilgenfritz, J; McGill, JB; Meneghini, L; Riddle, M; Rosenstock, J | 1 |
| Dai, X; Gong, Z; Huang, Q; Liu, Z; Wu, J; Yin, J; Zhou, F; Zhou, H | 1 |
| Bayraktar, N; Berberoglu, Z; Demirag, NG; Yazici, AC | 1 |
| Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC | 1 |
| Guo, XH; Hui, Y; Yuan, GH; Zhang, WY | 1 |
| Doubova, SV; Flores-Hernández, S; Mino-León, D; Reyes-Morales, H | 1 |
| Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W | 1 |
| Lane, PW | 1 |
| Greevy, RA; Griffin, MR; Grijalva, CG; Hung, AM; Ikizler, TA; Liu, X; Murff, HJ; Roumie, CL | 1 |
| Elased, KM; Lucot, JB; Sharma, AN | 1 |
| Ao, X; Hou, Q; Li, G; Zhang, Y | 1 |
| Addabbo, F; Montagnani, M; Potenza, MA; Sgarra, L | 1 |
| Gao, W; Jusko, WJ | 1 |
| Nauck, MA | 1 |
| Bao, YQ; Hu, C; Jia, WP; Jiang, F; Li, Q; Lu, JY; Tang, SS; Wang, CR; Xiang, KS; Yu, WH; Zhang, R | 1 |
| Pan, D; Pan, LF; Teng, BS; Wang, CD; Wu, JS; Yang, HJ; Zhang, D; Zhou, P | 1 |
| Wilding, JP | 1 |
| Coleman, J; Fenrick, B; Gleason, PP; Starner, CI; Wickersham, P | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Banerjee, PS; Samanta, S | 1 |
| Aubert, JP; Bouée, S; Detournay, B; Fontbonne, A; Guillausseau, PJ; Halimi, S; Nachit, F | 1 |
| de Bie, S; Geelhoed-Duijvestijn, PH; Herings, RM; Mol, PG; Romio, SA; Ruiter, R; Straus, SM; Stricker, BH; van Herk-Sukel, MP; Visser, LE | 1 |
| Allen, DB | 1 |
| Arslanian, S; Copeland, K; Cuttler, L; Hirst, K; Kaufman, F; Linder, B; Nathan, DM; Pyle, L; Tollefsen, S; Wilfley, D; Zeitler, P | 1 |
| Guo, Z; Li, J; Qin, Z; Yin, Y; Zhang, R | 1 |
| Ishii, R; Kaku, K; Kikuchi, M; Momomura, S; Odawara, M | 1 |
| Home, P | 1 |
| Domínguez, RO; González, SE; Marschoff, ER; Repetto, MG; Serra, JA | 1 |
| Donnelly, R; Idris, I; Warren, G | 1 |
| Fernández-Real, JM; Moreno-Navarrete, JM; Ortega, F; Ricart, W; Sabater, M; Sánchez-Garrido, MÁ; Tena-Sempere, M; Zorzano, A | 1 |
| Choi, MS; Do, GM; Jeon, SM; Jung, UJ; Kwon, EY; McGregor, RA; Park, HJ | 1 |
| Bornstein, SR; Gross, P; Herbrig, K; Passauer, J; Pistrosch, F; Schwanebeck, U | 1 |
| Khalaf, KI; Taegtmeyer, H | 1 |
| Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE | 1 |
| Choy-Shan, A; Danoff, A; Donnino, R; Grossi, E; Lorin, JD; Schwartzbard, AZ; Sedlis, SP; Shah, B; Zinn, A | 1 |
| Pouwels, KB; van Grootheest, K | 1 |
| Bowker, SL; Colmers, IN; Johnson, JA; Majumdar, SR | 1 |
| Gupta-Rajoria, R; Jadhav, R; Pal, T; Subramanian, RC | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Li, D; Liu, JH; Wang, GL; Wang, L; Wu, LN; Zhu, DZ | 1 |
| Atar, D; Serebruany, VL | 1 |
| Leal, I; Oteri, A; Romio, SA; Schuemie, M; Sturkenboom, M; Trifirò, G | 1 |
| Bøgelund, M; Ericsson, Å; Jendle, J; Nilsen, B; Ridderstråle, M; Torffvit, O | 1 |
| Bilker, WB; Glanz, K; Haynes, K; Lewis, JD; Mamtani, R; Strom, BL; Vaughn, DJ | 1 |
| Colhoun, HM; Donnan, PT; Guthrie, B; Leese, GP; Lindsay, RS; Livingstone, SJ; Looker, HC; McKeigue, P; McKnight, J; Morris, AD; Pearson, DW; Pearson, E; Petrie, JR; Philip, S; Reed, C; Sattar, N; Sullivan, FM; Wild, SH | 1 |
| Choi, MG; Jung, JS; Kang, YJ; Kim, CH; Kim, SJ; Kim, SS; Park, SH; Ryu, OH; Sim, YB; Suh, HW | 1 |
| Ametov, AS; Goncharenko, ON; Isakova, MR | 1 |
| Aziz, AR; Deliard, S; Grant, SF; Zhao, J | 1 |
| Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME | 1 |
| Tannen, R; Wang, X; Weiner, MG; Xie, D; Yu, M | 1 |
| Christensen, LP; Kristiansen, K; Rimbach, G; Schrader, E; Wein, S; Wolffram, S | 1 |
| Gnudi, L; Karalliedde, J; Manoharan, D; Mohan, V; Parthasarathy, N; Subramani, P; Subramaniyam, G; Sundaramoorthy, C; Viberti, G; Viswanathan, V | 1 |
| Brooks-Worrell, BM; Palmer, JP | 1 |
| Beydoun, H; Beydoun, M; Kancherla, V; Stadtmauer, L | 1 |
| Braddon, J; Phillips, P | 1 |
| Goa, KL; Wagstaff, AJ | 2 |
| Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K | 1 |
| Mohan, V; Vidhya, S | 1 |
| Häring, HU; Stumvoll, M | 1 |
| Heise, M; Kreider, M | 1 |
| Berry, RA; Freed, MI; Greene, DA; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Lachin, JM; Levy, D; Viberti, G; Zinman, B | 1 |
| Herrmann, A; Hesselbarth, N; Hippius, M; Hoffmann, A; Kuschel, U | 1 |
| Biswas, N; Carey, DG; Cowin, GJ; Doddrell, DM; Galloway, GJ; Jones, NP; Richards, JC | 1 |
| Yamanouchi, T | 1 |
| Oka, Y | 1 |
| Aleksunes, LM; Reagan, LA; Vergara, CM; Wang, F | 1 |
| Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R | 1 |
| Dandona, P; Dole, JF; Freed, M; Murphy, K; Patel, J; Patwardhan, R; Rendell, M; St John Sutton, M | 1 |
| German, JB; Leiter, EH; Pan, HJ; Reifsnyder, PR; Watkins, SM | 1 |
| Bradley, C | 1 |
| Göke, B; Parhofer, KG | 1 |
| LaCivita, KA; Villarreal, G | 1 |
| Hällsten, K; Knuuti, J; Lönnqvist, F; Nuutila, P; Oksanen, A; Rönnemaa, T; Sipilä, H; Viikari, J; Viljanen, T; Virtanen, KA | 1 |
| Craft, S; Watson, GS | 1 |
| Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM | 1 |
| Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M | 1 |
| Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA | 1 |
| Ben Khalifa, F; Chow, WH; Menon, PS; Quimpo, JA; Vongthavaravat, V; Waitman, JN; Wajchenberg, BL | 1 |
| Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM | 1 |
| Grossman, E | 1 |
| Froehlich, J; Hombach, V; Ittner, J; Koenig, W; Marx, N; Scharnagl, H; Schmidt, A; Siam, L; Wierse, G | 1 |
| Apolito, RA | 1 |
| Plosker, SM | 1 |
| Viberti, GC | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
| Froehlich, J; Hombach, V; Imhof, A; Ittner, J; Koenig, W; Maerz, W; Marx, N; Schmidt, A; Siam, L; Wierse, G | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Moses, R | 1 |
| Tuepker, J | 1 |
| Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX | 1 |
| Barnett, AH; Grant, PJ; Hitman, GA; Mather, H; Pawa, M; Robertson, L; Trelfa, A | 1 |
| Foley, JE; Fonseca, V; Grunberger, G; Gupta, S; Shen, S | 1 |
| Bell, DS; Braunstein, S; Drexler, AJ; Miller, JL; Nuckolls, JG; Wyne, KL | 1 |
| Ahn, YB; Cha, BY; Kang, SK; Ko, SH; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH | 1 |
| Chen, H; Cobitz, AR; Goldstein, BJ; Hand, LM | 1 |
| Rochester, CD; Samuel, J | 1 |
| Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D | 1 |
| Diamant, M; Heine, RJ | 1 |
| Ferrannini, E; Hallsten, K; Iozzo, P; Kemppainen, J; Knuuti, J; Lonnqvist, F; Nuutila, P; Oikonen, V; Parkkola, R; Solin, O; Virtanen, KA | 1 |
| Debard, C; Frayn, KN; Humphreys, SM; Karpe, F; Langin, D; Tan, GD; Tiraby, C; Vidal, H | 1 |
| Ballary, C; Desai, A | 1 |
| Graham, M; Lindsey, C; McMurphy, J | 1 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Chen, J; Di, F; He, R; Wang, D; Wang, Y; Yang, J; Yang, M; Yuan, S; Zhu, X | 1 |
| Gavish, D; Gavish, E; Leibovitz, E; Leibovitz, Z; Matas, D; Matas, Z; Shargorodsky, M; Wainstein, G; Wainstein, J; Zimlichman, R | 1 |
| Haffner, SM | 1 |
| Bandyopadhyay, G; Beeson, M; Dizon, M; Farese, RV; Gomez-Daspet, J; Grebenev, D; Kanoh, Y; Miura, A; Powe, J; Sajan, MP; Standaert, ML | 1 |
| DeFronzo, RA; He, H; Mandarino, LJ; Miyazaki, Y | 1 |
| Gozansky, WS; Page, RL; Ruscin, JM | 1 |
| de Koning, EJ; Martens, EP; Rabelink, TJ; van Wijk, JP | 1 |
| Hollingdal, M; Juhl, CB; Lönnqvist, F; Prange, A; Pørksen, N; Schmitz, O | 1 |
| Bell, DS | 2 |
| Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY | 1 |
| Zhu, XX | 1 |
| Barringhaus, KG; Chen, M; Czarnik, AC; Hesselbacher, S; Ley, K; Nadler, J; Phillips, JW; Sanders, JM; Sarembock, IJ; Yang, Z | 1 |
| Papoushek, C | 1 |
| Bagi, Z; Kaley, G; Koller, A | 1 |
| Chilton, RJ; Stolar, MW | 1 |
| Henry, RR | 1 |
| Lau, H; Marchetti, A; Olansky, L | 1 |
| Dawood, T; Honisett, SY; Kingwell, BA; Komesaroff, PA; Stojanovska, L; Sudhir, K | 2 |
| Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
| Narce, M; Poisson, JP | 1 |
| Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK | 1 |
| Burton, B | 1 |
| Barnett, AH; Chetty, R; Clark, PM; Fisher, FM; Harte, A; Kumar, S; McTernan, CL; McTernan, PG; Smith, SA; Valsamakis, G | 1 |
| Marescaux, J; Rubino, F | 1 |
| Agrawal, A; Jones, NP; Sautter, MC | 1 |
| Benelli, C; Duplus, E; Forest, C; Fouque, F; Reis, AF; Velho, G | 1 |
| Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN | 1 |
| Fischer, S; Fuecker, K; Gross, P; Hanefeld, M; Passauer, J; Pistrosch, F | 1 |
| Campbell, RK; Iltz, JL; Setter, SM; Thams, J | 1 |
| Harman-Boehm, I; Hershkovitz, T; Mouritzen, U; Raz, I; Vaz, J; Wainstein, J | 1 |
| James, R; Kerenyi, Z; Samer, H; Stewart, M; Yan, Y | 1 |
| Bruce, S; Dailey, GE; Fiedorek, FT; Noor, MA; Park, JS | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Chan, JC; Chan, NN; Chiu, CK; Leung, WY; So, WY; Tong, PC | 1 |
| Petersen, KU | 1 |
| Boyle, PJ; Buse, JB; Kendall, DM; Lau, H; Marchetti, A; Peters Harmel, AL | 1 |
| Beverley, C; Chilcott, J; Cowan, J; Czoski-Murray, C; Psyllaki, MA; Warren, E | 1 |
| Cappleman, JM; Hale, PM; Kaye, W; Khutoryansky, N; McGill, J; Raskin, P; Saad, MF | 1 |
| Béréziat, V; Burnol, AF; Capitaine, N; Cariou, B; Girard, J; Kergoat, M; Laville, M; Le Marcis, V; Vega, N; Vidal, H | 1 |
| Baldwin, D; Duffin, KE | 1 |
| Kipnes, MS; Lewin, AJ; Maccubbin, DL; Meneghini, LF; Mitchel, YB; Perevozskaya, IT; Plotkin, DJ; Shah, S; Tobert, JA | 1 |
| Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S | 1 |
| Roden, M; Stingl, H | 1 |
| Baldeweg, S; Barbaro, D; Capaldo, B; Ferrannini, E; Gastaldelli, A; Natali, A; Toschi, E; Yudkin, JS | 1 |
| Del Prato, S; Volpe, L | 1 |
| Le Feuvre, C | 2 |
| Durbin, RJ | 1 |
| Al-Haddad, W; Aljada, A; Dandona, P; Dhindsa, S; Ghanim, H; Hofmeyer, D; Mohanty, P; Syed, T; Tripathy, D | 1 |
| Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD | 1 |
| Davidson, MB; Navar, M; Palomeno, G; Roy, R | 1 |
| Davidson, MB | 1 |
| Mikhail, N | 1 |
| Baksi, A; James, RE; Nolan, JJ; Zhou, B | 1 |
| Atar, M; Atar-Zwillenberg, DR; Spornitz, UM; Verry, P | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Monnier, L; Sauvanet, JP | 1 |
| Häkkinen, AM; Korsheninnikova, E; Mäkimattila, S; Nyman, T; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Bell, DS; Ovalle, F | 2 |
| Ambrosi, B; Arosio, M; Beck-Peccoz, P; Cannavo, S; Chiodini, I; Dall'Asta, C; Epaminonda, P; Ferrero, S; Libe, R; Trimarchi, F; Vigo, T | 1 |
| Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AN; Tziolas, IM; Yovos, JG; Zebekakis, PE | 1 |
| Mooradian, AD | 1 |
| Collins, JN; Gee, MK; Kauffman, RF; Rankin, SE; Wagner, JD; Zhang, L | 1 |
| Ahn, IS; Do, MS; Hong, SE; Jung, HS; Rayner, DV | 1 |
| Dinneen, SF; Martin, SC; O'Rahilly, S; Sarker, A; Semple, RK | 1 |
| Ahn, CW; Cha, BS; Choi, D; Choi, SH; Jang, Y; Kim, SK; Ko, YG; Lee, HC; Lim, SK | 1 |
| Chiquette, E; Defronzo, R; Ramirez, G | 1 |
| Cox, SL | 1 |
| Füchtenbusch, M; Löbner, K | 1 |
| Colman, PG; Hussein, Z; Nankervis, AJ; Proietto, J; Wentworth, JM | 1 |
| Cluxton, RJ; Heaton, PC; Hsu, VD; Li, Z; Moomaw, CJ; Rodriguez, EM; Weiss, SR; Zuckerman, IH | 1 |
| De, P | 1 |
| Bullock, M; Gaillard, T; Kaplow, J; Osei, K; Schuster, D | 1 |
| Hällsten, K; Janatuinen, T; Knuuti, J; Lehtimäki, T; Lönnqvist, F; Nuutila, P; Rönnemaa, T; Turiceanu, M; Viikari, J; Virtanen, KA | 1 |
| Biswas, N; Freed, MI; Porter, LE; Smith, SA | 1 |
| Anderson, TJ; Edwards, A; Hubacek, J; Ross, SJ; Shewchuk, L; Verma, S | 1 |
| Currie, JM; Désage, M; Fielding, BA; Frayn, KN; Humphreys, SM; Karpe, F; Laville, M; Tan, GD; Vidal, H | 1 |
| Ahn, CW; Cha, BS; Choi, SH; Huh, KB; Kim, DJ; Kim, KR; Kim, SK; Kim, YM; Lee, HC; Lim, SK | 1 |
| Biery, JC; Goins, JA; Lee, TA; Marceille, JR; Soni, R | 1 |
| McCluskey, D; Melis, R; Schleusener, DS; Touger, MS | 1 |
| Kazim, M; Levin, F; Marcovici, E; Smith, TJ | 1 |
| Bayramiçli, OU; Gözü, H; Orbay, E; Sargin, H; Sargin, M; Yayla, A | 1 |
| Haas, T; Perusicová, J | 1 |
| Gavrilova, O; Haluzik, M; Kim, H; LeRoith, D; Pajvani, UB; Portas, J; Scherer, PE; Sun, H; Yakar, S | 1 |
| Bao, W; Cui, J; Gu, JL; Jucker, BM; Ma, XL; Ohlstein, EH; Tao, L; Yue, TL | 1 |
| Sauvanet, JP | 1 |
| Baldeweg, S; Baldi, S; Casolaro, A; Ferrannini, E; Natali, A; Sironi, AM; Toschi, E; Yudkin, JS | 1 |
| Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
| Boden, G; Cheung, P; Homko, C; Mozzoli, M; Nichols, C; Showe, LC | 1 |
| Cho, YM; Jung, HS; Kim, SY; Lee, HK; Park, HJ; Park, KS; Shin, CS; Youn, BS; Yu, KY | 1 |
| Carey, D; Carr, A; Cooper, DA; Emery, S; Feneley, MP; Kovacic, JC; Mallon, PW; Martin, A; Wand, H | 1 |
| Hitoglou-Makedou, AD; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AA; Yovos, JG | 1 |
| Acikel, C; Bingol, N; Caglar, K; Eyileten, T; Gok, DE; Kilic, S; Oguz, Y; Sonmez, A; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
| Barkhem, T; Beno, DW; Cherrington, A; Edgerton, DS; Efendic, S; Fey, T; Fung, S; Goos-Nilsson, A; Grynfarb, M; Jacobson, PB; Kym, PR; Lane, BC; Link, JT; Marsh, K; Mika, A; Nga-Nguyen, B; Nguyen, PT; Ohman, L; Opgenorth, TJ; Osterland, M; Tu, N; von Geldern, TW; Wang, J; Wilcox, D; Zinker, B | 1 |
| Castro Cabezas, M; de Koning, EJ; Rabelink, TJ; van Wijk, JP | 1 |
| Hussein, MA; Perry, A; Vanderpoel, DR; Watson-Heidari, T | 1 |
| Adachi, M; Akiyama, TE; Gonzalez, FJ; Nicol, CJ | 1 |
| Barr, R; Bensch, WR; Brozinick, JT; Bull, C; Dana, S; Hawkins, E; Klausing, K; Martin, JA; Otto, K; Rafaeloff-Phail, R; Rafizadeh-Montrose, C; Reifel-Miller, A; Rhodes, G; Robey, R; Rojo, I; Rungta, D; Snyder, D; Warshawsky, A; Wilbur, K; Zhang, T; Zink, R | 1 |
| Bakst, A; Dirani, RG; Freed, MI; Heise, MA; Herman, WH; Horblyuk, R; Kravitz, B; O'Neill, MC | 1 |
| Ciardullo, AV | 1 |
| Chatterjee, VK; Currie, J; Fielding, BA; Frayn, KN; Karpe, F; Neville, MJ; O'Rahilly, S; Risérus, U; Savage, DB; Tan, GD | 1 |
| Björnholm, M; Chibalin, AV; Hällsten, K; Heinonen, OJ; Karlsson, HK; Lönnqvist, F; Nuutila, P; Tsuchida, H; Virtanen, KA; Zierath, JR | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kim, HJ; Kim, KR; Lee, HC; Lim, SK; Nam, M; Park, SY | 1 |
| Guan, Y; Jin, N; Mao, J; Wang, G; Wang, X; Wei, J | 1 |
| Campbell, IW | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S | 1 |
| Schumm-Draeger, PM | 1 |
| Fischer, S; Gross, P; Herbrig, K; Oelschlaegel, U; Passauer, J; Pistrosch, F; Richter, S | 1 |
| Abchee, AB; Alam, S; Ayach, K; Dakik, HA; Mehio-Sibai, A; Nasrallah, A; Sawaya, J; Sibai, T; Skouri, HN; Wehbeh, C | 1 |
| Cuneo, ML; Lee, S; Petrofsky, J | 1 |
| Leiter, EH; Pan, HJ; Reifsnyder, P; Vance, DE; Xiao, Q | 1 |
| Maaravi, Y; Stessman, J | 1 |
| Chalasani, N; Hall, SD; Teal, E | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S | 1 |
| Gonzalez, FJ; Kohan, DE; Nelson, RD; Yang, T; Zhang, A; Zhang, H | 1 |
| Mukhtar, R; Reckless, JP | 1 |
| Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Pinaire, JA; Tan, MH; Zagar, AJ | 1 |
| Moreno Sánchez, D | 1 |
| Debard, C; Frayn, KN; Funahashi, T; Humphreys, SM; Karpe, F; Matsuzawa, Y; Tan, GD; Vidal, H | 1 |
| Ouyang, JP; Wang, SS; Wen, CY; Wu, K; Wu, Y; Xia, ZY | 1 |
| Arnold, N; Cheung, NW; Chipps, DR; McLean, M | 1 |
| Anderson, MA; Chensue, SW; Menees, SB; Moseley, RH | 1 |
| Altuntas, Y; Basat, O; Seber, S; Ucak, S | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Smith, CM | 1 |
| Cho, L; Lewis, BE; Leya, FS; Steen, LH | 1 |
| Beck-Nielsen, H; Biswas, N; Dargie, H; Gomis, R; Gubb, J; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ | 1 |
| Graham, TE; Kahn, BB; Kotani, K; Mody, N; Peroni, OD; Preitner, F; Quadro, L; Yang, Q; Zabolotny, JM | 1 |
| Bergenstal, RM; Bode, BW; Cefalu, WT; DeFronzo, RA; Lerman, S; Phillips, LS; Pullman, J | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kim, CS; Kim, HJ; Lee, HC; Lim, SK; Nam, CM; Park, SY | 1 |
| Whitelaw, D | 1 |
| Ni, ZZ; Sun, KH; Zhu, CR | 1 |
| Chen, HL; Lei, MX; Sun, ZX; Wu, J | 1 |
| Airaksinen, KE; Ball, E; Borra, R; Härkönen, R; Iozzo, P; Knuuti, J; Lautamäki, R; Luotolahti, M; Nuutila, P; Seppänen, M; Stewart, M; Toikka, J | 1 |
| Kiuru, A; Savage, RL | 1 |
| Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Mouslech, TF; Nilsson, PM; Sarafidis, PA; Stafylas, PC; Tourkantonis, AA; Yovos, JG | 1 |
| Dazzi, D; Hassan, H; Mangieri, T; Negro, R; Pezzarossa, A | 1 |
| Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I | 1 |
| Cabezas, MC; Coll, B; de Koning, EJ; Joven, J; Rabelink, TJ; van Wijk, JP | 1 |
| Chen, HL; Liao, L; Wu, J | 1 |
| Baik, SH; Choi, DS; Choi, KC; Choi, KM; Kim, HY; Kim, NH; Kim, SG; Lee, KW; Ryu, OH; Seo, JA | 1 |
| Colucciello, M | 1 |
| Ceska, R; Dolezalova, R; Kasalova, Z; Krejci, H; Stulc, T | 1 |
| Digman, C; Klein, AK; Pittas, AG | 1 |
| Dehmel, B; Petzoldt, R; Reblin, T; Rosak, C; Seidel, D; Wolf, R | 1 |
| Chow, KM; Lam, CW; Leung, CB; Li, PK; Szeto, CC; Wong, TY | 1 |
| Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR | 1 |
| D'Amico, E; Perfetti, R | 1 |
| Ferrannini, E; Hällsten, K; Iozzo, P; Järvisalo, MJ; Lönnqvist, F; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, AP; Virtanen, KA | 1 |
| Bhansali, A; Modi, P | 1 |
| Kjølhede, P; Nystrom, FH; Sauma, L; Söderström, M; Stenkula, KG; Strålfors, P | 1 |
| Leiter, EH; Mistry, J; Pan, HJ; Reifsnyder, PC; Xiao, Q; Zhang, W | 1 |
| Bullock, M; Cook, C; Gaillard, T; Kaplow, J; Osei, K; Schuster, D | 1 |
| Ardecky, RJ; Boehm, MF; Broderick, CL; Carfagna, MA; Crombie, DL; D'Arrigo, J; Etgen, GJ; Faul, MM; Grese, TA; Havel, H; Hein, NI; Heyman, RA; Jolley, D; Klausing, K; Leibowitz, MD; Liu, S; Mais, DE; Mapes, CM; Marschke, KB; Michellys, PY; Montrose-Rafizadeh, C; Ogilvie, KM; Pascual, B; Reifel-Miller, A; Rungta, D; Tyhonas, JS; Urcan, MS; Wardlow, M; Yumibe, N | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S | 1 |
| Abbasi, F; Chu, JW; Lamendola, C; McLaughlin, T; Reaven, GM; Tsao, PS | 1 |
| Bauer, TA; Regensteiner, JG; Reusch, JE | 1 |
| Cuneo-Libarona, M; Lee, S; Petrofsky, JS | 1 |
| Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K | 1 |
| Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J | 1 |
| Bagdonas, A; Bailey, CJ; Biswas, N; Donaldson, J; McMorn, SO; Rubes, J; Stewart, MW | 1 |
| Brunzell, JD | 1 |
| Baldwin, D; Villanueva, G | 1 |
| Dagdelen, S; Gedik, O | 1 |
| Ciociaro, D; Defronzo, RA; Ferrannini, E; Gastaldelli, A; Miyazaki, Y; Pettiti, M; Santini, E | 1 |
| Dirani, RG; Freed, MI; Goldstein, BJ; Heise, MA; Kravitz, B; O'neill, MC; Porter, LE; Rosenstock, J; Vinik, AI | 1 |
| Cobitz, AR; Goldstein, BJ; Rosenstock, J; Strow, LJ; Waterhouse, B; Weissman, P; Wooddell, MJ | 1 |
| Lee, S; Petrofsky, JS | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Brismar, K; Catrina, SB; Hällsten, K; Lönnqvist, F; Nuutila, P; Virtanen, K | 1 |
| Blaak, EE; Hesselink, MK; Mensink, M; Moonen-Kornips, E; Russell, AP; Schaart, G; Schrauwen, P; Sels, JP | 1 |
| Cobitz, AR; Freed, MI; Rood, JA; Ryan, CM; Strachan, MW; Waterhouse, BR | 1 |
| Arikan, E; Demir, M; Fareed, J; Guldiken, S; Kara, M; Tugrul, A; Turgut, B; Vural, O | 1 |
| Bruce, S; Garber, A; Klein, E; Mohideen, P; Sankoh, S | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Gaddi, AV; Ghelfi, M; Piccinni, MN; Salvadeo, S | 1 |
| Edwards, KL; Greene, RS; Irons, BK; Mazzolini, TA; Sleeper, RB | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC | 1 |
| Friedmann, PS; Krentz, AJ | 1 |
| Choi, KM; Choo, HJ; Han, SS; Kim, JH; Ko, YG; Kwon, OB; Lee, CS; Mun, JY; Yoon, G; Yoon, YS | 1 |
| Baldi, A; Baldi, F; Cacciapuoti, F; Carbonara, O; Ceriello, A; Cirillo, F; Coppola, L; Crescenzi, B; D'Amico, M; D'Andrea, F; Di Filippo, C; Esposito, K; Giugliano, D; Marfella, R; Nicoletti, GF; Portoghese, M; Rossi, F; Sasso, FC; Siniscalchi, M; Verza, M | 1 |
| Costello, M; Crunkhorn, S; Gami, H; Goldfine, AB; Jimenez-Chillaron, J; Landaker, EJ; Lo, D; Niinobe, M; Patti, ME; Warren, A; Yoshikawa, K | 1 |
| Dailey, G; Rosenstock, J; Soltes-Rak, E; Stewart, JA; Strange, P; Sugimoto, D | 1 |
| Iyer, S; Kalsekar, I; Kavookjian, J; Mody, R; Rajagopalan, R | 1 |
| Ciccarelli, L; Cicero, AF; Dangelo, A; Derosa, G; Ferrari, I; Fogari, R; Gaddi, A; Ghelfi, M; Montagna, L; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, S | 1 |
| Das, S; Maji, D; Roy, RU | 1 |
| Andreelli, F; Beauloye, C; Bertrand, L; Foretz, M; Guigas, B; Horman, S; Taleux, N; Viollet, B | 1 |
| Kulenović, I | 1 |
| Ahn, CW; Cha, BS; Hur, KY; Kang, ES; Kim, HJ; Kim, SH; Lee, HC; Lee, HJ; Shim, WS | 1 |
| Davidson, MB; Navar, MD; Tran, MT | 1 |
| Chen, YE; Leiter, EH; Lin, Y; Pan, HJ; Vance, DE | 1 |
| Ecelbarger, CA; Hu, X; Khan, O; Riazi, S; Tiwari, S | 1 |
| Berhanu, P; Demissie, S; Fleck, PR; Khan, MA; Kipnes, MS; Kupfer, SF; Perez, AT; Spanheimer, RC | 1 |
| Parson, H; Ullal, J; Vinik, A | 1 |
| Smits, P; Tack, CJ | 1 |
| Chen, JW; Jen, HL; Lin, SJ; Yin, WH; Young, MS | 1 |
| Bagust, A; Beale, S; Hulme, L; Martin, A; Shearer, AT | 1 |
| Bagust, A; Goertz, A; Liebl, A; Schoeffski, O; Shearer, AT | 1 |
| Ampudia-Blasco, FJ; Bagust, A; Martínez-Lage Alvarez, B; París, G; Pérez Escolano, I; Shearer, AT | 1 |
| Aljada, A; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Viswanathan, P | 1 |
| Huang, Z; Lei, MX; Liu, L; Tang, QB | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Bandyopadhyay, GK; Ofrecio, J; Olefsky, JM; Yu, JG | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 2 |
| Bakris, GL; Sarafidis, PA | 1 |
| Frayn, KN; Karpe, F; Olivecrona, G; Tan, GD; Vidal, H | 1 |
| Favreau, CM; Gutschi, LM; Malcolm, JC; Ooi, TC | 1 |
| Johansen, OE; Jørgensen, AP | 1 |
| Gerstein, HC; Hanley, AJ; Harris, SB; Neuman, J; Raboud, JM; Young, TK; Zinman, B | 1 |
| Scherbaum, WA | 1 |
| Ahn, HK; Choi, JS; Han, JY; Koong, MK; Nava-Ocampo, AA; Shin, JS; Yang, JH | 1 |
| Reblin, T; Rosak, C; Seidel, DK; Stammer, H; Standl, E | 1 |
| Currie, CJ; Palmer, AJ | 1 |
| Huang, YJ; Lei, MX; Liu, L; Wu, J | 1 |
| Bakris, GL; Freed, MI; Heise, MA; McMorn, SO; Porter, LE; Ruilope, LM; Weston, WM | 1 |
| Chung, CH; Leung, CH; Liu, SC; Wang, CH | 1 |
| Cobitz, AR; Goldstein, BJ; Waterhouse, BR; Weissman, PN; Wooddell, MJ | 1 |
| Biswas, N; Cirkel, DT; Donaldson, J; Furuseth, K; Hamann, A; Phenekos, C; Starkie, MG; Stewart, MW | 1 |
| Ahn, CW; Cha, BS; Do, MY; Hur, KY; Kang, ES; Kim, HJ; Kim, SK; Lee, HC; Lim, SK; Shim, WS | 1 |
| Burggraaf, K; Cohen, A; de Kam, M; Jones, R; Kemme, M; Ouwens, M; Romijn, H; Schoemaker, R; van Doorn, M; van Hoogdalem, EJ | 1 |
| Bosch, J; Dinccag, N; Gerstein, HC; Hanefeld, M; Holman, RR; Hoogwerf, B; Laakso, M; Mohan, V; Pogue, J; Shaw, J; Sheridan, P; Yusuf, S; Zinman, B | 1 |
| Hamid, Z; Simmons, DL | 1 |
| Elhadd, TA; Fiad, T; Meer, L | 1 |
| Biswas, N; Chou, H; Cobitz, A; Garber, A; Rood, J; Rosenstock, J | 1 |
| Tuomilehto, J; Wareham, N | 1 |
| Chow, WS; Hoo, RL; Kraegen, EW; Lam, KS; Sweeney, G; Tso, AW; Wang, Y; Wat, NM; Xu, A; Xu, JY; Zhang, J | 1 |
| Berlie, HD; Jaber, LA; Kalus, JS | 1 |
| Cersosimo, E; De Filippis, E; DeFronzo, RA; Gastaldelli, A; Glass, L; Miyazaki, Y; Triplitt, C; Wajcberg, E | 1 |
| Bošanská, L; Doležalová, R; Haluzík, M; Haluzík, MM; Kasalová, Z; Lacinová, Z; Stulc, T | 1 |
| Buckingham, R; Karalliedde, J; Lorand, D; Starkie, M; Stewart, M; Viberti, G | 1 |
| Ahmed, S; Coletti, C; Gordon, MS; Hollenberg, NK; Lansang, MC | 1 |
| Comeau, P | 1 |
| Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B | 1 |
| Adamiec, R; Bednarska-Chabowska, D; Dobosz, T; Gacka, M; Sadakierska-Chudy, A; Szymaniec, S | 1 |
| Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; O'Neill, MC; Viberti, G; Zinman, B | 1 |
| Nathan, DM | 2 |
| Eriksson, P; Fisher, RM; Hamsten, A; Kannisto, K; Kolak, M; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Brunzell, JD; Chen, H; Cobitz, A; Marcovina, SM; Murdoch, SJ; Parikh, SJ; Yu, D | 1 |
| Gaillard, T; Osei, K; Schuster, D | 1 |
| Herder, C; Kempf, K; Kolb, H; Martin, S; Rose, B | 1 |
| Hanefeld, M; Jones, NP; Patwardhan, R | 1 |
| Cabezas, MC; Camps, J; Coll, B; Joven, J; Koning, E; Mackness, B; van Wijk, J | 1 |
| Seissler, J | 1 |
| Bottomley, J; Diamantopoulos, A; Mariz, S; O'Bryan-Tear, G; Tilden, DP | 1 |
| Chiang, CK; Ho, TI; Hsu, SP; Hung, KY; Pai, MF; Peng, YS; Wu, KD; Yang, SY | 1 |
| Boden, G; Cheung, P; Homko, C; Kresge, K; Mozzoli, M; Zhang, M | 1 |
| Iversen, PB; Vondeling, H | 1 |
| Allemann, S; Braun, M; Chappuis, B; Christ, ER; Diem, P; James, R; Lumb, PJ; Stettler, C; Wierzbicki, AS | 1 |
| Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M | 1 |
| Balasubramani, M; Capps, N; Milles, J; Ramachandran, S; Shetty, C | 1 |
| Karounos, DG; Kingsley, FJ; Reynolds, LR; Tannock, LR | 1 |
| Bilous, R | 1 |
| Vinik, AI; Zhang, Q | 1 |
| Baron, MA; Dejager, S; Mills, D; Rosenstock, J; Schweizer, A | 1 |
| Chen, LM; Duan, L; Li, H; Li, XW; Li, Y; Qin, Y; Wen, YB | 1 |
| Albertini, JP; Chen, H; Mather, RA; McMorn, SO; Valensi, P | 1 |
| Fövényi, J | 1 |
| Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A | 1 |
| Jezior, MR; Langley, RW; Stocker, DJ; Taylor, AJ; Vigersky, RA | 1 |
| Gradiser, M; Matovinovic, M; Vrkljan, M | 1 |
| Hesselink, MK; Mensink, M; Russell, AP; Schaart, G; Schrauwen, P; Sels, JP | 1 |
| Antoniou, T; Berger, P; Kennie, N | 1 |
| Ari, N; Aslamaci, S; Irat, AM; Karasu, C | 1 |
| Campbell, AG; Hart, CM; Hwang, J; Kleinhenz, DJ; Rupnow, HL; Sutliff, RL; Thulé, PM | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Bryant, B; Jain, SK; Yaturu, S | 1 |
| Berkwits, M; Nathan, DM | 1 |
| Veneman, TF | 1 |
| Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R | 1 |
| Kanna, B; Pokharna, H | 1 |
| Kokkoris, S; Korantzopoulos, P; Kountouris, E; Melidonis, A; Protopsaltis, I; Siogas, K | 1 |
| Garg, R | 1 |
| Beaser, RS; Levy, P | 1 |
| Caelles, C; Díaz-Delfín, J; Morales, M | 1 |
| Ahn, CW; Cha, BS; Jung, TW; Kang, ES; Kim, DJ; Kim, HJ; Lee, HC; Lee, KW | 1 |
| Epstein, L; Grey, M; Hirst, K; Kaufman, F; Tamborlane, W; Wilfley, D; Zeitler, P | 1 |
| Lindenfeld, J; Masoudi, FA | 1 |
| Dargie, HJ; Hildebrandt, PR; McMorn, SO; McMurray, JJ; Riegger, GA; Roberts, JN; Wilding, JP; Zambanini, A | 1 |
| Asano, S; Hansen, MK; Higashiyama, H; Mattie, MD; Okamoto, Y; Qiu, Y; Rong, JX; Ryan, TE; Strum, JC; Xie, M; Zhang, V; Zhu, L | 1 |
| Cho, BP; Chung, CH; Koh, JH; Lee, BJ; Lee, EY; Lee, MY; Shin, JY; Shin, YG; Won, CS | 1 |
| Stroup, JS | 2 |
| Karalliedde, J; Viberti, GC | 1 |
| Burggraaf, J; Cohen, A; Tas, A; van der Greef, J; van Doorn, M; van Hoogdalem, EJ; Vogels, J | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA | 1 |
| Beck-Nielsen, H; Curtis, P; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ | 1 |
| Nissen, SE; Wolski, K | 1 |
| Furberg, CD; Psaty, BM | 2 |
| Schwartz, AV; Sellmeyer, DE | 1 |
| Bao, Y; Jia, W; Lu, J; Wang, C; Wu, H; Xiang, K; Zhu, J | 1 |
| Beck-Nielsen, H; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Curfman, GD; Drazen, JM; Morrissey, S | 1 |
| Koro, C; Landon, J; McAfee, AT; Walker, AM; Ziyadeh, N | 1 |
| Klomp, CM; Schaper, NC | 1 |
| Smiley, D; Umpierrez, G | 1 |
| Cefalu, WT; Wang, ZQ | 1 |
| Abdul Rahman, AR; Ismail, AA; Ismail, SB; Naing, NN; Rahman, S | 1 |
| Kazi, D | 1 |
| Krall, RL | 2 |
| Baek, NI; Bang, MH; Choi, MS; Chung, HG; Jeong, TS; Jung, UJ; Kang, YJ; Kim, HJ; Lee, KT; Lee, MK; Yeo, JY; Yoo, JS | 1 |
| Forst, T; Pfützner, A; Wilhelm, B | 1 |
| Littenberg, B; MacLean, CD; Ramos-Nino, ME | 1 |
| Alevizos, M; Angelopoulou, N; Iliadis, F; Kadoglou, NP; Liapis, CD; Perrea, D | 2 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Salvadeo, SA | 1 |
| Bahlmann, FH; Besler, C; Doerries, C; Drexler, H; Fliser, D; Haller, H; Horváth, T; Kirchhoff, N; Landmesser, U; Limbourg, A; Limbourg, F; Müller, M; Schulz, S; Sorrentino, SA | 1 |
| Chou, HS; Hollander, P; Yu, D | 1 |
| Bascil Tutuncu, N; Bayraktar, N; Berberoglu, Z; Gursoy, A; Guvener Demirag, N; Yazici, AC | 1 |
| Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ | 1 |
| Garber, A | 1 |
| Lepor, NE; McCullough, PA | 1 |
| Einecke, D | 1 |
| Jacob, S | 1 |
| Bossuyt, PM; de Vries, JH; Hoekstra, JB | 1 |
| Bandeira-Echtler, E; Bergerhoff, K; Clar, C; Ebrahim, SH; Richter, B | 1 |
| Brophy, S; Brunt, H; Davies, H; Mannan, S; Williams, R | 1 |
| Isom, R; Kiryluk, K | 1 |
| Betteridge, DJ; Chow, WS; Hoo, RLC; Lam, KSL; Tan, KCB; Tse, HF; Tso, AWK; Xu, A | 1 |
| Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B | 1 |
| McGuire, DK | 1 |
| Grant, PJ | 1 |
| Marx, N | 1 |
| Ahn, CW; Cha, BS; Cho, YW; Hur, KY; Kim, HJ; Kim, SK; Lee, HC; Lim, SK; Park, SW; Shim, WS | 1 |
| Matthaei, S | 1 |
| Baran, R; Bhattacharya, M; Gerrits, CM; Kupfer, S; Manthena, S; Perez, A | 1 |
| Bax, L; Diamond, GA; Kaul, S | 1 |
| McFarlane, SI; Provilus, A; Shin, JJ | 1 |
| Drzewoski, J; Grzeszczak, W | 1 |
| Jatwa, R; Kar, A; Panda, S; Parmar, HS | 1 |
| Apodaca, P; Cuneo-Libarona, M; Lee, S; Petrofsky, J | 1 |
| Atar, A; Biyiklioglu, Z; Dogruk Unal, A; Güvener Demirag, N; Türkmen Kemal, Y; Yildirir, A | 1 |
| Boaz, M; Gavish, D; Michaelova, K; Shargorodsky, M; Zimlichman, R | 1 |
| Gursoy, A; Guvener Demirag, N; Sahin, M; Yilmaz, H | 1 |
| Colca, JR | 1 |
| Jenkins, JK; Joffe, HV; Meyer, RJ; Parks, MH; Temple, R | 1 |
| Bracken, MB | 1 |
| Susman, J | 1 |
| Bolusani, H; Evans, LM; Geen, J; Jackson, SK; Khanolkar, MP; Morris, RH; Roberts, AW; Thomas, AW | 1 |
| Ambery, P; Bagust, A; Home, P; Mendes da Costa, S; Taylor, M | 1 |
| Cersosimo, E; DeFronzo, RA; Miyazaki, Y; Triplitt, C | 1 |
| Brett, AS | 1 |
| Jeon, MJ; Kim, M; Kim, MS; Kim, SW; Kim, SY; Koh, EH; Lee, KU; Park, HS; Park, IS; Park, JY; Ryu, JW; Youn, JH | 1 |
| Nitschmann, S; Standl, E | 1 |
| Solomon, DH; Winkelmayer, WC | 1 |
| Ceska, R; Stulc, T | 1 |
| Gao, H; He, J; Liang, Y; Yi, L; Yuan, D; Zhou, H | 1 |
| Jin, N; Mao, J; Wang, G; Wang, X; Yu, J; Zhang, F | 1 |
| Arena, RA; Balaban, RS; Cannon, RO; Johnson, DT; Minerbi, DC; Pagel-Langenickel, I; Sack, MN; Schwartz, DR; Tripodi, DJ; Waclawiw, MA | 1 |
| Atkin, SL; Cleland, JG | 1 |
| Lago, RM; Nesto, RW; Singh, PP | 1 |
| Hamilton, PK; Lockhart, CJ; McVeigh, GE; Quinn, CE | 1 |
| Joshi, SR; Mohan, V | 1 |
| Itakura, Y; Nakagawa, T; Noguchi, H; Taiji, M; Tsuchida, A; Yamanaka, M | 1 |
| Chan, L; Chow, WS; Fong, CH; Hoo, RL; Lam, KS; Tam, S; Tse, HF; Tso, AW; Xu, A; Yau, MH | 1 |
| Cornell, J; Localio, AR; Mulrow, CD | 1 |
| D'Arrigo, T | 1 |
| Hjelmesaeth, J; Røislien, J | 1 |
| Halse, J | 1 |
| Granér, M; Juurinen, L; Kotronen, A; Yki-Järvinen, H | 1 |
| Roussel, R | 2 |
| De Flines, J; Paquot, N; Scheen, AJ | 1 |
| Elasy, T; Stafford, JM | 1 |
| Wolffenbuttel, BH | 1 |
| Bruin, JE; Gerstein, HC; Holloway, AC; Petrik, JJ | 1 |
| Florez, H; Meneghini, LF; Tamariz, L | 1 |
| Boyle, P | 1 |
| Baek, NI; Bang, MH; Choi, MS; Chung, HG; Jeong, TS; Jung, UJ; Kang, YJ; Kim, HJ; Lee, KT; Lee, MK; Yeo, J | 1 |
| Vergès, B | 1 |
| Charbonnel, B | 1 |
| Guan, Y; Zheng, F | 1 |
| Cobitz, AR; Davidson, JA; McMorn, SO; Waterhouse, BR | 1 |
| Bao, YQ; Hu, C; Jia, WP; Lu, JX; Wang, CR; Xiang, KS; Xu, J; Zhang, H; Zhang, R | 1 |
| Anderson, RT; Arondekar, BV; Balkrishnan, R; Camacho, FT; Horblyuk, R; Shenolikar, RA | 2 |
| Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S | 1 |
| Koro, C; McAfee, AT; Walker, AM | 1 |
| Misbin, RI | 1 |
| Bolek, W; Kauschke, SG; Potterat, O; Puder, C; Vettermann, R; Wagner, K | 1 |
| Fehér, J; Lengyel, G | 1 |
| Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D | 1 |
| Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M | 1 |
| Lasaridis, AN; Sarafidis, PA; Stafylas, PC | 1 |
| Deeks, ED; Keam, SJ | 1 |
| Badenhoop, K; Bölck, B; Busse, R; Cohen, RA; Dixit, M; Fleming, I; Pistrosch, F; Randriamboavonjy, V; Schwinger, RH | 1 |
| Bahia, LR; Bottino, DA; Bouskela, E; Kraemer de Aguiar, LG; Nivoit, P; Villela, NR | 1 |
| Atkin, SL; Cho, LW | 1 |
| Donaldson, J; Garcia-Puig, J; Hamann, A; Paul, G; Stewart, M | 1 |
| Demidova, TIu; Erokhina, EN | 1 |
| Choi, MS; Jeon, SM; Jung, UJ; Jung, YM; Lee, MK; Lee, YH; Yeo, J | 1 |
| Dorais, M; LeLorier, J | 1 |
| Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Bao, YQ; Hu, C; Jia, WP; Lu, JX; Wang, CR; Wang, J; Xiang, KS; Zhang, R | 1 |
| Berneis, K; Braun, M; Chappuis, B; Christ, ER; Diem, P; Rizzo, M; Stettler, C | 1 |
| Doggrell, SA | 1 |
| Honisett, SY; Komesaroff, PA; Stojanovska, L | 1 |
| Carson, S; Norris, SL; Roberts, C | 1 |
| Aftring, RP; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Viberti, G; Yu, D; Zinman, B | 1 |
| Goenka, N; Kotonya, C; O'Hare, JP; Penney, MD; Randeva, HS | 1 |
| Seidel, D; Strohmeyer, T | 1 |
| Dachs, R; Darby-Stewart, A; Graber, MA | 1 |
| Erdmann, E; Scherbaum, WA | 1 |
| Bégaud, B; Bernard, MH; Eschwège, E; Grimaldi, A; Oppert, JM; Pouchain, D; Slama, G | 1 |
| Chen, JL; Escaron, P; Furukawa, N; Learned, RM; Lee, G; Li, Y; Lindstrom, M; Liu, J; Liu, X; Plotnikova, O; Prasad, V; Walker, N; Wang, Z; Weiszmann, J; Xu, H | 1 |
| Ceska, R; Dobiásová, M; Dolezalová, R; Fait, T; Kasalová, Z; Prázný, M; Stulc, T; Vrablík, M | 1 |
| Schatz, DA; Shuster, JJ | 1 |
| Hayden, MR | 1 |
| Cha, BS; Hwang, YC; Lee, EY; Lee, MK; Lee, WJ; Park, KS; Yoon, KH | 1 |
| Bauersachs, J; Thum, T | 1 |
| Kanna, B; Lopez, CA | 1 |
| Zhou, JY; Zhou, SW | 1 |
| Berger, JP; Chang, CH; Doebber, TW; McCann, ME; McNamara, LA; Meinke, PT; Muise, ES; Tan, Y; Thompson, JR; Wood, HB; Wu, MS | 1 |
| Costa, B | 1 |
| Kapoor, JR | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA | 1 |
| Lamanna, C; Mannucci, E; Marchionni, N; Monami, M | 1 |
| Grey, AB | 1 |
| Koro, CE; Landon, J; Walker, AM | 1 |
| Chaikledkeaw, U; Chaiyakunapruk, N; Chirakup, S; Ongphiphadhanakul, B; Palmer, AJ; Pongcharoensuk, P; Roze, S; Valentine, WJ | 1 |
| Baran, I; Cangur, S; Dirican, M; Ersoy, C; Eryilmaz, S; Fazlioglu, M; Gul, CB; Imamoglu, S; Ocak, N; Oz, O; Tuncel, E | 1 |
| Ahn, CW; Cha, BS; Hur, KY; Kang, ES; Kim, HJ; Kim, SK; Lee, HC; Lee, JH; Lim, SK; Shim, WS | 1 |
| Al-Kadhi, Y; Al-Omary, M; El-Naggar, MH; Habib, B; Helmy, A; Moawad, M | 1 |
| Atabek, ME | 1 |
| Arrigoni, F; Costanza, F; Di Blasi, P; Longobardi, A; Merante, D; Tatti, P | 1 |
| Chilton, R; Sulistio, MS; Thukral, N; Zion, A | 1 |
| Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV | 1 |
| Gong, ZC; Guo, ZW; Liu, HL; Liu, YZ; Liu, ZQ; Sun, H; Wu, J; Yin, JY; Zhou, HH | 1 |
| Alemao, E; Chen, J; Cook, J; Yin, D | 1 |
| Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D | 1 |
| Beck-Nielsen, H; Curtis, P; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ; Zambanini, A | 1 |
| Gong, ZC; Hu, PC; Lin, YG; Liu, HL; Liu, ZQ; Sun, H; Wang, D; Wu, J; Yin, JY; Zhang, W; Zhou, HH | 1 |
| Anand, SS; Gerstein, HC; McDonald, SD; Sheridan, P; Yusuf, S | 1 |
| Hesselink, MK; Kooi, ME; Mensink, M; Schrauwen, P; Schrauwen-Hinderling, VB; Sels, JP | 1 |
| Blüher, M; Kirsch, K; Kovacs, P; Krist, J; Lehmann, S; Linke, A; Oberbach, A; Sonnabend, M; Stumvoll, M; Tönjes, A | 1 |
| Abbasi, F; Basina, M; Itakura, H; Lamendola, C; Reaven, G | 1 |
| DeFronzo, RA; Miyazaki, Y | 1 |
| Cawthorne, MA; Coyle, PJ; Holder, JC; Holman, GD; Kirkham, DM; Kozka, IJ; Lister, CA; Smith, SA; Young, PW | 1 |
| Kliewer, SA; Lehmann, JM; Moore, LB; Smith-Oliver, TA; Wilkison, WO; Willson, TM | 1 |
| Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR | 1 |
| Connor, SC; Hughes, MG; Lister, CA; Moore, G; Smith, SA | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Buckingham, RE; Chattington, PD; Naderali, EK; Walker, AB; Williams, G | 1 |
| Balfour, JA; Plosker, GL | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Henney, JE | 1 |
| Oberpichler-Schwenk, H | 1 |
| Diamond, RH; Forman, LM; Simmons, DA | 1 |
| Al-Salman, J; Arjomand, H; Kemp, DG; Mittal, M | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Miller, JL | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Kuzuya, T | 1 |
| Shimizu, N | 1 |
| Kameda, N; Oka, Y; Okuya, S | 1 |
| Fonseca, V; Patwardhan, R; Rosenstock, J; Salzman, A | 1 |
| Cole, ST; Freed, MI; Patwardhan, R; Rappaport, EB; Raskin, P; Yan, Y | 1 |
| Arch, JR; Buckingham, RE; Cai, XJ; Lister, CA; Pickavance, L; Wilding, J; Williams, G; Wilson, S | 1 |
| Brown, MN | 1 |
| Deacon, LF; Jones, NP; Nolan, JJ; Patwardhan, R | 1 |
| King, AB | 1 |
| Cowley, H; Cox, PJ; Harris, AM; Hollis, FJ; Miller, AK; Ryan, DA; Vousden, M | 1 |
| Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
| DeFronzo, RA | 1 |
| Bledsoe, RK; Gampe, RT; Kliewer, SA; Lambert, MH; Milburn, MV; Miller, AB; Montana, VG; Willson, TM; Xu, HE | 1 |
| Bakris, G | 1 |
| Krische, D | 1 |
| Böhm, S | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Hishinuma, T; Mizugaki, M; Yamazaki, T | 1 |
| Baum, U | 1 |
| Goldstein, BJ | 1 |
| Ludvik, B | 1 |
| Stiefelhagen, P | 1 |
| Filz, HP | 1 |
| Chen, L; Cohen, SE; Kahn, CR | 1 |
| Bolesta, S; Malinowski, JM | 1 |
| Bryan, J | 1 |
| Blumenthal, RS; Nass, CM | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Meneilly, GS; Tessier, D | 1 |
| Funk, WB; Lenhard, MJ | 1 |
| Lloyd, SJ; Thomas, ML | 1 |
| Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM | 1 |
| Grunberger, G; Miller, E; Patwardhan, R; Phillips, LS; Rappaport, EB; Salzman, A | 1 |
| Anderson, RJ; Patel, J; Rappaport, EB | 1 |
| Robinson, S; Schachter, M; Valabhji, J | 1 |
| Buckingham, RE; Lister, CA; Smith, SA; Toseland, CD | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Dole, JF; Freed, MI; Lebovitz, HE; Patwardhan, R; Rappaport, EB | 1 |
| Dharmalingam, M; Kumar, P | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Bandyopadhyay, G; Farese, RV; Kanoh, Y; Sajan, MP; Standaert, ML | 1 |
| Matthews, DR | 2 |
| Porterfield, LM | 1 |
| Janka, HU | 1 |
| Buckingham, RE; Finegood, DT; Kojwang, D; Leonard, T; McArthur, MD; Thomas, MJ; Topp, BG | 1 |
| Huijberts, MS; Sels, JP; Wolffenbuttel, BH | 1 |
| Bragg, T | 1 |
| Gale, EA | 1 |
| Dole, JF; Freed, MI; Raskin, P; Rendell, M; Riddle, MC; Rosenstock, J | 1 |
| Blicklé, JF | 2 |
| Burge, MR; Colleran, K; Sood, V | 1 |
| Csermely, P; Jermendy, G | 1 |
| Chapman, H; Clapham, JC; Holder, JC; Lister, CA; Moore, GB; Piercy, V; Smith, SA | 1 |
| Algenstaedt, P; Hamann, A | 1 |
| Travaglini, MT; Werner, AL | 1 |
| Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T | 1 |
| Birkeland, KI | 1 |
| Finegood, DT; Topp, BG | 1 |
| Zinman, B | 1 |
| Cusi, K; DeFronzo, RA; Glass, L; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y; Triplitt, C | 1 |
| Chen, CL; Chuang, LM; Funahashi, T; Jeng, CY; Matsuzawa, Y; Tai, TY; Tanaka, S; Wang, JP; Wu, TJ; Yang, WS | 1 |
| Berg, AH; Berger, J; Charron, MJ; Chatterjee, K; Combs, TP; Doebber, T; Gertz, BJ; Gottesdiener, KM; Larson, PJ; Moller, DE; O'Rahilly, S; Savage, DB; Scherer, PE; Tanen, M; Wagner, JA; Wang, WJ; Weiss, S; Zhang, BB | 1 |
| Lotz, N | 1 |
| Befroy, D; Cline, GW; Dufour, S; Enocksson, S; Hundal, RS; Inzucchi, SE; Lebon, V; Mayerson, AB; Petersen, KF; Shulman, GI | 1 |
| Groop, L; Ridderstråle, M | 1 |
| Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Boyle, PJ; King, AB; Lau, H; Magar, R; Marchetti, A; Martin, J; Olansky, L | 1 |
| Berrebi-Bertrand, I; Bril, A; Buckingham, RE; Delerive, P; Khandoudi, N; Staels, B | 1 |
| Freed, MI; Kreider, M; Lebovitz, HE | 1 |
| Lawrence, IG | 1 |
| Greenberg, AS; Pittas, AG | 1 |
| Valensi, P | 1 |
| O'Moore-Sullivan, TM; Prins, JB | 1 |
| Kiayias, JA; Lakka-Papadodima, E; Theodosopoulou, E; Vlachou, ED | 1 |
| Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM | 1 |
| Anderson, JW; Frederich, RC; Konz, EC; Reynolds, LR | 1 |
181 review(s) available for rosiglitazone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mass Screening; Metformin; Obesity; Prediabetic State; Preventive Health Services; Randomized Controlled Trials as Topic; Rosiglitazone | 2022 |
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2022 |
Thiazolidinediones: the Forgotten Diabetes Medications.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2019 |
Youth-onset type 2 diabetes: translating epidemiology into clinical trials.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Life Style; Male; Metformin; Prospective Studies; Rosiglitazone; Translational Science, Biomedical; Young Adult | 2021 |
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Pioglitazone; PPAR delta; PPAR gamma; PPAR-beta; Rosiglitazone; Thiazolidinediones | 2017 |
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Memory Disorders; Metformin; Piperidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2017 |
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vildagliptin | 2017 |
Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Patient Safety; Risk; Rosiglitazone | 2018 |
Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Lipids; Prognosis; Rosiglitazone | 2018 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins | 2019 |
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; Microcirculation; Preventive Medicine; Ramipril; Risk Factors; Rosiglitazone; Treatment Outcome | 2019 |
An overview of Canadian and U.S. approaches to drug regulation and responses to postmarket adverse drug reactions.
Topics: Canada; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Humans; Hypoglycemic Agents; Patient Safety; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Is there U-turn from insulin back to pills in diabetes?
Topics: Administration, Oral; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones | 2014 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pharmacogenetics; Pioglitazone; Piperidines; Polymorphism, Genetic; Prediabetic State; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2014 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.
Topics: Adipose Tissue; Animals; Cachexia; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Muscular Atrophy; Neoplasms; Nutritional Support; Proteins; Rosiglitazone; Thiazolidinediones | 2014 |
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Rosiglitazone; Thiazolidinediones | 2016 |
Type 2 diabetes: a well-characterised but suboptimally controlled disease. Can we bridge the divide?
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Reference Values; Rosiglitazone; Thiazolidinediones | 2008 |
The cardiovascular safety of rosiglitazone.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2008 |
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Topics: Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
The safety of rosiglitazone in the treatment of type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Cardiovascular risk of rosiglitazone: another perspective.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Monitoring; Edema; Humans; Hypoglycemic Agents; Patient Selection; Risk Factors; Rosiglitazone; Thiazolidinediones; Weight Gain | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Topics: Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Ligands; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Effects of thiazolidinediones beyond glycaemic control.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Vascular Diseases | 2009 |
Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
[Insulin sensitizing drugs].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2009 |
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipoproteins; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides | 2009 |
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Quinolines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2009 |
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2009 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance | 2009 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Practice Guidelines as Topic; Prognosis; Risk Assessment; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2009 |
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Thiazolidinediones and the liver in humans.
Topics: Diabetes Mellitus, Type 2; Fats; Fatty Liver; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gluconeogenesis; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Pioglitazone; PPAR gamma; Quinolines; Retinoid X Receptors; Rosiglitazone; Sulfonamides; Thiazolidinediones | 2010 |
Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Topics: Animals; Bone Density; Cell Differentiation; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Osteoporosis; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Disease Progression; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Prediabetic State; Rosiglitazone; Thiazolidinediones; Weight Loss | 2010 |
The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.
Topics: C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Neoplasms; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2011 |
Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
Topics: Animals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucagon-Like Peptide 1; Heart Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; Models, Statistical; Myocardial Infarction; Outcome Assessment, Health Care; Pregnancy; Risk; Rosiglitazone; Thiazolidinediones | 2012 |
A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.
Topics: Asian People; Blood Glucose; Body Mass Index; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Pioglitazone; Prevalence; Rosiglitazone; Thiazolidinediones | 2011 |
The safety of thiazolidinediones.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2011 |
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Prognosis; Publication Bias; Risk Factors; Rosiglitazone; Thiazolidinediones | 2011 |
Mitochondrial function in skeletal muscle in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Electron Transport; Humans; Hyperglycemia; Hypoglycemic Agents; Life Style; Mitochondria; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Oxidative Stress; Oxygen Consumption; Rosiglitazone; Saponins; Thiazolidinediones | 2011 |
Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Meta-Analysis as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
Meta-analysis of incidence of rare events.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2013 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; PPAR gamma; Protein Binding; Rosiglitazone; Thiazolidinediones | 2013 |
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2012 |
After avandia: the use of antidiabetic drugs in patients with heart failure.
Topics: Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Myocardium; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2012 |
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
Topics: Adult; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Humans; Incidence; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2012 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Intestinal Absorption; Liver; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2002 |
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuresis; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
The glitazones: a new treatment for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dosage Forms; Drug Monitoring; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United Kingdom | 2002 |
The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2003 |
Polycystic ovary syndrome and insulin resistance.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; Women's Health | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
Topics: Administration, Oral; Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Combination agents for diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Pre-diabetes, insulin resistance, inflammation and CVD risk.
Topics: Age Factors; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Humans; Inflammation; Insulin Resistance; Prediabetic State; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones | 2003 |
Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.
Topics: Aged; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Thiazolidinediones | 2003 |
Thiazolidinediones and blood lipids in type 2 diabetes.
Topics: Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linear Models; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2003 |
The "glitazones": rosiglitazone and pioglitazone.
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Female; Heart Failure; Humans; Hypoglycemic Agents; Lactation; Pioglitazone; Pregnancy; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2003 |
Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Topics: Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
Topics: Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Health Services Research; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosiglitazone; State Medicine; Thiazolidinediones; Treatment Outcome; United Kingdom | 2004 |
[Future targets in the treatment of type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Glycogen Synthase Kinase 3; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Peroxidation; Metabolic Syndrome; Mice; Oxazines; Peptide Fragments; Phenylpropionates; Protein Precursors; Rats; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors | 2004 |
Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2004 |
[Heart, diabetes and glitazones].
Topics: Contraindications; Diabetes Mellitus, Type 2; Edema; Heart; Heart Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazolidinediones | 2004 |
[Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Lipids; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2004 |
[Cardiovascular effects of rosiglitazone].
Topics: Cardiovascular Diseases; Cardiovascular System; Cause of Death; Diabetes Mellitus, Type 2; Drug Monitoring; Edema; France; Heart Failure; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Morbidity; Primary Prevention; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2004 |
Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
[Glucose-independent impact of the glitazones on the cardiovascular outcome].
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Middle Aged; Obesity; Pioglitazone; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2002 |
The Clinical Significance of PPAR Gamma Agonism.
Topics: Animals; Blood Glucose; Blood Pressure; Cardiovascular System; Coagulants; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Models, Chemical; Obesity; Phenotype; Pioglitazone; PPAR gamma; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hyperlipidemias; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Rational drug design and PPAR agonists.
Topics: Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipogenesis; Allosteric Regulation; AMP-Activated Protein Kinases; Animals; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Design; Energy Intake; Energy Metabolism; Enzyme Activation; Fatty Acids; Glucose; Homeostasis; Humans; Hypothalamus; Lipogenesis; Mammals; Metformin; Models, Biological; Multienzyme Complexes; Myocardium; Obesity; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Subunits; Rosiglitazone; Thiazolidinediones | 2006 |
The role of PPARs in the microvascular dysfunction in diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Microcirculation; Nitric Oxide; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Skin; Thiazolidinediones; Vasculitis | 2006 |
Thiazolidinedione derivatives in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Models, Economic; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones; United Kingdom | 2006 |
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
Topics: Administration, Oral; Adult; Aged; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Germany; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Models, Economic; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones | 2006 |
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Topics: Adult; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Spain; Thiazolidinediones | 2006 |
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone | 2006 |
Thiazolidinediones and the risk of edema: a meta-analysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
[Experiences of the DREAM trial].
Topics: Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Incidence; Insulin Resistance; Male; Middle Aged; Prospective Studies; Ramipril; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Odds Ratio; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Muscle, Skeletal; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2007 |
The rosiglitazone meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone for type 2 diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Interventions for latent autoimmune diabetes (LADA) in adults.
Topics: Adult; Autoimmune Diseases; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Hypoglycemic Agents; Metformin; Prediabetic State; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
Future directions for insulin sensitizers in disease prevention.
Topics: Animals; Anti-Inflammatory Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Mice; Mice, Knockout; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Topics: Cardiac Output, Low; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Topics: Adipokines; Animals; Atherosclerosis; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
[What about the controversy regarding rosiglitazone].
Topics: Advisory Committees; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Troglitazone | 2007 |
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
[Therapy with glitazones--a risk for cardiovascular disease?].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk: weighing recent evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone : a review of its use in type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Topics: Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2008 |
The anti-atherogenic effects of thiazolidinediones.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypolipidemic Agents; Kidney; Lipid Metabolism; Models, Biological; Pioglitazone; Postmenopause; Rosiglitazone; Thiazolidinediones | 2007 |
Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Prediabetic State; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Middle Aged; Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides | 2008 |
Pleiotropic effects of thiazolidinediones.
Topics: Atherosclerosis; Body Fat Distribution; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Polypharmacy; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone | 2000 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2000 |
The glitazones: proceed with caution.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 2000 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Topics: Aged; Area Under Curve; Biological Availability; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Diabetes in elderly adults.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Female; Glyburide; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2001 |
New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Topics: Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Peptide Fragments; Protein Precursors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Rosiglitazone.
Topics: Animals; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
[Thiazolidinediones: clinical data and perspectives].
Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Thiazolidinediones: a comparative review of approved uses.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gene Expression Regulation; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazone--a new class of drugs for the treatment of type 2 diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
A review of rosiglitazone in type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone and rosiglitazone for diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Beta-cell deterioration--prospects for reversal or prevention.
Topics: Animals; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Lipids; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Insulin resistance and beta-cell function--a clinical perspective.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Thiazolidinediones in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Rosiglitazone: clinical data].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
[Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Topics: Albuminuria; Animals; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Plasminogen Activator Inhibitor 1; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinediones and type 2 diabetes: new drugs for an old disease.
Topics: Adult; Aged; Australia; Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Medication of the month. Rosiglitazone (Avandia)].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Prognosis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
314 trial(s) available for rosiglitazone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.
Topics: Adolescent; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucokinase; Hepatocyte Nuclear Factor 4; Humans; Insulin Resistance; Insulin-Secreting Cells; Life Style; Longitudinal Studies; Male; Metformin; Mutation; Pediatric Obesity; Risk Reduction Behavior; Rosiglitazone | 2020 |
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Male; Metformin; Risk Reduction Behavior; Rosiglitazone | 2020 |
Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes.
Topics: Adolescent; Beverages; Body Mass Index; Cardiometabolic Risk Factors; Child; Diabetes Mellitus, Type 2; Diet; Diet Records; Dietary Sugars; Drug Combinations; Energy Intake; Female; Humans; Life Style; Longitudinal Studies; Male; Metformin; Rosiglitazone; Surveys and Questionnaires; Sweetening Agents; Thiazoles | 2020 |
Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rosiglitazone | 2021 |
Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Intestinal Mucosa; Male; Metformin; Middle Aged; Rats; Rosiglitazone; Thiazolidinediones | 2017 |
Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study.
Topics: Adolescent; Biomarkers; Cardiovascular Diseases; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet Therapy; Drug Therapy, Combination; Echocardiography; Exercise Therapy; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypoglycemic Agents; Male; Metformin; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Ventricular Function, Left | 2018 |
Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study.
Topics: Aged; Blood Glucose; Blood Pressure; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Exercise Test; Exercise Tolerance; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Rest; Rosiglitazone | 2018 |
Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes.
Topics: Biomarkers; Bone and Bones; Bone Remodeling; Collagen Type I; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Male; Metformin; Middle Aged; Peptide Fragments; Peptides; Procollagen; Rosiglitazone | 2018 |
Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study.
Topics: Adolescent; Androgens; Aspartate Aminotransferases; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Estradiol; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Menstruation Disturbances; Metformin; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone | 2018 |
Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes.
Topics: Acarbose; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds | 2018 |
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Substitution; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Postmenopause; Rosiglitazone; Thiazolidinediones | 2013 |
The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Lipoproteins; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2013 |
Discordant effects of rosiglitazone on novel inflammatory biomarkers.
Topics: Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lymphotoxin beta Receptor; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Rosiglitazone; Thiazolidinediones | 2013 |
Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
Topics: Aged; Aryldialkylphosphatase; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Malondialdehyde; Metabolome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2013 |
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Aged; Angioplasty; Comorbidity; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2013 |
Carbamylation of LDL and its relationship with myeloperoxidase in type 2 diabetes mellitus.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Lipoproteins, LDL; Male; Middle Aged; Peroxidase; Rosiglitazone; Thiazolidinediones | 2014 |
Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study.
Topics: Administration, Oral; Adult; Biomarkers; Blood Glucose; Case-Control Studies; Cholecalciferol; Diabetes Mellitus, Type 2; Dietary Supplements; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Saudi Arabia; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Vitamin D; Young Adult | 2013 |
Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Antioxidants; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Insulin-Secreting Cells; Lipids; Male; Malondialdehyde; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Thioctic Acid; Time Factors | 2013 |
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Calcium-Binding Proteins; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2014 |
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Genotype; Glucuronosyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Peroxisome Proliferator-Activated Receptors; Polymorphism, Genetic; Propionates; Rosiglitazone; Thiazoles; Thiazolidinediones | 2014 |
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glutamine; Humans; Hypoglycemic Agents; Lactic Acid; Lipoproteins; Male; Middle Aged; Myocardium; PPAR gamma; Rosiglitazone; Thiazolidinediones; Time Factors | 2014 |
Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Topics: Absorptiometry, Photon; Adipokines; Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Glucose; Humans; Intra-Abdominal Fat; Liver; Male; Obesity; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Remodeling; Cell Lineage; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Osteoclasts; Postmenopause; Rosiglitazone; Stem Cells; Thiazolidinediones | 2014 |
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Topics: Aged; Animals; Aorta; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pioglitazone; Rabbits; Rosiglitazone; Thiazolidinediones; Vasodilation | 2014 |
Cancer and bone fractures in observational follow-up of the RECORD study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Thromboplastin | 2015 |
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; United States; United States Department of Veterans Affairs | 2015 |
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Longitudinal Studies; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2015 |
Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones; Troponin | 2016 |
Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint.
Topics: Cortical Bone; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Femur Neck; Fractures, Bone; Humans; Hypoglycemic Agents; Longitudinal Studies; Postmenopause; Risk Factors; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed | 2016 |
Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes.
Topics: Adiposity; Adult; Aged; Body Mass Index; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Waist Circumference | 2016 |
Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes.
Topics: Adiposity; Adult; Aged; Albuminuria; Blood Pressure; Body Size; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypogonadism; Intra-Abdominal Fat; Lipids; Longitudinal Studies; Male; Middle Aged; Pilot Projects; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Treatment Outcome; Up-Regulation | 2008 |
Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test.
Topics: Adult; Area Under Curve; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Metformin; Prospective Studies; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2008 |
[Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes].
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
[Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study].
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Rosiglitazone; Thiazolidinediones | 2008 |
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelins; Female; Humans; Hypoglycemic Agents; In Vitro Techniques; Inflammation; Male; Mice; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2008 |
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Neovascularization, Pathologic; Patient Selection; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2009 |
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fibrinolysis; Follow-Up Studies; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2008 |
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.
Topics: Adiponectin; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Echocardiography, Doppler, Pulsed; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Malondialdehyde; Metformin; Middle Aged; Myocardial Contraction; Myocardium; Oxidative Stress; Pilot Projects; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States; Veterans | 2009 |
The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.
Topics: Adult; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise Test; Fibrinolytic Agents; Heart; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Reproducibility of Results; Research Design; Rosiglitazone; Thiazolidinediones; Triglycerides; Young Adult | 2009 |
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Rosiglitazone; Stents; Thiazolidinediones; Vasodilator Agents | 2009 |
[Effects of combined treatment with rosiglitazone and intermediate-acting insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin, Isophane; Lipids; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Liraglutide; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
Topics: Adult; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fruit; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Momordica charantia; N-Acetylneuraminic Acid; Phytotherapy; Plant Preparations; Rosiglitazone; Thiazolidinediones; Triglycerides | 2009 |
Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Blood Glucose; C-Reactive Protein; Cohort Studies; Coronary Vessels; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Middle Aged; Myocardium; Positron-Emission Tomography; Reactive Nitrogen Species; Rosiglitazone; Thiazolidinediones; Tyrosine; von Willebrand Factor | 2009 |
Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Male; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Patient Satisfaction; Piperidines; Rosiglitazone; Tablets; Thiazolidinediones; Young Adult | 2009 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Fibroblast Growth Factors; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2009 |
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.
Topics: Adiponectin; Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intracellular Space; Male; Metformin; Middle Aged; Molecular Weight; Protein Isoforms; Protein Multimerization; Rosiglitazone; Substrate Specificity; Thiazolidinediones; Young Adult | 2009 |
Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Imaging, Three-Dimensional; Magnetic Resonance Angiography; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2009 |
Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2009 |
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Transaminases; Treatment Outcome | 2010 |
Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
Topics: Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Vascular Resistance | 2009 |
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Pilot Projects; Pioglitazone; Placebos; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Solubility; Thiazolidinediones | 2010 |
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coron
Topics: Adult; Aged; Angina Pectoris; Atherosclerosis; Blood Glucose; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Postoperative Complications; Prospective Studies; Quebec; Rosiglitazone; Spain; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2009 |
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liver Diseases; Male; Metformin; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Insulin; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2010 |
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Topics: Adult; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Time; Treatment Outcome; Weight Gain | 2010 |
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Topics: Adipokines; Aged; Apelin; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Ghrelin; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio | 2010 |
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Topics: Adamantane; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Pioglitazone; Rosiglitazone; Thiazolidinediones; Young Adult | 2009 |
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Resorption; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Rosiglitazone; Thiazolidinediones | 2010 |
Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.
Topics: Aged; Body Composition; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2010 |
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neuroprotective Agents; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Venoms; Weight Gain | 2010 |
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2010 |
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiov
Topics: Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2010 |
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
Topics: Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Diabetes Mellitus, Type 2; Double-Blind Method; Ethnicity; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Osteogenesis; Peptide Fragments; Peptides; Postmenopause; PPAR gamma; Procollagen; Reference Values; Rosiglitazone; Texas; Thiazolidinediones | 2010 |
Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study.
Topics: Blood Pressure; Cardiovascular System; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Systole; Thiazolidinediones | 2010 |
Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Cognition; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Thiazolidinediones | 2010 |
Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.
Topics: Adult; Aged; Capillary Permeability; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Vasodilation | 2010 |
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines; Treatment Outcome | 2010 |
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk; Rosiglitazone; Saphenous Vein; Thiazolidinediones | 2010 |
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Exercise Test; Female; Humans; Hypoglycemic Agents; Magnetic Resonance Angiography; Male; Middle Aged; Oxygen Consumption; Plasma Volume; Rosiglitazone; Stroke Volume; Thiazolidinediones; Treatment Outcome | 2010 |
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones | 2011 |
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Ramipril; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2010 |
Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Lipids; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Rosiglitazone; Serpins; Thiazolidinediones | 2011 |
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Carbamates; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; KCNQ1 Potassium Channel; Male; Middle Aged; Pharmacogenetics; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones | 2011 |
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Topics: Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Quality of Life; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States | 2011 |
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2011 |
The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adult; C-Peptide; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Interleukin-6; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Incidence of diabetes following ramipril or rosiglitazone withdrawal.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Ramipril; Rosiglitazone; Substance Withdrawal Syndrome; Thiazolidinediones; Treatment Outcome | 2011 |
Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment.
Topics: Aged; Biomarkers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Edema; Exercise Test; Female; Heart Failure; Hematocrit; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxygen Consumption; Plasma Volume; Prospective Studies; Rosiglitazone; Serum Albumin; Single-Blind Method; Stroke Volume; Texas; Thiazolidinediones; Time Factors; Ventricular Function; Weight Gain | 2011 |
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebo Effect; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States | 2011 |
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.
Topics: Diabetes Mellitus, Type 2; Incidence; Myocardial Infarction; Prevalence; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Greece; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Vasodilation | 2011 |
Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Topics: Administration, Oral; Adult; Anthropometry; Asian People; Body Composition; China; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Young Adult | 2011 |
Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Osteoprotegerin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholecalciferol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Neoplasms; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Acid-Binding Proteins; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Receptor Cross-Talk; Rosiglitazone; Thiazolidinediones | 2011 |
A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; N-Acetylneuraminic Acid; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2012 |
The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial.
Topics: Aged; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Linear Models; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardium; Placebos; Prevalence; Prospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Stroke Volume; Texas; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides; Ventricular Function, Left | 2012 |
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Rosiglitazone decreases fasting plasma peptide YY3-36 in type 2 diabetic women: a possible role in weight gain?
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Down-Regulation; Fasting; Female; Humans; Middle Aged; Peptide YY; Rosiglitazone; Thiazolidinediones; Weight Gain | 2012 |
[Investigation of amylin level changes among obese patients at different glucose metabolic states and effects of rosiglitazone intervention].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2011 |
[Puerarin combined with avandia for diabetic nephropathy].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Isoflavones; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2012 |
Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.
Topics: Carbamates; Cation Transport Proteins; China; Diabetes Mellitus, Type 2; Female; Gene Frequency; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones; Zinc Transporter 8 | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Failure; Weight Loss | 2012 |
Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study.
Topics: Adult; Age of Onset; Aged; Algorithms; Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2012 |
Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Pilot Projects; PPAR gamma; Proteinuria; Renal Circulation; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2012 |
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Receptors, Glucagon; Rosiglitazone; Thiazolidinediones; Venoms | 2012 |
Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.
Topics: Adult; Aged; Amiloride; Diabetes Mellitus, Type 2; Diuretics; Edema; Female; Humans; Male; Middle Aged; Rosiglitazone; Spironolactone; Thiazolidinediones | 2013 |
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
Topics: Adult; Aged; Autoantibodies; Autoimmunity; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Immunosuppression Therapy; Interferon-gamma; Interleukin-12; Islets of Langerhans; Male; Middle Aged; PPAR gamma; Rosiglitazone; T-Cell Antigen Receptor Specificity; T-Lymphocytes; Thiazolidinediones | 2013 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glyburide; Humans; Hypoglycemic Agents; Metformin; Research Design; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Treatment Outcome | 2002 |
Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Composition; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; North America; Pyrroles; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome | 2002 |
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Physiological Phenomena; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Racial Groups; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Ventricular Function, Left | 2002 |
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Fasting; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leg; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Radionuclide Imaging; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lactates; Lipids; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Weight Loss | 2003 |
An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Apolipoproteins; Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Serum Amyloid A Protein; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; CD40 Ligand; Coronary Artery Disease; Diabetes Mellitus, Type 2; E-Selectin; Female; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Receptors, Interleukin-2; Reference Values; Rosiglitazone; Solubility; Thiazoles; Thiazolidinediones; Time; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Environmental Exposure; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Hepatitis B; Hepatitis C; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Rosiglitazone; Safety; Single-Blind Method; Thiazolidinediones; Time Factors | 2003 |
The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Korea; Lipids; Lipoprotein(a); Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
A "futile cycle" induced by thiazolidinediones in human adipose tissue?
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Carrier Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Activation; Fasting; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Glycerol; Glycerol Kinase; Humans; Hypoglycemic Agents; Insulin; Mice; Middle Aged; Neoplasm Proteins; Nerve Tissue Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Tumor Suppressor Proteins | 2003 |
Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteries; Blood Glucose; Blood Pressure; Compliance; Diabetes Mellitus, Type 2; Elasticity; Female; Heart Rate; Humans; Hyperinsulinism; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Weight Gain | 2003 |
Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Isoenzymes; Male; Middle Aged; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoproteins; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Topics: Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Male; Middle Aged; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Tyrosine | 2003 |
Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
Topics: Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Entropy; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Rosiglitazone; Stimulation, Chemical; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.
Topics: Blood Pressure; Compliance; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Postmenopause; Rosiglitazone; Thiazolidinediones | 2003 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycolysis; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2003 |
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Topics: Acetylcholine; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Fasting; Female; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Reference Values; Rosiglitazone; Thiazolidinediones | 2004 |
Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
Topics: Adult; Aged; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructosamine; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin, Isophane; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2003 |
Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
Topics: Adult; Aged; Area Under Curve; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lactation; Liver; Male; Metformin; Middle Aged; Pregnancy; Rosiglitazone; Tablets; Thiazolidinediones | 2004 |
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain | 2004 |
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pioglitazone; Rosiglitazone; Simvastatin; Thiazolidinediones | 2004 |
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Stents; Thiazolidinediones | 2004 |
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
Topics: Acetylcholine; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Forearm; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones | 2004 |
Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Evidence for a potent antiinflammatory effect of rosiglitazone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I-kappa B Proteins; Insulin; Insulin Resistance; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Male; Middle Aged; NF-kappa B; Obesity; Rosiglitazone; Solubility; Thiazolidinediones; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population.
Topics: Algorithms; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Los Angeles; Male; Metformin; Middle Aged; Minority Groups; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2004 |
Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Male; Middle Aged; Placebos; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Topics: Adipose Tissue; Cholesterol; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Cushing Syndrome; Diabetes Mellitus, Type 2; Female; Humans; Hydrocortisone; Hypoglycemic Agents; Immunohistochemistry; Ligands; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2004 |
Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone.
Topics: Aged; Blood Pressure; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Estradiol; Female; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Postmenopause; Progesterone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Middle Aged; Proinsulin; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
Topics: Adult; Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2004 |
Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes.
Topics: Adiponectin; Adult; Black or African American; Blood Glucose; Blood Pressure; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Intercellular Signaling Peptides and Proteins; Islets of Langerhans; Lipids; Longitudinal Studies; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardium; Positron-Emission Tomography; PPAR gamma; Rosiglitazone; Statistics, Nonparametric; Stimulation, Chemical; Thiazolidinediones | 2004 |
Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Proinsulin; Rosiglitazone; Thiazolidinediones | 2004 |
Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes.
Topics: Administration, Oral; Adult; Aged; Alberta; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Evaluation Studies as Topic; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Compliance; Reference Values; Risk Assessment; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2004 |
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Muscle, Skeletal; Placebos; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Korea; Male; Middle Aged; Patient Selection; Rosiglitazone; Thiazolidinediones | 2005 |
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2004 |
Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.
Topics: Acetylcholine; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Forearm; Hematocrit; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vasodilation; Vasodilator Agents | 2005 |
Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.
Topics: Adipose Tissue; Biological Transport; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Female; Gene Expression; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidation-Reduction; Oxidative Phosphorylation; Rosiglitazone; Thiazolidinediones; Troglitazone; Up-Regulation | 2005 |
The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Homeostasis; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones | 2005 |
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Topics: Adult; Anti-HIV Agents; Australia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Vasodilation | 2005 |
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
Topics: Aged; Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Electrolytes; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Kidney; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2005 |
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.
Topics: Adipocytes; Adiponectin; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Intercellular Signaling Peptides and Proteins; Male; Matched-Pair Analysis; Middle Aged; Models, Biological; PPAR gamma; Proteinuria; Reference Values; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Postprandial Period; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Health Services; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Kinetics; Mutation; PPAR gamma; Reference Values; Rosiglitazone; Stearoyl-CoA Desaturase; Thiazolidinediones | 2005 |
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones | 2005 |
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Chemokine CCL2; Chemokines; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Inflammation; Lipopolysaccharides; Male; Middle Aged; Monocytes; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tissue Plasminogen Activator | 2005 |
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Topics: Aged; Blood Pressure; Body Size; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2005 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Topics: Aged; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.
Topics: Adipose Tissue; Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Middle Aged; Muscle, Skeletal; Organ Specificity; Receptors, Adiponectin; Receptors, Cell Surface; Regional Blood Flow; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2005 |
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipid Metabolism; Middle Aged; PPAR alpha; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides; Uric Acid | 2006 |
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Rosiglitazone; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.
Topics: Administration, Inhalation; Adult; Aged; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Patient Selection; Research Design; Rosiglitazone; Thiazolidinediones | 2005 |
Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Polymorphism, Genetic; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.
Topics: Aged; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Myocardium; Rosiglitazone; Thiazolidinediones | 2005 |
The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Topics: Aged; Arteriosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fibrinogen; Homocysteine; Humans; Hypertension; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Triglycerides | 2005 |
Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Leukocyte Count; Leukocytes; Male; Middle Aged; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis.
Topics: Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Injections, Subcutaneous; Insulin; Insulin Resistance; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Thiazolidinediones; Uremia; Weight Gain | 2005 |
Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Topics: Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Perfusion; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow; Rosiglitazone; Subcutaneous Tissue; Thiazolidinediones | 2005 |
Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.
Topics: Adiponectin; Adipose Tissue; Adult; Black or African American; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Obesity; Pilot Projects; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2005 |
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects.
Topics: Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Selectins; Thiazolidinediones | 2005 |
Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Mass Index; Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Fasting; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Middle Aged; Oxygen Consumption; Physical Fitness; Rosiglitazone; Thiazolidinediones | 2005 |
The impact of rosiglitazone on heat tolerance in patients with type 2 diabetes.
Topics: Aged; Body Temperature Regulation; Diabetes Mellitus, Type 2; Hot Temperature; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Skin Temperature; Thiazolidinediones | 2005 |
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
Topics: Adiponectin; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Proinsulin; Prospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
Topics: Adolescent; Adult; Aged; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones | 2006 |
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides | 2006 |
Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Tract; Humans; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2005 |
Effect of rosiglitazone on early-morning plasma cortisol levels.
Topics: Circadian Rhythm; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hydrocortisone; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Improving metabolic control leads to better working memory in adults with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Memory; Metformin; Middle Aged; Psychological Tests; Rosiglitazone; Stress, Psychological; Thiazolidinediones | 2006 |
The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Homeostasis; Humans; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Tissue Plasminogen Activator | 2006 |
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Rosiglitazone; Tablets; Thiazolidinediones; Treatment Outcome | 2006 |
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2006 |
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents | 2006 |
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
Topics: Aged; Atherosclerosis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Middle Aged; NF-kappa B; Oxidative Stress; PPAR gamma; Proteasome Endopeptidase Complex; Rosiglitazone; Superoxides; Thiazolidinediones; Ubiquitin | 2006 |
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Prevention of type 2 diabetes in the prediabetic population.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Prediabetic State; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipid Metabolism; Lipids; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
Topics: Adiponectin; Aged; Blood Glucose; Body Mass Index; Cohort Studies; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Ligands; Lipids; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocystine; Humans; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2006 |
Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone.
Topics: Adipose Tissue; Binding Sites; Biological Transport; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Insulin; Kinetics; Lipoprotein Lipase; Muscle, Skeletal; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; Research Design; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2006 |
Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.
Topics: Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Leukocyte Count; Male; Middle Aged; Patient Compliance; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Compliance; Rosiglitazone; Thiazolidinediones | 2006 |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2006 |
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Effect of various diuretic treatments on rosiglitazone-induced fluid retention.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Edema; Extracellular Fluid; Female; Furosemide; Hematocrit; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Male; Middle Aged; Plasma Volume; Rosiglitazone; Spironolactone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; PPAR gamma; Renal Circulation; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones | 2006 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; North America; Racial Groups; Rosiglitazone; Sex Distribution; Thiazolidinediones | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Waist-Hip Ratio; Weight Gain | 2006 |
Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Female; Gene Expression; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
Topics: Black People; Blood Glucose; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Liver; Longitudinal Studies; Middle Aged; Pilot Projects; Rosiglitazone; Thiazolidinediones | 2007 |
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.
Topics: Adult; Aryldialkylphosphatase; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Fasting; Female; Humans; Hypoglycemic Agents; Lipid Peroxides; Male; Postprandial Period; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects.
Topics: C-Reactive Protein; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Middle Aged; Prospective Studies; Renal Dialysis; Rosiglitazone; Safety; Thiazolidinediones; Virus Diseases | 2007 |
Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.
Topics: Adiponectin; Blood Glucose; Body Water; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Fenofibrate; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Single-Blind Method; Thiazolidinediones | 2007 |
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2006 |
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
Topics: Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Male; Metformin; Pioglitazone; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Administration Schedule; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-18; Interleukin-6; Metformin; Multivariate Analysis; Resistin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Health Status; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Psychometrics; Quality of Life; Rosiglitazone; Surveys and Questionnaires; Thiazolidinediones | 2007 |
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Edema; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Rosiglitazone; Thiazolidinediones; Vildagliptin | 2007 |
Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima | 2007 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Multivariate Analysis; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media; Vasodilator Agents | 2007 |
Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Topics: Biopsy; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2007 |
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
Topics: Administration, Oral; Belgium; Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; European Union; Glyburide; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Quality of Life; Rosiglitazone; Thiazolidinediones; Treatment Outcome; United States | 2007 |
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Irbesartan; Leptin; Lipids; Male; Middle Aged; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2006 |
Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
Topics: Aged; Cardiac Output, Low; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Ventricular Function, Left; Water-Electrolyte Balance | 2007 |
Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Middle Aged; Principal Component Analysis; Rosiglitazone; Thiazolidinediones | 2007 |
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Topics: Adiponectin; Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Irbesartan; Lipids; Male; Metabolic Syndrome; Resistin; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Topics: Adult; Aged; Australia; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; New Zealand; Prospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Myocardial Infarction; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arteries; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Middle Aged; Pulsatile Flow; Ramipril; Rosiglitazone; Stroke Volume; Thiazolidinediones; Vascular Diseases | 2007 |
Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Aged; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women.
Topics: Alkaline Phosphatase; Body Composition; Body Mass Index; Bone and Bones; Bone Remodeling; Diabetes Mellitus, Type 2; Female; Haptoglobins; Humans; Hypoglycemic Agents; Interleukin-1beta; Interleukin-6; Middle Aged; Postmenopause; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones | 2007 |
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
Topics: Adiponectin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2008 |
Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Prediabetic State; Ramipril; Rosiglitazone; Thiazolidinediones | 2007 |
The effect of rosiglitazone on orthostatic tolerance during heat exposure in individuals with type II diabetes.
Topics: Aged; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heart Rate; Hot Temperature; Humans; Hypoglycemic Agents; Hypotension, Orthostatic; Microcirculation; Middle Aged; Posture; Reference Values; Rosiglitazone; Skin; Thiazolidinediones | 2007 |
Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Echocardiography; Female; Glycated Hemoglobin; Heart; Heart Function Tests; Humans; Hypoglycemic Agents; Male; Middle Aged; Natriuretic Peptide, Brain; Rosiglitazone; Thiazolidinediones; Ventricular Function, Left | 2007 |
Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Topics: Acarbose; Age of Onset; Aged; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Selection; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
Topics: Adult; Aged; Blood Glucose; Blood Platelets; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidative Stress; Platelet Aggregation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone decreases albuminuria in type 2 diabetic patients.
Topics: Adiponectin; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Linear Models; Middle Aged; Multivariate Analysis; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Blood Flow Velocity; C-Reactive Protein; Chemokine CCL2; Coronary Disease; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Exercise Test; Female; Glucose; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Physical Exertion; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2007 |
Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Topics: 3T3-L1 Cells; Adenoviridae; Adipocytes; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Fibrinolytic Agents; Genetic Vectors; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Plasminogen Activator Inhibitor 1; PPAR gamma; Recombinant Proteins; RNA, Messenger; Rosiglitazone; Serpin E2; Serpins; Sulfonylurea Compounds; Thiazolidinediones; Transduction, Genetic; Treatment Outcome | 2007 |
[Three studies in type 2 diabetes: ADOPT Rosiglitazone monotherapy in type 2 diabetes: what indication?].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazolidinediones | 2007 |
[Three studies in type 2 diabetes: DREAM the wash-out results].
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hyperglycemia; Hypoglycemic Agents; Ramipril; Rosiglitazone; Thiazolidinediones | 2007 |
A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes
Topics: Black or African American; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Glyburide; Hispanic or Latino; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2007 |
[The effect of single nucleotide polymorphism SNP + 45 of the adiponectin gene on the rosiglitazone maleate response in patients with type 2 diabetes].
Topics: Adiponectin; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gene Frequency; Genotype; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
Topics: Adult; Aged; Blood Platelets; Calpain; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Megakaryocytes; Middle Aged; Nitro Compounds; Platelet Endothelial Cell Adhesion Molecule-1; PPAR gamma; Rosiglitazone; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Thiazolidinediones | 2008 |
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Metformin; Obesity; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
[Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
Topics: Adipose Tissue; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Single-Blind Method; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2008 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
Topics: Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Fasting; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pioglitazone; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Blood Volume; Diabetes Mellitus, Type 2; Homeostasis; Humans; Hypoglycemic Agents; Immersion; Kidney; Male; Middle Aged; Natriuresis; Renin; Rosiglitazone; Thiazolidinediones; Water-Electrolyte Imbalance | 2008 |
Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Lipoproteins; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Phosphatidylcholine-Sterol O-Acyltransferase; Predictive Value of Tests; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise; Female; Humans; Hypoglycemic Agents; Male; Metalloproteases; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones | 2008 |
Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Single-Blind Method; Thiazolidinediones | 2008 |
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Leptin; Male; Metformin; Middle Aged; Obesity; Overweight; Resistin; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
Topics: Adiponectin; Arteries; Blood Glucose; Body Mass Index; Capillary Resistance; Diabetes Mellitus, Type 2; Elasticity; Female; Glycemic Index; Humans; Hypoglycemic Agents; Leptin; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones | 2008 |
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
Dysglycemia and a history of reproductive risk factors.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Middle Aged; Ontario; Parity; Poverty; Pregnancy; Pregnancy Complications; Ramipril; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene.
Topics: Diabetes Mellitus, Type 2; Down-Regulation; Exercise; Female; Genotype; Glucose Intolerance; Humans; Hypoglycemic Agents; Interleukin-6; Male; Middle Aged; Physical Endurance; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.
Topics: Adipose Tissue; Animals; Arteries; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Eating; Fasting; Female; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Europe; Female; Fructosamine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.
Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; Middle Aged; Rosiglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones | 2001 |
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides; United States | 2001 |
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Osmolar Concentration; Oxidation-Reduction; Regression Analysis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Topics: Adiponectin; Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multivariate Analysis; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice; Mice, Inbred C57BL; Pilot Projects; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Male; Metformin; Middle Aged; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
Topics: Biomarkers; Blood Pressure; Body Constitution; Body Mass Index; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Obesity; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Loss | 2002 |
693 other study(ies) available for rosiglitazone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Thiazoles | 1994 |
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2001 |
Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.
Topics: Administration, Oral; Animals; Biological Availability; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Isoxazoles; Mice; Mice, Mutant Strains; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Inhibitory Concentration 50; Mice; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors | 2003 |
5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors | 2003 |
Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model.
Topics: Amides; Animals; Biological Availability; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Stability; Female; Humans; In Vitro Techniques; Mice; Microsomes, Liver; Oxazines; Rats; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Structure-Activity Relationship; Transcription Factors | 2004 |
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
Topics: Animals; Benzopyrans; Chromans; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macaca mulatta; Male; Mesocricetus; Mice; Phenyl Ethers; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Structure-Activity Relationship; Trans-Activators; Transcription Factors | 2004 |
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Topics: Adipose Tissue; Administration, Oral; Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Hypolipidemic Agents; Ketones; Lipid Metabolism; Mice; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship | 2004 |
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
Topics: Animals; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Zucker; Structure-Activity Relationship; Triglycerides | 2005 |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Carrier Proteins; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Type 2; Dogs; Fatty Acid-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isoxazoles; Mice; Mice, Obese; PPAR alpha; PPAR gamma; Propionates; Radioligand Assay; RNA, Messenger; Structure-Activity Relationship; Transcriptional Activation; Triglycerides; Weight Gain | 2005 |
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
Topics: Animals; Cricetinae; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dogs; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Models, Animal; Models, Molecular; Molecular Structure; Phenylacetates; PPAR alpha; PPAR delta; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2005 |
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Mice; Phenyl Ethers; Phenylpropionates; PPAR alpha; PPAR delta; PPAR gamma; Radioligand Assay; Stereoisomerism; Transcriptional Activation; Weight Gain | 2006 |
Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.
Topics: Amides; Animals; Combinatorial Chemistry Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Indoles; Molecular Structure; PPAR delta; PPAR gamma; Rats | 2007 |
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
Topics: Acetylation; Allosteric Site; Animals; Blood Glucose; Caloric Restriction; Catalytic Domain; Cell Line; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Drosophila melanogaster; Heterocyclic Compounds, 4 or More Rings; Humans; Insulin; Male; Mice; Mitochondria; Rats; Rats, Sprague-Dawley; Rats, Zucker; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes | 2007 |
Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis.
Topics: Anisoles; Anti-Infective Agents; Chlorine; Diabetes Mellitus, Type 2; Diterpenes; Fungi; Humans; Hydrocarbons, Chlorinated; Magnetic Resonance Spectroscopy; Mass Spectrometry; Methanol; Models, Chemical; Phenyl Ethers; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Topics: Animals; Combinatorial Chemistry Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley | 2008 |
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation | 2008 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Mice; Oximes; PPAR alpha; PPAR gamma; Quinolines; Rats; Structure-Activity Relationship | 2009 |
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
Topics: Animals; Blood Volume; Body Fluids; Diabetes Mellitus, Type 2; Dogs; Haplorhini; Humans; Hypoglycemic Agents; Indoles; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2009 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
Topics: Animals; Caprylates; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Genes, Reporter; Humans; Hydroxyeicosatetraenoic Acids; Hypoglycemic Agents; Kinetics; Metabolic Syndrome; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Quinolines; Recombinant Fusion Proteins; Structure-Activity Relationship; Transcriptional Activation | 2010 |
Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazo
Topics: 3T3-L1 Cells; Animals; Carboxylic Acids; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; PPAR gamma; Pyrimidines; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2010 |
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Topics: Animals; Benzimidazoles; Binding Sites; Chlorocebus aethiops; COS Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dimethadione; Drug Partial Agonism; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Mice; Models, Molecular; Mutagenesis; Nuclear Receptor Coactivators; Oxazoles; Pioglitazone; PPAR gamma; Protein Conformation; Rats; Rats, Zucker; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2011 |
Discovery and characterization of an inhibitor of glucosylceramide synthase.
Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gangliosides; Glucose Tolerance Test; Glucosyltransferases; Humans; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Nude; Phenylalanine; Rats; Rats, Sprague-Dawley; Rats, Zucker; Structure-Activity Relationship; Triglycerides | 2012 |
Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.
Topics: Animals; Benzofurans; Cell Line, Tumor; Chemistry Techniques, Synthetic; Diabetes Mellitus, Type 2; Female; Genes, Reporter; Humans; Hypoglycemic Agents; Models, Molecular; PPAR gamma; Protein Conformation; Rats | 2012 |
Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Chemical; Molecular Structure; Muscle, Skeletal; Rosiglitazone; Structure-Activity Relationship; Thiazines; Thiazolidinediones; Thiazolidines; Triglycerides | 2013 |
Structure-based identification of novel PPAR gamma ligands.
Topics: Benzimidazoles; Benzoates; Databases, Pharmaceutical; Diabetes Mellitus, Type 2; Drug Discovery; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; PPAR gamma; Protein Binding | 2013 |
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Hep G2 Cells; Humans; Indoleacetic Acids; Mice; Mice, Mutant Strains; Molecular Structure | 2015 |
Steroidal Alkaloids from Veratrum nigrum Enhance Glucose Uptake in Skeletal Muscle Cells.
Topics: Alkaloids; Diabetes Mellitus, Type 2; Glucose; Molecular Structure; Muscle, Skeletal; Plant Roots; Plants, Medicinal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Republic of Korea; Rhizome; Rosiglitazone; Stereoisomerism; Steroids; Thiazolidinediones; Veratrum | 2015 |
Cafestol, a Bioactive Substance in Coffee, Stimulates Insulin Secretion and Increases Glucose Uptake in Muscle Cells: Studies in Vitro.
Topics: Alkaloids; Animals; Butylene Glycols; Caffeic Acids; Chlorogenic Acid; Coffee; Diabetes Mellitus, Type 2; Diterpenes; Glucose; Guinea Pigs; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Lignans; Muscle, Skeletal | 2015 |
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.
Topics: 3T3 Cells; Administration, Oral; Animals; Benzamides; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Hypertension; In Vitro Techniques; Metabolic Syndrome; Mice; Microsomes, Liver; PPAR gamma; Rats; Structure-Activity Relationship | 2016 |
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
Topics: 3T3-L1 Cells; Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Design; HEK293 Cells; Humans; Ligands; Lipid Metabolism; Mice; Molecular Docking Simulation; PPAR alpha; PPAR gamma; Small Molecule Libraries | 2015 |
Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Topics: Animals; CHO Cells; Cricetulus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Molecular Docking Simulation; PPAR gamma; Receptors, G-Protein-Coupled; Thiazolidinediones | 2016 |
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Structure; Piperidines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; Spiro Compounds; Structure-Activity Relationship | 2016 |
Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hypoglycemic Agents; Mice; Molecular Structure; Pyrroles; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2018 |
Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
Topics: Animals; Cells, Cultured; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Keto Acids; Microalgae; Molecular Structure; Palmitic Acids; PPAR alpha; PPAR gamma; Structure-Activity Relationship | 2018 |
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Topics: Animals; CHO Cells; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; HEK293 Cells; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Obese; Models, Molecular; Molecular Structure; PPAR delta; PPAR gamma; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2018 |
Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance.
Topics: Anti-Inflammatory Agents; Antioxidants; Aquaporin 2; Cells, Cultured; Coumaric Acids; Diabetes Mellitus, Type 2; Drug Design; Glucose Intolerance; Humans; Kidney Tubules, Collecting; Metabolic Syndrome; Microsomes, Liver; Nitric Oxide Donors; Rosiglitazone | 2019 |
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Topics: 3T3-L1 Cells; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mice; Oxadiazoles; PPAR gamma; Proof of Concept Study; Pyrimidines; Pyrimidinones; Structure-Activity Relationship | 2019 |
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
Topics: Cheminformatics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipids; Peroxisome Proliferator-Activated Receptors; PPAR gamma | 2022 |
18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Biological Products; Cardiotoxicity; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Fatty Acids; Heart; Hypoglycemic Agents; Lipids; Liver; Lysophospholipids; Male; Medicine, Chinese Traditional; Mice; Molecular Docking Simulation; PPAR gamma; Rosiglitazone | 2021 |
Rosiglitazone induces adipogenesis of both marrow and periosteum derived mesenchymal stem cells during endochondral fracture healing.
Topics: Adipogenesis; Animals; Bone Marrow; Cell Differentiation; Diabetes Mellitus, Type 2; Fracture Healing; Mesenchymal Stem Cells; Mice; Osteogenesis; Periosteum; Rosiglitazone; X-Ray Microtomography | 2023 |
Preventive effect of salicin ether against type-2 diabetes mellitus through targeting PPARγ-regulated gene expression.
Topics: AMP-Activated Protein Kinases; Benzyl Alcohols; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Diabetes Mellitus, Type 2; Ether; Gene Expression; Glucosides; Humans; PPAR gamma; Proto-Oncogene Proteins c-akt; Rosiglitazone | 2022 |
Rosiglitazone protects INS-1E cells from human islet amyloid polypeptide toxicity.
Topics: Amyloid; Animals; Apoptosis; Diabetes Mellitus, Type 2; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Rats; Rosiglitazone | 2022 |
Focal Microscopy Observe the Mechanism of Gegen Qinlian Decoction Treating Type 2 Diabetic Nephropathy in Nude Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drugs, Chinese Herbal; Mice; Mice, Nude; Microscopy; Rosiglitazone | 2022 |
Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay.
Topics: Adipogenesis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Pharmacophore; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2023 |
Identification of an allosteric hotspot for additive activation of PPARγ in antidiabetic effects.
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones; Weight Gain | 2021 |
Long-Term High-Fat Diet Decreases Renal Insulin-Degrading Enzyme Expression and Function by Inhibiting the PPARγ Pathway.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Insulin; Insulin Resistance; Insulysin; Kidney; Mice; Mice, Inbred C57BL; Mice, Obese; Palmitic Acid; PPAR gamma; RNA, Messenger; Rosiglitazone | 2023 |
Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Topics: Adult; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Propensity Score; Prostatic Neoplasms; Rosiglitazone | 2023 |
Effects of Moringa Oleifera Leaf Extract Plus Rosiglitazone on Serum Leptin and Glucose and Lipid Metabolism in Type 2 Diabetic Rats.
Topics: Animals; beta Catenin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Leptin; Lipid Metabolism; Lipids; Male; Moringa oleifera; Plant Extracts; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tumor Necrosis Factor-alpha | 2023 |
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice; Niclosamide; Non-alcoholic Fatty Liver Disease; Obesity; Rosiglitazone | 2024 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |
The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Topics: Adult; Aged; Arrhythmias, Cardiac; Databases, Factual; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Medicaid; Middle Aged; Pioglitazone; Protective Factors; Risk Assessment; Risk Factors; Rosiglitazone; Time Factors; Treatment Outcome; United States | 2020 |
Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; beta Catenin; Cell Differentiation; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Insulin; Insulin Resistance; Mice; Molecular Docking Simulation; Phthalimides; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones | 2020 |
Rosiglitazone ameliorates skeletal muscle insulin resistance by decreasing free fatty acids release from adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Asialoglycoproteins; Cell Communication; Coculture Techniques; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin Resistance; Lectins, C-Type; Lipase; Lipid Metabolism; Lipolysis; Membrane Proteins; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Rosiglitazone; Sterol Esterase | 2020 |
Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model.
Topics: Aged; Alzheimer Disease; Animals; Cognition; Diabetes Mellitus, Type 2; Disease Models, Animal; Hippocampus; Humans; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; PPAR gamma; Proteomics; Rosiglitazone | 2021 |
Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies.
Topics: Adipogenesis; Aging; Animals; Bone Diseases, Metabolic; Cell Differentiation; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Fatty Acids, Omega-3; Female; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Primary Cell Culture; RAW 264.7 Cells; Rosiglitazone | 2021 |
Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acid-Binding Proteins; Fatty Liver; Hepatocytes; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Models, Animal; Obesity; Primary Cell Culture; Rosiglitazone; Triglycerides | 2021 |
Human cell-based anti-inflammatory effects of rosiglitazone.
Topics: Anti-Inflammatory Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Humans; Hypoglycemic Agents; Inflammation; Interferon-gamma; Interleukin-8; Myocytes, Cardiac; NF-kappa B; Prognosis; Rosiglitazone; T-Lymphocytes, Helper-Inducer; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2022 |
Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in
Topics: Animals; Biomarkers; Blood Glucose; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Mice; Phlorhizin; Rosiglitazone; Thiazolidinediones | 2017 |
The effects of troglitazone on AMPK in HepG2 cells.
Topics: AMP-Activated Protein Kinases; Chromans; Diabetes Mellitus, Type 2; Enzyme Activation; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Phosphorylation; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2017 |
Activation of PPARγ at an Early Stage of Differentiation Enhances Adipocyte Differentiation of MEFs Derived from Type II Diabetic TSOD Mice and Alters Lipid Droplet Morphology.
Topics: Adipocytes; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Embryo, Mammalian; Fibroblasts; Hypoglycemic Agents; Lipid Droplets; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2017 |
Circulating ApoJ is closely associated with insulin resistance in human subjects.
Topics: Blood Glucose; Clusterin; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2018 |
Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.
Topics: Animals; Antihypertensive Agents; Creatinine; Dependovirus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Female; Genetic Vectors; Hypertension; Hypoglycemic Agents; Janus Kinases; Lac Operon; Lisinopril; Male; Mice; Nephrectomy; Nitric Oxide Synthase Type III; Renin; Rosiglitazone; Serum Albumin; Severity of Illness Index; Signal Transduction; STAT Transcription Factors | 2018 |
Codonopsis lanceolata Water Extract Increases Hepatic Insulin Sensitivity in Rats with Experimentally-Induced Type 2 Diabetes.
Topics: 3T3-L1 Cells; Adiposity; Animals; Biomarkers; Blood Glucose; Codonopsis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Energy Metabolism; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Pancreatectomy; Phosphorylation; Phytotherapy; Plant Extracts; Plants, Medicinal; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Solvents; Thiazolidinediones; Time Factors; Water | 2017 |
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Topics: Alzheimer Disease; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Glucose Tolerance Test; Humans; Insulin; Insulysin; Learning; Mice; Mice, Transgenic; PPAR gamma; Ribonucleotides; Rosiglitazone; Streptozocin; Thiazolidinediones | 2018 |
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Topics: Animals; Antioxidants; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Hypoglycemic Agents; Insulin; Kidney; Lipid Peroxidation; Nicotinamide Phosphoribosyltransferase; Obesity; Oxidative Stress; PPAR gamma; Rats, Wistar; Rosiglitazone; Signal Transduction; Streptozocin | 2018 |
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Hypoglycemic Agents; Insulin Resistance; Male; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Spectrophotometry, Atomic; Thiazolidinediones; Trace Elements | 2018 |
Rosiglitazone rescues human neural stem cells from amyloid-beta induced ER stress via PPARγ dependent signaling.
Topics: Amyloid beta-Peptides; Cell Survival; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neural Stem Cells; Neurons; Neuroprotective Agents; PPAR gamma; Rosiglitazone | 2018 |
Cited4 is a sex-biased mediator of the antidiabetic glitazone response in adipocyte progenitors.
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Mice; Molecular Targeted Therapy; PPAR gamma; Rosiglitazone; Sex Factors; Stem Cells; Thermogenesis; Transcription Factors; Transcription, Genetic; Uncoupling Protein 1 | 2018 |
Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
Topics: Abscess; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incidence; Liver Abscess; Male; Metformin; Middle Aged; National Health Programs; Pioglitazone; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones; Treatment Outcome | 2018 |
Rosiglitazone up-regulates glial fibrillary acidic protein via HB-EGF secreted from astrocytes and neurons through PPARγ pathway and reduces apoptosis in high-fat diet-fed mice.
Topics: Animals; Apoptosis; Astrocytes; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glial Fibrillary Acidic Protein; Heparin-binding EGF-like Growth Factor; Hypoglycemic Agents; Mice; Neurons; PPAR gamma; Rosiglitazone; Signal Transduction; Up-Regulation | 2019 |
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
Topics: Animals; Aorta, Abdominal; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression; Humans; Hypoglycemic Agents; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phytotherapy; Rosiglitazone; Signal Transduction | 2018 |
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Humans; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Rosiglitazone; Young Adult | 2019 |
Patient Adipose Stem Cell-Derived Adipocytes Reveal Genetic Variation that Predicts Antidiabetic Drug Response.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; ATP Binding Cassette Transporter 1; Base Sequence; Cell Line; Cholesterol; Diabetes Mellitus, Type 2; Gene Editing; Genetic Loci; Genetic Variation; Humans; Hypoglycemic Agents; Middle Aged; NFI Transcription Factors; Polymorphism, Single Nucleotide; PPAR gamma; Protein Binding; Rosiglitazone; Stem Cells | 2019 |
Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients.
Topics: Aged; Case-Control Studies; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone | 2019 |
Peroxisome Proliferator-Activated Receptor Gamma (PPAR) Suppresses Inflammation and Bacterial Clearance during Influenza-Bacterial Super-Infection.
Topics: Animals; Bacterial Infections; Coinfection; Cytokines; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; Inflammation; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Mice; PPAR gamma; Rosiglitazone; Signal Transduction; Viral Load | 2019 |
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; Cytochrome P-450 CYP2C8; Diabetes Mellitus, Type 2; Edema; Female; Genetic Association Studies; Glycated Hemoglobin; Heat-Shock Proteins; Humans; Male; Middle Aged; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphatidate Phosphatase; Polymorphism, Single Nucleotide; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2013 |
In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats.
Topics: Adipose Tissue, Brown; Animals; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Lipid Metabolism; Liver; Muscle, Skeletal; Obesity; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2013 |
Oral green tea catechins transiently lower plasma glucose concentrations in female db/db mice.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Camellia sinensis; Catechin; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Flavonoids; Hyperglycemia; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; Mice, Knockout; Mice, Obese; Obesity; Phytotherapy; Plant Extracts; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain | 2013 |
Rosiglitazone is not associated with an increased risk of bladder cancer.
Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Urinary Bladder Neoplasms | 2013 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |
The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone.
Topics: Animals; Antibodies; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Male; Nitric Oxide Synthase Type III; Rats; Receptor, Insulin; Rosiglitazone; Thiazolidinediones | 2013 |
Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Urinary Bladder Neoplasms | 2013 |
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; United States; Veterans | 2013 |
Rosiglitazone and cardiovascular outcomes: is there a clear answer?
Topics: Angioplasty; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Rosiglitazone; Thiazolidinediones | 2013 |
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Topics: Advisory Committees; Decision Making; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fibroblast Growth Factors; Glucose; Islets of Langerhans; Klotho Proteins; Male; Membrane Proteins; Mice; Phosphorylation; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2013 |
GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Palmitic Acids; Rats; Rats, Wistar; Rats, Zucker; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones; Tissue Culture Techniques | 2013 |
The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity.
Topics: 3T3-L1 Cells; Adipogenesis; Adipose Tissue; Adiposity; Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Body Mass Index; Cell Differentiation; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Middle Aged; Obesity; Omentum; PPAR gamma; Proteins; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2013 |
Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.
Topics: Adiponectin; Adiposity; Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Glucose Intolerance; Insulin Resistance; Insulin-Secreting Cells; Male; Piperidines; Pyrazoles; Rats; Rats, Inbred OLETF; Receptor, Cannabinoid, CB1; Rimonabant; Rosiglitazone; Thiazolidinediones | 2013 |
Impact of thiazolidinediones on macular thickness and volume in diabetic eyes.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Macular Edema; Male; Middle Aged; Pilot Projects; Pioglitazone; Prospective Studies; Retina; Rosiglitazone; Subretinal Fluid; Thiazolidinediones; Tomography, Optical Coherence; Visual Acuity | 2013 |
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Europe; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Young Adult | 2013 |
Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Population Surveillance; Rosiglitazone; Stomach Neoplasms; Thiazolidinediones | 2013 |
Antihyperglycemic effect of carvacrol in combination with rosiglitazone in high-fat diet-induced type 2 diabetic C57BL/6J mice.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cymenes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Monoterpenes; Rosiglitazone; Thiazolidinediones | 2014 |
Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models.
Topics: Adipocytes; Aminopyridines; Animals; Diabetes Mellitus, Type 2; Drug Discovery; Glucose; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Mice; Mice, Mutant Strains; Rosiglitazone; Sulfonamides; Thiazolidinediones | 2013 |
Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Rosiglitazone; Taiwan; Thiazolidinediones; Thyroid Neoplasms; Treatment Outcome | 2013 |
US regulators relax restrictions on rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model.
Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Wistar; Rosiglitazone; Spirulina; Thiazolidinediones | 2013 |
Is rosiglitazone as safe as BARI 2D and the reanalysis of RECORD imply?
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2014 |
Rosiglitazone: a case of regulatory hubris.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Urtica dioica extract attenuates depressive like behavior and associative memory dysfunction in dexamethasone induced diabetic mice.
Topics: Animals; Antidepressive Agents; Association Learning; Avoidance Learning; Blood Glucose; Corticosterone; Depression; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Female; Glucose Transporter Type 4; Hippocampus; Hypoglycemic Agents; Immobilization; Insulin; Male; Maze Learning; Memory Disorders; Mice; Oxidative Stress; Phytotherapy; Plant Extracts; RNA, Messenger; Rosiglitazone; Stress, Psychological; Swimming; Thiazolidinediones; Urtica dioica | 2014 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2014 |
Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
Topics: Adipocytes; Animals; Bone Density; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Isoquinolines; Osteoblasts; Osteoporosis, Postmenopausal; Ovariectomy; Oxazoles; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Inbred F344; Receptor, Insulin; Risk; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
In brief: rosiglitazone (Avandia) unbound.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones | 2014 |
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
Topics: Adverse Drug Reaction Reporting Systems; Australia; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones | 2014 |
Objective Bayesian meta-analysis for sparse discrete data.
Topics: Bayes Theorem; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Epilepsy; Female; gamma-Aminobutyric Acid; Hormone Replacement Therapy; Humans; Meta-Analysis as Topic; Models, Statistical; Multicenter Studies as Topic; Pregnancy; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
Topics: Angioplasty; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists.
Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Gene Expression Profiling; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Obesity; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Receptors, Adrenergic, alpha-1; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2014 |
Rosiglitazone influences the expression of leukocyte adhesion molecules and CD14 receptor in type 2 diabetes mellitus patients.
Topics: Aged; Biomarkers; Blood Glucose; Case-Control Studies; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Down-Regulation; Female; Humans; Hypoglycemic Agents; Inflammation Mediators; Lipopolysaccharide Receptors; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
An in vitro study reveals the nutraceutical potential of punicic acid relevant to diabetes via enhanced GLUT4 expression and adiponectin secretion.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Dietary Supplements; Gene Expression Regulation; Glucose Transporter Type 4; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linolenic Acids; Lythraceae; Mice; PPAR gamma; Rosiglitazone; Seeds; Thiazolidinediones; Triglycerides | 2014 |
Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Blotting, Western; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Eating; Flavanones; Hypoglycemic Agents; Kidney; Male; NF-kappa B; Nitric Oxide Synthase Type II; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Transforming Growth Factor beta1; Treatment Outcome | 2014 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Managed Care Programs; Maryland; Medicaid; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States; Young Adult | 2014 |
Integrative analysis of transcriptomics, proteomics, and metabolomics data of white adipose and liver tissue of high-fat diet and rosiglitazone-treated insulin-resistant mice identified pathway alterations and molecular hubs.
Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression Profiling; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Networks and Pathways; Metabolomics; Mice, Inbred C57BL; Obesity; Proteomics; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones; Transcriptome | 2014 |
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Topics: Aged; British Columbia; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Rosiglitazone; Scotland; Thiazolidinediones; Urinary Bladder Neoplasms | 2015 |
Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression.
Topics: Administration, Oral; Animals; Brain-Derived Neurotrophic Factor; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression; Hippocampus; Hypoglycemic Agents; Injections, Intraventricular; Insulin Resistance; Male; Memory; Mice, Inbred C57BL; Molecular Targeted Therapy; Neuronal Plasticity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2015 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Evaluation of the synuclein-γ (SNCG) gene as a PPARγ target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; gamma-Synuclein; Ganglia, Spinal; Humans; Hypoglycemic Agents; Male; Mice; Middle Aged; Neoplasm Proteins; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Protein Binding; Rosiglitazone; Sensory Receptor Cells; Thiazolidinediones; Transcription, Genetic; Transcriptional Activation | 2015 |
Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway.
Topics: Animals; Diabetes Mellitus, Type 2; Hippocampus; Insulin; Learning; Male; Memory; Neurons; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2015 |
How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
Topics: Cardiovascular Diseases; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Utilization; Humans; Hypoglycemic Agents; Medicaid; Pioglitazone; Reimbursement Mechanisms; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2015 |
Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes.
Topics: Adipocytes, White; Adipose Tissue, Brown; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; PPAR gamma; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Ubiquitin-Conjugating Enzymes | 2015 |
Padina arborescens Ameliorates Hyperglycemia and Dyslipidemia in C57BL/KsJ-db/db Mice, a Model of Type 2 Diabetes Mellitus.
Topics: Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Dyslipidemias; Fasting; Glucose Tolerance Test; Glycated Hemoglobin; Glycogen; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Phaeophyceae; Rosiglitazone; Thiazolidinediones | 2015 |
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Plants, Medicinal; Rosiglitazone; Thiazolidinediones | 2015 |
Resolution of Inflammation by Resolvin D1 Is Essential for Peroxisome Proliferator-activated Receptor-γ-mediated Analgesia during Postincisional Pain Development in Type 2 Diabetes.
Topics: Analgesia; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Docosahexaenoic Acids; Hypoglycemic Agents; Inflammation; Macrophages; Male; Mice; Pain, Postoperative; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2015 |
Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ.
Topics: Benzamides; Carotid Artery Diseases; Cell Differentiation; Cells, Cultured; Chemotaxis; Combined Modality Therapy; Depression, Chemical; Diabetes Mellitus, Type 2; Down-Regulation; Endarterectomy, Carotid; Gene Expression Regulation; Humans; Macrophages; Pioglitazone; PPAR alpha; PPAR gamma; Pyridines; Receptors, CXCR; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones | 2015 |
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Proteomics; Risk Factors; Rosiglitazone; Thiazolidinediones | 2016 |
Low-event-rate meta-analyses of clinical trials: implementing good practices.
Topics: Biostatistics; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Models, Statistical; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones | 2016 |
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2016 |
Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Body Mass Index; Carbamates; China; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Genetic Loci; Genotype; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linear Models; Male; Middle Aged; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones | 2016 |
Pioglitazone use and risk of bladder cancer: population based cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; General Practice; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom; Urinary Bladder Neoplasms | 2016 |
Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Anti-Obesity Agents; Antioxidants; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Rosiglitazone; Second Messenger Systems; Thiazolidinediones; Triterpenes; Ursolic Acid; Weight Gain | 2016 |
Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pharmacovigilance; Portugal; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones | 2016 |
CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.
Topics: Aged; Blood Glucose; Cytochrome P-450 CYP2C8; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypoglycemic Agents; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Pharmacogenetics; Pioglitazone; Polymorphism, Single Nucleotide; Rosiglitazone; Scotland; Thiazolidinediones; Treatment Outcome; White People | 2016 |
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2016 |
Bmp4 Promotes a Brown to White-like Adipocyte Shift.
Topics: Adipocytes, Brown; Adipocytes, White; Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Bone Morphogenetic Protein 4; Cell Differentiation; Cell Line, Transformed; Cyclic AMP; Diabetes Mellitus, Type 2; Gene Expression Regulation; Humans; Insulin Resistance; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Smad Proteins; Sterol Esterase; Thiazolidinediones | 2016 |
Regulated and Functional Expression of the Corepressor MTA3 in Rodent Testis.
Topics: Animals; Cells, Cultured; Chorionic Gonadotropin; Cyclic AMP; Dexamethasone; Diabetes Mellitus, Type 2; Female; Leydig Cells; Male; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Pregnancy; Progesterone; Rats; RNA, Messenger; RNA, Ribosomal, 18S; Rosiglitazone; Testis; Testosterone; Thiazolidinediones | 2016 |
A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2016 |
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Cell Line; Cells, Cultured; Chemokines; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Hep G2 Cells; Hepatic Stellate Cells; Hepatocytes; Hepcidins; Humans; Hydrocarbons, Fluorinated; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Leptin; Lipocalin-2; Liver; Liver X Receptors; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Severity of Illness Index; Sulfonamides; Thiazolidinediones; Waist-Hip Ratio; Young Adult | 2017 |
Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark.
Topics: Denmark; Diabetes Mellitus, Type 2; Drug Interactions; Drug Labeling; Drug Prescriptions; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Germany; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2016 |
Meta-analysis of aggregate data on medical events.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Likelihood Functions; Meta-Analysis as Topic; Models, Statistical; Patient Dropouts; Randomized Controlled Trials as Topic; Rosiglitazone; Statistics as Topic; Thiazolidinediones; Time Factors | 2017 |
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Drug Synergism; Female; Humans; Hypoglycemic Agents; Incidence; Middle Aged; Population Surveillance; Proportional Hazards Models; Risk; Rosiglitazone; Taiwan; Thiazolidinediones; Young Adult | 2017 |
FAK signalling controls insulin sensitivity through regulation of adipocyte survival.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Adiposity; Adult; Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Female; Focal Adhesion Kinase 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Middle Aged; Obesity; PPAR gamma; Primary Cell Culture; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
Database assessment of the effectiveness of brand versus generic rosiglitazone in patients with type 2 diabetes mellitus.
Topics: Databases as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone and delayed onset of proliferative diabetic retinopathy.
Topics: Aged; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Macular Edema; Male; Medical Records; Middle Aged; PPAR gamma; Retrospective Studies; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Visual Acuity | 2008 |
Initiating antidiabetic drug therapy.
Topics: Diabetes Mellitus, Type 2; Health Care Costs; Humans; Hypoglycemic Agents; Medicaid; Pioglitazone; Rosiglitazone; Thiazolidinediones; Time Factors; United States | 2008 |
Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment.
Topics: Adult; Aged; Apoptosis; C-Reactive Protein; Case-Control Studies; CD11b Antigen; Diabetes Mellitus, Type 2; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Leukocytes, Mononuclear; Metformin; Middle Aged; Oxidative Stress; Rosiglitazone; Superoxides; Thiazolidinediones; Transferrin | 2008 |
Beneficial effect of chungkukjang on regulating blood glucose and pancreatic beta-cell functions in C75BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fermentation; Glucagon; Glucokinase; Glycated Hemoglobin; Glycine max; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Isoflavones; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Pancreas; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2008 |
A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes.
Topics: Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipogenesis; Male; Pilot Projects; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2008 |
Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hypoglycemic Agents; Macular Edema; Male; Middle Aged; Remission, Spontaneous; Rosiglitazone; Thiazolidinediones; Visual Acuity | 2008 |
New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.
Topics: Animals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Gene Expression Profiling; Insulin; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Rosiglitazone; Thiazolidinediones | 2008 |
A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Topics: Cardiomyopathies; Diabetes Mellitus, Type 2; Drug Approval; Gene Expression Regulation; Humans; Hypoglycemic Agents; National Institutes of Health (U.S.); Product Surveillance, Postmarketing; Public Policy; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2008 |
Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis.
Topics: Animals; Apoptosis; Caspase 3; Cell Line; Cell Survival; Cholesterol; Diabetes Mellitus, Type 2; DNA Damage; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Immunoblotting; In Situ Nick-End Labeling; Insulin; Insulin-Secreting Cells; Male; Palmitates; Rats; Rats, Inbred OLETF; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference?
Topics: Diabetes Mellitus, Type 2; Endothelins; Humans; Inflammation; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2008 |
Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; PPAR gamma; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2008 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2008 |
Intensive glucose control in type 2 diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2008 |
Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Numerical Analysis, Computer-Assisted; Rosiglitazone; Thiazolidinediones | 2009 |
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Topics: Adiponectin; Aged; Coronary Artery Disease; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone no longer recommended.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2008 |
Major US consumer group asks FDA to ban drug for diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2008 |
Thiazolidinediones: do harms outweigh benefits?
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones; Treatment Outcome | 2009 |
The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Blood Platelets; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Leukocytes; Male; Membrane Glycoproteins; Middle Aged; PPAR gamma; Receptors, Urokinase Plasminogen Activator; Rosiglitazone; Thiazolidinediones; Thrombosis | 2009 |
[Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones].
Topics: Adiponectin; Adipose Tissue; Diabetes Mellitus, Type 2; Drug Combinations; Female; Fibrinolytic Agents; Ghrelin; Humans; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
Capillary endothelial but not lymphatic function is restored under rosiglitazone in Zucker diabetic fatty rats.
Topics: Albumins; Animals; Capillaries; Capillary Permeability; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium; Lymphatic System; Male; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A | 2009 |
Rosiglitazone increases testosterone in hypogonadal type 2 diabetic men.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypogonadism; Male; Obesity; Rosiglitazone; Testosterone; Thiazolidinediones; Vasodilator Agents | 2009 |
Glitazone use associated with diabetic macular edema.
Topics: Adult; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Macular Edema; Middle Aged; Pioglitazone; PPAR gamma; Prospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Smoking; Sulfonylurea Compounds; Survival Analysis; Survivors; Thiazolidinediones | 2009 |
[LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus type 2].
Topics: Adult; Aged; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Topics: Acute Disease; Cardiovascular Diseases; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2009 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
Diabetes treatment.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Peroxisome Proliferator-Activated Receptors; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones | 2009 |
Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study.
Topics: Aged; Cohort Studies; Confidence Intervals; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Risk; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones; Time Factors | 2009 |
GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Topics: Algorithms; Cardiovascular Diseases; Consensus Development Conferences as Topic; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Industry; Europe; Humans; Hypoglycemic Agents; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2009 |
The new rosiglitazone story: its place today in type 2 diabetes management.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heart Diseases; Humans; Hypoglycemic Agents; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; HSP47 Heat-Shock Proteins; Inflammation; Male; MAP Kinase Signaling System; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2009 |
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Knee Joint; Male; Obesity; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Purines; Rats; Rats, Inbred OLETF; Risk Factors; Rosiglitazone; Thiazolidinediones; Uric Acid | 2009 |
Thiazolidinediones: antidiabetic agents with effects on bone.
Topics: Aged; Animals; Bone and Bones; Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Male; Mice; Osteoporosis; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Rosiglitazone; Thiazolidinediones | 2009 |
Editorial: What have we lost in the wake of the rosiglitazone controversy?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Withholding Treatment | 2009 |
Clinical practice effect of rosiglitazone discontinuation on glycemic control.
Topics: Adult; Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Compliance; Rosiglitazone; Thiazolidinediones; Withholding Treatment | 2009 |
Thiazolidinedione use and the risk of fractures.
Topics: Bone Density; Case-Control Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Greece; Humans; Hypoglycemic Agents; Incidence; Male; Odds Ratio; Pioglitazone; Reference Values; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2009 |
Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone in Canada: experience in clinical practice.
Topics: Aged; Blood Glucose; Canada; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2009 |
Rosiglitazone: to be or not to be?
Topics: Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones | 2009 |
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain | 2009 |
Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.
Topics: Cell Line; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Fibroblast Growth Factors; Gene Expression Regulation; Glucose Clamp Technique; Glycerol; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Agents; Lecithins; Male; Obesity; PPAR alpha; PPAR gamma; Reference Values; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2009 |
Glucose control and vascular complications in type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dyspnea; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.
Topics: Attitude of Health Personnel; Awareness; Cardiovascular Diseases; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Information Services; Evidence-Based Medicine; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Mass Media; Meta-Analysis as Topic; Pioglitazone; Practice Patterns, Physicians'; Risk Assessment; Rosiglitazone; Scotland; Surveys and Questionnaires; Thiazolidinediones; Time Factors | 2009 |
Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Lactobacillus; Male; Mice; Mice, Inbred C57BL; Milk, Human; Models, Animal; Rosiglitazone; Thiazolidinediones | 2009 |
PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Topics: Adipogenesis; Administration, Oral; Animals; Blood Glucose; Blood Volume; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Genes, Reporter; Humans; Hypoglycemic Agents; Isoxazoles; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; PPAR gamma; Propionates; Rosiglitazone; Thiazolidinediones; Thiophenes; Transfection; Water-Electrolyte Balance | 2009 |
Rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Europe; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2009 |
Thiazolidinediones and clinical outcomes in type 2 diabetes.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease.
Topics: Adipose Tissue; Alanine Transaminase; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Blood Glucose; Butyrylcholinesterase; Diabetes Mellitus, Type 2; Dietary Fats; Drugs, Chinese Herbal; Fatty Liver; Inflammation; Interleukin-6; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Topics: Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Demography; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prevalence; Regression Analysis; Rosiglitazone; Spinal Fractures; Thiazolidinediones | 2009 |
Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Young Adult | 2009 |
Cardiovascular risk and TZD: safe therapy for the elderly?
Topics: Age Factors; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Medical Records Systems, Computerized; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Regression Analysis; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
Topics: Animals; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dinoprostone; Gastric Mucosa; Hypoglycemic Agents; Indomethacin; Male; Malondialdehyde; Metformin; Mucins; Nitric Oxide; Rats; Rats, Wistar; Rosiglitazone; Stomach Ulcer; Thiazolidinediones | 2010 |
Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2009 |
Adipocyte differentiation-related protein and OXPAT in rat and human skeletal muscle: involvement in lipid accumulation and type 2 diabetes mellitus.
Topics: Animals; Biomarkers; Carrier Proteins; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Lipid Metabolism; Membrane Proteins; Muscle Proteins; Muscle, Skeletal; Perilipin-1; Perilipin-2; Perilipin-3; Perilipin-5; Phosphoproteins; Pregnancy Proteins; Rats; Rosiglitazone; Thiazolidinediones; Vesicular Transport Proteins | 2009 |
Case series of liver failure associated with rosiglitazone and pioglitazone.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Failure; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2009 |
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].
Topics: Austria; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Myocardial Infarction; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2009 |
Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypoglycemic Agents; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Polymorphism, Genetic; Receptors, Adrenergic, beta-3; Rosiglitazone; Thiazolidinediones; Uncoupling Protein 2; Young Adult | 2009 |
Thiazolidinediones and fractures in men and women.
Topics: Adult; Aged; British Columbia; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk; Rosiglitazone; Sex Factors; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines | 2009 |
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Rosiglitazone or pioglitazone in type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots.
Topics: Adiposity; Animals; Base Sequence; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; DNA Primers; Energy Metabolism; Gene Expression Profiling; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Lipids; Rats; Rats, Long-Evans; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2010 |
Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2009 |
A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Acetyl Coenzyme A; Animals; Chlorocebus aethiops; Cloning, Molecular; COS Cells; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Hypoglycemic Agents; Lysophosphatidylcholines; Male; Mice; Platelet Activating Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection | 2009 |
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
Topics: Aged; Bone and Bones; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom | 2009 |
In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Glucose; Glucose Transport Proteins, Facilitative; Heart Diseases; Hemodynamics; Hypoglycemic Agents; Male; Metformin; Myocardium; Oxidation-Reduction; Phenotype; Positron-Emission Tomography; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors | 2009 |
Rosiglitazone and pioglitazone. Beware fractures.
Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Complement factor H is expressed in adipose tissue in association with insulin resistance.
Topics: Adipose Tissue; Complement Factor B; Complement Factor H; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Omentum; Organ Specificity; Reference Values; Rosiglitazone; Skin; Thiazolidinediones; Weight Loss; White People | 2010 |
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.
Topics: Blotting, Western; Breast Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Type 2; Female; Gene Expression; Gene Expression Regulation; Gene Silencing; Humans; Hypoglycemic Agents; Immunohistochemistry; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Rosiglitazone; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Thiazolidinediones; Transfection | 2009 |
Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Topics: Animals; Body Weight; Cardiomyopathies; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Fibrosis; Glucose Tolerance Test; Male; Myocardium; PPAR gamma; Rats; Rats, Inbred OLETF; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones | 2010 |
[Rosiglitazone: no increase in cardiovascular mortality].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Bone Density; Diabetes Mellitus, Type 2; Fractures, Bone; Gene Expression Regulation; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Mice; Osteogenesis; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Wnt Proteins | 2010 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.
Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides | 2009 |
Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.
Topics: Albuminuria; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Macular Edema; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
[Diabetic edematous maculopathy associated with rosiglitazone treatment: report of a case].
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Hypoglycemic Agents; Macular Edema; Middle Aged; Rosiglitazone; Thiazolidinediones | 2009 |
The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes.
Topics: Adipokines; Adult; Aged; Body Fat Distribution; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Muscle, Skeletal; Rosiglitazone; Thiazolidinediones | 2010 |
Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Erythropoietin; Exophthalmos; Female; Humans; Hypoglycemic Agents; Lipodystrophy; Middle Aged; Myelodysplastic Syndromes; Rosiglitazone; Thiazolidinediones | 2009 |
The rise and fall of rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2010 |
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.
Topics: Advisory Committees; American Heart Association; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Prevalence; Risk Factors; Rosiglitazone; Thiazolidinediones; United States | 2010 |
A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
Topics: Advisory Committees; American Heart Association; Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Pioglitazone; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones; United States | 2010 |
Seeking alternatives to Hard End Points: is imaging the best APPROACH?
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2010 |
[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Topics: Apolipoprotein A-I; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2010 |
Setting the RECORD Straight.
Topics: Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Thiazolidinediones | 2010 |
Ensuring integrity in industry-sponsored research: primum non nocere, revisited.
Topics: Clinical Trials Data Monitoring Committees; Data Collection; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Endpoint Determination; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Peer Review, Research; Physician's Role; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? It depends on how you measure it.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2011 |
Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
Topics: Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Drug Utilization; Humans; Hypoglycemic Agents; Patient Compliance; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2010 |
Rosiglitazone, marketing, and medical science.
Topics: Clinical Trials as Topic; Conflict of Interest; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Interprofessional Relations; Marketing of Health Services; Meta-Analysis as Topic; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Rosiglitazone in the UK: down but not out.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United Kingdom | 2010 |
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Postprandial Period; Prospective Studies; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2010 |
Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.
Topics: Adiposity; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Femoral Artery; Hypoglycemic Agents; Matrix Metalloproteinase 9; Myography; Nitric Oxide Synthase Type III; Pancreatic Elastase; Rats; Rats, Zucker; Receptors, Adrenergic, alpha; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2010 |
Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Topics: Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2011 |
Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus.
Topics: Adult; Alleles; Asian People; Diabetes Mellitus, Type 2; Female; Genotype; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Postprandial Period; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2010 |
The rise and fall of rosiglitazone: reply.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2010 |
Researcher urges Health Canada to suspend "unethical" diabetes drug trial.
Topics: Canada; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2010 |
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2010 |
Diabetes drug woes spell trouble for the entire drug family.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Health Canada named in class action lawsuit.
Topics: Canada; Compensation and Redress; Diabetes Mellitus, Type 2; Drug Industry; Humans; Liability, Legal; National Health Programs; Rosiglitazone; Thiazolidinediones | 2010 |
Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Risk; Rosiglitazone; Thiazolidinediones; Time Factors; United States; United States Food and Drug Administration | 2010 |
Diabetes drug safety update: Avandia and your heart.
Topics: Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Diabetes: making sense of the rosiglitazone controversy.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Patient Selection; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Rosiglitazone, thiazolidinediones and atherosclerosis.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Leukocytes, Mononuclear; Nitric Oxide; Obesity; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Managed Care Programs; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone and the case for safety over certainty.
Topics: Decision Making; Diabetes Mellitus, Type 2; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones | 2010 |
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Medicare Part D; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Stroke; Thiazolidinediones; United States | 2010 |
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Preventing type 2 diabetes with low-dose combinations.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: Role of STAT1 inhibition and nephrin restoration.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Kidney; Kidney Glomerulus; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Nephrectomy; Protective Agents; Rosiglitazone; STAT1 Transcription Factor; Thiazolidinediones | 2010 |
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Topics: Diabetes Mellitus, Type 2; Edema; Female; Humans; Hypoglycemic Agents; Male; NFATC Transcription Factors; Polymorphism, Single Nucleotide; Ramipril; Rosiglitazone; Thiazolidinediones | 2010 |
Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical | 2010 |
Increase in plasma glucose lowering action of rosiglitazone by electroacupuncture at bilateral Zusanli acupoints (ST.36) in rats.
Topics: Acupuncture Points; Animals; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Models, Animal; Electroacupuncture; Humans; Hypoglycemic Agents; Male; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2009 |
FDA committee urges tight restrictions on rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.
Topics: Body Mass Index; Cell Respiration; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2010 |
Diabetes drugs offered fresh start.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Mice; Myocardial Infarction; PPAR gamma; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.
Topics: Animals; Blotting, Western; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Hypoglycemic Agents; Infant; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C57BL; Neurons; Phosphorylation; Polymerase Chain Reaction; PPAR gamma; Rats; Rats, Inbred OLETF; Rosiglitazone; tau Proteins; Thiazolidinediones; Transfection; Treatment Outcome | 2010 |
Revisiting the rosiglitazone story--lessons learned.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Labeling; Government Regulation; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Odds Ratio; Pioglitazone; PPAR gamma; Product Recalls and Withdrawals; Research Design; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Avandia panel member may be investigated for possible conflicts of interest.
Topics: Conflict of Interest; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States | 2010 |
Concurrently using rosiglitazone prevents glucosamine-induced islet beta-cell apoptosis and dysfunction.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Glucosamine; Humans; Insulin-Secreting Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rosiglitazone; Thiazolidinediones | 2010 |
Licensing drugs for diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2010 |
Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Rosiglitazone: what went wrong?
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Humans; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
A systems biology approach to identify effective cocktail drugs.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Gene Expression Profiling; Hypoglycemic Agents; Metformin; Models, Molecular; Pilot Projects; Rosiglitazone; Systems Biology; Thiazolidinediones | 2010 |
PPARγ ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination.
Topics: Animals; Candida albicans; Candidiasis; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Intestines; Macrophage Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
The Avandia debate: an unhappy conclusion.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Government Agencies; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
[Rosiglitazone].
Topics: Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Humans; Myocardial Infarction; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction.
Topics: Adenosine Triphosphate; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Biopsy; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Genetic Vectors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Proteins; Reactive Oxygen Species; RNA; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2011 |
Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Models, Animal; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin-Like Growth Factor I; Insulin-Secreting Cells; Mitochondria; Nicotine; Pregnancy; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2010 |
Therapy: What evidence should guide the use of thiazolidinediones?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2010 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2010 |
Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
Topics: Adiposity; Analysis of Variance; Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Metformin; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; N-Acetylneuraminic Acid; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2010 |
The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
Topics: Adult; Aged; Atherosclerosis; Carotid Artery, Internal; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk; Rosiglitazone; Thiazolidinediones; Ultrasonography | 2010 |
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Drug Labeling; Drug Prescriptions; Drug Utilization; Geography; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2010 |
Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Patient Selection; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone, PPARγ, and type 2 diabetes.
Topics: Cyclin-Dependent Kinase 5; Diabetes Mellitus, Type 2; Gene Expression; Hypoglycemic Agents; Obesity; Phosphorylation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
FDA puts restrictions on use of controversial diabetes drug.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Drug Approval; Drug Industry; Drug Prescriptions; Humans; Hypoglycemic Agents; Mifepristone; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2011 |
Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Area Under Curve; Blood Glucose; Bupleurum; Coptis; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipid Metabolism; Lipids; Muscle, Skeletal; Phytotherapy; Rats; Rats, Inbred OLETF; Rheum; Rosiglitazone; Scutellaria baicalensis; Thiazolidinediones | 2011 |
Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.
Topics: Decision Making, Organizational; Diabetes Mellitus, Type 2; Drug Approval; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Theoretical; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2011 |
The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids.
Topics: Administration, Oral; Analysis of Variance; Animals; Blood Glucose; Body Composition; Curcumin; Diabetes Mellitus, Type 2; Dietary Fats; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2011 |
Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cytoplasm; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Eukaryotic Translation Initiation Factor 5A; Fatty Acid-Binding Proteins; Gene Expression Profiling; Gene Expression Regulation; Insulin; Mice; Obesity; Peptide Initiation Factors; Proteome; RNA-Binding Proteins; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones | 2011 |
Contending mediated risk messages: a grounded theory of the physician-patient discussion of a prescription medication's changing risk.
Topics: Aged; Chronic Disease; Communication; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Male; Patient Education as Topic; Physician-Patient Relations; Physician's Role; Primary Health Care; Risk; Rosiglitazone; Thiazolidinediones | 2011 |
Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; United States | 2011 |
Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Practice Patterns, Physicians'; Risk Factors; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United Kingdom | 2011 |
Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones | 2011 |
[Benefits and harms - two sides of the same medal?].
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Germany; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones | 2011 |
Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Topics: Aged; Animals; Brain; Diabetes Mellitus, Type 2; Energy Metabolism; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Knockout; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Weight Gain | 2011 |
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Topics: Atherosclerosis; Blood Coagulation Tests; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Malaysia; Male; Middle Aged; Plasminogen; Prothrombin; Rosiglitazone; Thiazolidinediones | 2011 |
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones | 2011 |
[Glycemic control and cardiovascular benefit: what do we know today?].
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones | 2011 |
[Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2011 |
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; Edema; Female; France; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2011 |
Intensive glucose lowering and cardiovascular outcomes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone REMS arrives in November.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Pharmacies; PPAR gamma; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; Vasodilator Agents | 2011 |
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Hypolipidemic Agents; Lipids; Male; Pyrroles; Rats; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes.
Topics: Adipocytes; Adipokines; Adiposity; Adult; Case-Control Studies; Cell Separation; Culture Media, Conditioned; Cytokines; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; I-kappa B Kinase; Immunohistochemistry; Insulin; JNK Mitogen-Activated Protein Kinases; Male; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Phosphorylation; Recombinant Proteins; Rosiglitazone; Subcutaneous Fat, Abdominal; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Theoretical; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2011 |
What's next for diabetes prevention?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Insulin-Secreting Cells; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2011 |
Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Lipopolysaccharides; Macrophage Activation; Macrophages; Mice; Rosiglitazone; Thiazolidinediones | 2011 |
Is rosiglitazone use associated with an increase in intensive eye treatment in diabetic patients? A community based study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Laser Therapy; Lasers, Gas; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Vitrectomy | 2011 |
The long Avandia endgame.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United Kingdom; United States; United States Food and Drug Administration | 2011 |
Red wine: a source of potent ligands for peroxisome proliferator-activated receptor γ.
Topics: Binding, Competitive; Cardiovascular Diseases; Catechin; Coumaric Acids; Diabetes Mellitus, Type 2; Ellagic Acid; Flavonoids; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Ligands; Models, Chemical; Phenols; Plant Extracts; Polyphenols; PPAR gamma; Rosiglitazone; Spectroscopy, Fourier Transform Infrared; Thiazolidinediones; Wine | 2011 |
Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Rosiglitazone; Serpins; Thiazolidinediones | 2011 |
Decreased STAMP2 expression in association with visceral adipose tissue dysfunction.
Topics: Adipocytes; Adult; Aged; Cell Differentiation; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Membrane Proteins; Middle Aged; Obesity; Oxidoreductases; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
[The semi-quantitative method for evaluating lipid accumulation in pancreas of diabetic mice].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Hypoglycemic Agents; Insulin; Islets of Langerhans; Lipid Metabolism; Mice; Mice, Inbred C57BL; Pancreas; Random Allocation; Rosiglitazone; Thiazolidinediones; Triglycerides | 2011 |
Pioglitazone is a valid alternative to rosiglitazone.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2011 |
Two thiophenes compounds are partial peroxisome proliferator-activated receptor α/γ dual agonists.
Topics: Animals; Cell Culture Techniques; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Genes, Reporter; Hepatocytes; Humans; Hypoglycemic Agents; Mice; Molecular Targeted Therapy; Plasmids; PPAR alpha; PPAR gamma; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfoxides; Thenoyltrifluoroacetone; Thiazolidinediones; Thiophenes | 2011 |
N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Topics: 3T3-L1 Cells; Acetylcysteine; Animals; Cysteine; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; PPAR gamma; Protein Binding; Rosiglitazone; Thiazolidinediones | 2011 |
Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Transporter Type 4; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligonucleotides, Antisense; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones; Transfection | 2011 |
Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.
Topics: Acrolein; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Cholesterol, HDL; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose Intolerance; Glycated Hemoglobin; Hypoglycemic Agents; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Phytotherapy; Rosiglitazone; Saponins; Thiazolidinediones; Triglycerides; Xanthones | 2012 |
Fixed dose combination diabetes medicines - usage in the Australian veteran population.
Topics: Aged; Aged, 80 and over; Australia; Diabetes Mellitus, Type 2; Drug Combinations; Drug Prescriptions; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Practice Patterns, Physicians'; Rosiglitazone; Thiazolidinediones; Veterans | 2011 |
Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Polymorphism, Genetic; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Mexico; Middle Aged; Pharmacovigilance; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2012 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
Comparative effectiveness of incident oral antidiabetic drugs on kidney function.
Topics: Administration, Oral; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2012 |
Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice.
Topics: Animals; Antidepressive Agents; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Emotions; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Motor Activity; Psychotic Disorders; Rosiglitazone; Swimming; Thiazolidinediones | 2012 |
Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Random Allocation; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
Hypoglycemic effect and mechanism of a proteoglycan from ganoderma lucidum on streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fruiting Bodies, Fungal; Hypoglycemic Agents; Insulin; Lipids; Liver; Male; Metformin; Muscle, Skeletal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proteoglycans; Rats; Rats, Sprague-Dawley; Reishi; Rosiglitazone; Thiazolidinediones | 2012 |
Rosiglitazone prior authorization safety policy: a cohort study.
Topics: Blue Cross Blue Shield Insurance Plans; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Drug Utilization Review; Female; Humans; Hypoglycemic Agents; Insulin; Insurance, Health, Reimbursement; Male; Middle Aged; Nitrates; Rosiglitazone; Thiazolidinediones | 2012 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.
Topics: Adult; Aged; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; France; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Rosiglitazone; Smoking; Surveys and Questionnaires; Thiazolidinediones; Time Factors; Treatment Outcome | 2012 |
Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Diabetes Mellitus, Type 2; Drug Prescriptions; Drug Utilization; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Netherlands; Pharmacies; Pioglitazone; Practice Patterns, Physicians'; Risk; Rosiglitazone; Thiazolidinediones | 2012 |
TODAY--a stark glimpse of tomorrow.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2012 |
Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glucose Transporter Type 4; Hypoglycemic Agents; Male; Myocardium; NADPH Oxidases; Phosphorylation; Random Allocation; Rats; Rats, Wistar; Receptors, Adiponectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Streptozocin; Thiazolidinediones | 2012 |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Argentina; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Progression; Female; Geriatric Assessment; Hippocampus; Humans; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Neuropsychological Tests; Oxidative Stress; Pilot Projects; Psychiatric Status Rating Scales; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2012 |
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Logistic Models; Macular Edema; Male; Middle Aged; Odds Ratio; Pioglitazone; PPAR gamma; Retrospective Studies; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2012 |
Phosphorylated S6K1 (Thr389) is a molecular adipose tissue marker of altered glucose tolerance.
Topics: Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Biomarkers; Blotting, Western; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Glucose Tolerance Test; Humans; Insulin Receptor Substrate Proteins; Male; Obesity, Morbid; Phosphorylation; Rats; Rats, Wistar; Reference Values; Reproducibility of Results; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Thiazolidinediones; Threonine | 2013 |
Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Supplements; Dyslipidemias; Glucose Transporter Type 4; Glycated Hemoglobin; Glycogen; Insulin; Insulin Secretion; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle, Skeletal; Resveratrol; Rosiglitazone; Stilbenes; Thiazolidinediones; Triglycerides | 2012 |
Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; New York City; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Survival Rate; Thiazolidinediones; Time Factors; Treatment Outcome | 2012 |
The rosiglitazone decision process at FDA and EMA. What should we learn?
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Approval; Drug Synergism; Drug Therapy, Combination; Europe; European Union; Guidelines as Topic; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Meta-Analysis as Topic; Myocardial Ischemia; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2012 |
Design, synthesis and in-vivo hypoglycemic evaluation of novel non - TZD'S in a type - 2 diabetic model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Hypoglycemic Agents; Ligands; Models, Molecular; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2013 |
[Effects of ursolic acid in ameliorating insulin resistance in liver of KKAy mice via peroxisome proliferator-activated receptors α and γ].
Topics: Adiponectin; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Liver; Mice; Mice, Inbred C57BL; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triterpenes; Tumor Necrosis Factor-alpha; Ursolic Acid | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Labeling; Drug Prescriptions; Drug Substitution; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Practice Patterns, Physicians'; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom | 2013 |
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Topics: Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Management; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2012 |
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Topics: Aged; Cohort Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom; Urinary Bladder Neoplasms | 2012 |
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
Topics: Age Distribution; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Hip Fractures; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmacoepidemiology; Pioglitazone; Risk Factors; Rosiglitazone; Scotland; Sex Distribution; Thiazolidinediones | 2012 |
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.
Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Injections, Intraventricular; Injections, Spinal; Metformin; Mice; Mice, Inbred ICR; Pioglitazone; Rosiglitazone; Streptozocin; Thiazolidinediones | 2012 |
[Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2012 |
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23.
Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, Human, Pair 10; Diabetes Mellitus, Type 2; Gene Expression Profiling; Genetic Diseases, X-Linked; Genetic Loci; Genetic Predisposition to Disease; Gigantism; Heart Defects, Congenital; Homeodomain Proteins; Humans; Hypoglycemic Agents; Insulin Resistance; Insulysin; Intellectual Disability; Kinesins; Linkage Disequilibrium; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2012 |
A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone.
Topics: Adult; Aged; Cohort Studies; Comparative Effectiveness Research; Databases, Factual; Diabetes Mellitus, Type 2; Electronic Health Records; Feasibility Studies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2013 |
Plant extracts of winter savory, purple coneflower, buckwheat and black elder activate PPAR-γ in COS-1 cells but do not lower blood glucose in Db/db mice in vivo.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Echinacea; Fagopyrum; Female; Insulin; Mice; Plant Extracts; PPAR gamma; Rosiglitazone; Sambucus nigra; Satureja; Thiazolidinediones; Triglycerides | 2012 |
Alternative medications exist for controversial diabetes drug. Patients concerned about rosiglitazone (Avandia) should talk with their doctors about other options.
Topics: Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones | 2010 |
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Middle Aged; Nutrition Surveys; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2013 |
Rosiglitazone--useful drug but has side effects.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
Rosiglitazone in the management of older patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
[Severe electrolyte imbalance and edema in therapy with rosiglitazone].
Topics: Chemical and Drug Induced Liver Injury; Contraindications; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Liver Diseases, Alcoholic; Liver Function Tests; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Water-Electrolyte Imbalance | 2002 |
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Gene Expression; Heart; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Obese; Myocardium; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Weight Gain | 2002 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2002 |
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Initial management of glycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.
Topics: Adult; Aged; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Topics: Adipose Tissue; Biological Transport; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Lipids; Liver; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Regression Analysis; Rosiglitazone; Thiazolidinediones; Tomography, Emission-Computed | 2003 |
A retrospective review of thiazolidinediones with development of a troglitazone conversion protocol.
Topics: Aged; Alanine Transaminase; Chromans; Clinical Protocols; Contraindications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Monitoring; Drug Utilization Review; Guideline Adherence; Humans; Hypoglycemic Agents; Male; Middle Aged; Practice Guidelines as Topic; Quality Assurance, Health Care; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Troglitazone; United States; United States Department of Veterans Affairs | 2003 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
Unilateral edema due to a thiazolidinedione.
Topics: Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Leg; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Islets of Langerhans; Male; Muscle, Skeletal; Obesity; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Viscera | 2003 |
[The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China].
Topics: Adult; Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Middle Aged; Rosiglitazone; Thiazolidinediones | 2003 |
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Cells, Cultured; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Female; Homozygote; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Rosiglitazone; Thiazoles; Thiazolidinediones; Tunica Intima | 2003 |
PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes.
Topics: Acetylcholine; Adenosine; Animals; Arterioles; Biological Availability; Coronary Vessels; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Oxidative Stress; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilation | 2004 |
[Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Survival Rate; Thiazolidinediones | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Australian government tries to stop independent advice on diabetes drugs.
Topics: Australia; Diabetes Mellitus, Type 2; Drug Approval; Government; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2003 |
Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.
Topics: Adipocytes; Adult; Blotting, Western; Case-Control Studies; Cell Differentiation; Cross Reactions; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucose; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Lipid Metabolism; Lipolysis; Male; Middle Aged; Recombinant Proteins; Resistin; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Stem Cells; Subcutaneous Tissue; Thiazolidinediones | 2003 |
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.
Topics: Anastomosis, Surgical; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Eating; Follow-Up Studies; Gastric Bypass; Glucose Tolerance Test; Jejunum; Male; Obesity; Probability; Random Allocation; Rats; Rats, Inbred Strains; Reference Values; Rosiglitazone; Thiazolidinediones; Weight Loss | 2004 |
Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Enhancer Elements, Genetic; Gene Expression Regulation, Enzymologic; Gene Frequency; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); Humans; Hyperglycemia; Organ Specificity; Phosphoenolpyruvate Carboxykinase (GTP); Polymorphism, Genetic; PPAR gamma; Promoter Regions, Genetic; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2003 |
Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Catheterization; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Fenofibrate; Hyperplasia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Ligands; Models, Cardiovascular; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Triglycerides; Tunica Intima | 2003 |
[Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
Topics: Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Compliance; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Placebos; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2003 |
The metabolic effects of insulin and rosiglitazone combination therapy in Chinese type 2 diabetic patients with nephropathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemoglobin A; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2004 |
Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Insulin; Insulin Resistance; Liver; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone treatment of diabetes mellitus after solid organ transplantation.
Topics: Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Organ Transplantation; Rosiglitazone; Thiazolidinediones | 2004 |
Twice-Daily NPH or mixture insulins versus triple therapy: apples versus oranges: response to Poulsen et al.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin; Insulin Aspart; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to Poulsen et al.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Insulin; Insulin Aspart; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Defective enamel ultrastructure in diabetic rodents.
Topics: Animals; Calcium; Dental Enamel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Mice; Microscopy, Electron, Scanning; Phosphorus; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2004 |
Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
Topics: Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Regression Analysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
Topics: Animals; Biomarkers; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Macaca fascicularis; Male; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Characteristics; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
Effect of retinoic acid on leptin, glycerol, and glucose levels in mature rat adipocytes in vitro.
Topics: Adipocytes; Alitretinoin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation; Glycerol; Isomerism; Leptin; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Retinoid X Receptors; Rosiglitazone; Thiazolidinediones; Tretinoin | 2004 |
Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.
Topics: Apolipoprotein A-I; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.
Topics: Chromans; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Labeling; Drug Utilization Review; Evaluation Studies as Topic; Female; Humans; Liver; Liver Function Tests; Male; Medicaid; Middle Aged; Ohio; Pharmacoepidemiology; Practice Patterns, Physicians'; Rosiglitazone; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2005 |
Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulphonylurea agent: response to Roy et al.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.
Topics: Adolescent; Adult; Aged; Cardiac Output, Low; Chronic Disease; Cohort Studies; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone-induced proptosis.
Topics: Diabetes Mellitus, Type 2; Exophthalmos; Eye; Female; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazolidinediones; Thyroid Function Tests; Tomography, X-Ray Computed; Weight Gain | 2005 |
[Rosiglitazon in treatment of Type II diabetes mellitus--experience of diabetologists in the Czech Republic. Part I: compensation of diabetes, sugar metabolism].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury.
Topics: Administration, Oral; Animals; Blood Glucose; Coronary Vessels; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Heart; Hypoglycemic Agents; Insulin Resistance; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
[Rosiglitazone-metformin fixed dose combination for treatment of type 2 diabetes].
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2004 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Topics: 3T3 Cells; Adipocytes; Animals; Biotransformation; Blood Glucose; Cell Differentiation; Cholic Acids; Diabetes Mellitus, Type 2; Dogs; Drug Synergism; Estrone; Glucocorticoids; Glucose; Glutamate-Ammonia Ligase; Hypoglycemic Agents; Liver; Male; Mice; Obesity; Prednisolone; Rats; Rats, Zucker; Receptors, Glucocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Tyrosine Transaminase | 2005 |
Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Compliance; Rosiglitazone; Thiazolidinediones | 2004 |
PPARgamma in endothelial cells influences high fat diet-induced hypertension.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dietary Fats; Dose-Response Relationship, Drug; Endothelial Cells; Female; Heart Rate; Hypertension; Ligands; Male; Mice; Mice, Knockout; PPAR gamma; Rosiglitazone; Sodium Chloride; Thiazolidinediones | 2005 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Cinnamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fenofibrate; Gene Expression Regulation, Enzymologic; Glucose; Homozygote; Humans; Hyperlipidemias; In Vitro Techniques; Insulin; Intercellular Signaling Peptides and Proteins; Kinetics; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Models, Chemical; PPAR alpha; PPAR gamma; Protein Binding; Protein Isoforms; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Triglycerides; Two-Hybrid System Techniques | 2005 |
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?
Topics: Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazolidinediones | 2005 |
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Drug Resistance; Female; Haplotypes; Homozygote; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Rosiglitazone; Thiazolidinediones | 2005 |
PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.
Topics: AC133 Antigen; Antigens, CD; Antigens, CD34; Cell Count; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Diabetes Mellitus, Type 2; Endothelial Cells; Endothelium, Vascular; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycoproteins; Humans; Hyperinsulinism; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Monocytes; Peptides; PPAR gamma; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Triglycerides; Vascular Endothelial Growth Factor A | 2005 |
Prevalence of coronary artery calcium among asymptomatic men and women in a developing country: comparison with the USA data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Calcinosis; Calcium; Comorbidity; Coronary Artery Disease; Coronary Vessels; Developing Countries; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; Lebanon; Male; Middle Aged; Prevalence; Risk Factors; Rosiglitazone; Smoking; Thiazolidinediones; Tomography, X-Ray Computed; United States | 2005 |
Gait characteristics in patients with type 2 diabetes; improvement after administration of rosiglitazone.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gait; H-Reflex; Humans; Hypoglycemic Agents; Knee Joint; Male; Middle Aged; Muscle, Skeletal; Reaction Time; Reference Values; Rosiglitazone; Shoes; Thiazolidinediones; Video Recording | 2005 |
Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Female; Hypoglycemic Agents; Liver; Male; Mice; Mice, Congenic; Pharmacogenetics; Phenotype; Phosphatidylcholines; Rosiglitazone; Thiazolidinediones | 2005 |
Mild, reversible pancytopenia induced by rosiglitazone.
Topics: Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones | 2005 |
Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Transaminases; Treatment Outcome | 2005 |
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Topics: Aldosterone; Animals; Biological Transport; Body Weight; Coloring Agents; Diabetes Mellitus, Type 2; Evans Blue; Gene Deletion; Genotype; Heterozygote; Hypoglycemic Agents; Immunohistochemistry; Integrases; Kidney; Kidney Tubules, Collecting; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nephrons; PPAR gamma; Promoter Regions, Genetic; Radioimmunoassay; Rosiglitazone; Sodium; Thiazolidinediones | 2005 |
Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Glucose; Glucose Tolerance Test; Glycogen; Hepatocytes; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Liver Glycogen; Male; Muscle, Skeletal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2005 |
Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2005 |
Hepatic injury in a patient taking rosiglitazone.
Topics: Biopsy; Chemical and Drug Induced Liver Injury, Chronic; Diabetes Mellitus, Type 2; Diagnosis, Differential; Fatal Outcome; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Triglycerides; Vasculitis | 2005 |
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Rosiglitazone; Stents; Survival Rate; Thiazolidinediones | 2005 |
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose Transporter Type 4; Hepatocytes; Insulin; Insulin Resistance; Liver; Mice; Mice, Knockout; Monosaccharide Transport Proteins; Muscle Proteins; Muscles; Obesity; Oligonucleotide Array Sequence Analysis; Phosphoenolpyruvate Carboxykinase (GTP); Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2005 |
Management of diabetes during Ramadan.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2005 |
[A Markov model to access long-term effects of rosiglitazone natrium on the treatment of type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Markov Chains; Rosiglitazone; Thiazolidinediones; Time | 2005 |
[Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes].
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones | 2004 |
Thiazolidinediones and lowered HDL cholesterol.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2005 |
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones | 2005 |
[Effect of rosiglitazone on level of serum TNF-alpha and its relation with insulin resistance in type 2 diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2004 |
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Fenofibrate; Gene Expression; Glucose Tolerance Test; Insulin; Intercellular Signaling Peptides and Proteins; Lipids; Male; Nicotinamide Phosphoribosyltransferase; PPAR alpha; PPAR gamma; Rats; Rats, Inbred OLETF; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Viscera | 2005 |
Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Fluorescein Angiography; Humans; Hypoglycemic Agents; Macular Edema; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Vision Disorders | 2005 |
Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes.
Topics: Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Homocysteine; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2005 |
Leukopenia and thrombocytopenia caused by thiazolidinediones.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Humans; Hypoglycemic Agents; Leukopenia; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Thrombocytopenia | 2005 |
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes.
Topics: Aged; Blood Pressure; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones | 2005 |
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Middle Aged; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Thiazolidinediones in type 2 diabetes--have they lived up to expectations?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2005 |
PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids.
Topics: Adipocytes; Cells, Cultured; Diabetes Mellitus, Type 2; Fatty Acid Transport Proteins; Fatty Acids; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Luciferases; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transfection | 2006 |
Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.
Topics: Adiponectin; Analysis of Variance; Animals; Biomarkers; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin; Leptin; Male; Mice; Mice, Congenic; Mice, Inbred NOD; Mice, Obese; Obesity; Phenotype; Plasminogen Activator Inhibitor 1; Quantitative Trait, Heritable; Recombination, Genetic; Resistin; Rosiglitazone; Species Specificity; Syndrome; Thiazolidinediones | 2006 |
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Topics: Analysis of Variance; Animals; Apolipoprotein A-I; Area Under Curve; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Unsaturated; Female; Hypoglycemic Agents; Mice; Mice, Transgenic; Obesity; Phenyl Ethers; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Retinoid X Receptors; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Thyroid Gland; Triglycerides | 2006 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipids; Rosiglitazone; Thiazolidinediones | 2005 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Research Design; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone therapy of posttransplant diabetes mellitus.
Topics: Adult; Aged; Cyclosporine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Insulin; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Organ Transplantation; PPAR gamma; Prospective Studies; Rosiglitazone; Tacrolimus; Thiazolidinediones | 2005 |
Rosiglitazone-associated pseudotumour cerebri.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Pseudotumor Cerebri; Rosiglitazone; Thiazolidinediones | 2006 |
The impact of rosiglitazone on cardiovascular responses and endurance during isometric exercise in patients with Type 2 diabetes.
Topics: Adult; Blood Pressure; Cardiovascular System; Diabetes Mellitus, Type 2; Exercise; Forearm; Heart Rate; Humans; Hypoglycemic Agents; Isometric Contraction; Physical Endurance; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2006 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
Topics: Aged; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Prediabetic State; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Uncoupling Protein 3 | 2006 |
Type 2 diabetes, psoriasis and thiazolidinediones.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Psoriasis; Rosiglitazone; Thiazolidinediones | 2006 |
Mitochondria are impaired in the adipocytes of type 2 diabetic mice.
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Female; Male; Mice; Microscopy, Electron; Mitochondria; Mitochondrial Proteins; Rats; Rosiglitazone; Thiazolidinediones | 2006 |
Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Aged; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; E2F4 Transcription Factor; Female; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Middle Aged; Muscles; Nerve Tissue Proteins; Nuclear Proteins; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Topics: Diabetes Mellitus, Type 2; Drug Utilization; Fee-for-Service Plans; Female; Health Care Costs; Health Services; Humans; Hypoglycemic Agents; Insulin; Insurance Claim Review; Male; Medicaid; Middle Aged; Patient Compliance; Pioglitazone; Polypharmacy; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes.
Topics: Carrier Proteins; Diabetes Mellitus, Type 2; DNA Primers; Genetic Variation; Humans; Hypoglycemic Agents; Middle Aged; Perilipin-1; Phosphoproteins; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones; Weight Gain | 2006 |
Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2006 |
Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.
Topics: Animals; Cardiolipins; Cardiovascular System; Choline-Phosphate Cytidylyltransferase; Crosses, Genetic; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred NOD; Mice, Obese; Mitochondria, Heart; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat.
Topics: Animals; Diabetes Mellitus, Type 2; Epithelial Sodium Channels; Gene Expression Regulation; Kidney; Male; Obesity; Random Allocation; Rats; Rats, Zucker; Rosiglitazone; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1; Thiazolidinediones; Tissue Distribution | 2006 |
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
Topics: Adiponectin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Obesity; Resistin; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones | 2006 |
[Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients].
Topics: Adult; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media | 2006 |
Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Topics: Acetyl-CoA Carboxylase; Acyl Coenzyme A; Adult; AMP-Activated Protein Kinases; Carboxy-Lyases; Diabetes Mellitus, Type 2; Fatty Acid Transport Proteins; Fatty Acids; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Malonyl Coenzyme A; Middle Aged; Mitochondria, Muscle; Multienzyme Complexes; Muscle, Skeletal; Obesity; Oxidation-Reduction; Protein Serine-Threonine Kinases; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
[Glitazone treatment of type 2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Weight Gain | 2006 |
Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?
Topics: Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Injections, Subcutaneous; Insulin; Insulin Resistance; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Thiazolidinediones; Uremia; Weight Gain | 2006 |
Exposure to rosiglitazone and fluoxetine in the first trimester of pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fluoxetine; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, First; Rosiglitazone; Selective Serotonin Reuptake Inhibitors; Thiazolidinediones | 2006 |
Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Weight Loss | 2006 |
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2006 |
[Effects of rosiglitazone on endothelium-dependent vasodilation in patients with Type 2 diabetes].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Vasodilation; Vasodilator Agents | 2006 |
The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time; Triglycerides | 2006 |
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Ovarian stockpiling in polycystic ovary syndrome, infertility, and the combined use of rosiglitazone and metformin.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Rosiglitazone; Thiazolidinediones | 2006 |
Glucose lowering and diabetes prevention: are they the same?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2006 |
Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.
Topics: Acute-Phase Proteins; Adult; Age Factors; Aged; Animals; Biomarkers; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperglycemia; Inflammation; Insulin Resistance; Lipocalin-2; Lipocalins; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Middle Aged; Obesity; Oncogene Proteins; Polymerase Chain Reaction; PPAR gamma; Proto-Oncogene Proteins; Rosiglitazone; Sex Factors; Thiazolidinediones | 2007 |
Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adipose Tissue; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; E-Selectin; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Adhesion Molecule-1; Lipids; Matrix Metalloproteinase 9; Middle Aged; Peroxidase; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1 | 2007 |
More data needed on drug to delay the onset of diabetes.
Topics: Canada; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Life Style; Risk Factors; Rosiglitazone; Thiazolidinediones | 2006 |
Stimulation of the peroxisome proliferator-activated receptor gamma (PPAR gamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy.
Topics: Adult; Aged; Atherosclerosis; Cohort Studies; Diabetes Mellitus, Type 2; Down-Regulation; Endothelial Cells; Female; Gene Expression Regulation; Humans; Interleukin-8; Male; Middle Aged; Monocytes; Peripheral Vascular Diseases; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
Thiazolidinediones for initial treatment of type 2 diabetes?
Topics: Algorithms; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Weight Gain | 2006 |
The DREAM trial.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Rosiglitazone; Thiazolidinediones | 2006 |
The DREAM trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2006 |
[Diabetes manifestation. Should they be prevented with drugs?].
Topics: Clinical Trials as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Life Style; Prediabetic State; Rosiglitazone; Thiazolidinediones | 2006 |
[DREAM Study for prevention of diabetes. What conclusions may we draw?].
Topics: Clinical Trials as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Prediabetic State; Prognosis; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Topics: Blood Glucose; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Models, Economic; Monte Carlo Method; Pioglitazone; Rosiglitazone; Thiazolidinediones; United Kingdom | 2007 |
Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mellitus patients in Denmark.
Topics: Decision Making; Denmark; Diabetes Mellitus, Type 2; Health Care Costs; Health Policy; Humans; Hypoglycemic Agents; Pioglitazone; Reimbursement Mechanisms; Rosiglitazone; Thiazolidinediones | 2006 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; England; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
DREAM and ADOPT: rosiglitazone does what it says on the packet.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ramipril; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
[Effects of rosiglitazone on the expression connective tissue growth factor in tubulointerstitium in KKA(y) mice].
Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Female; Fibronectins; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Kidney Cortex; Kidney Tubules; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Up-Regulation | 2006 |
Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Rosiglitazone; Thiazolidinediones | 2007 |
Elevated creatine kinase and myalgia in a patient taking rosiglitazone.
Topics: Adult; Creatine Kinase; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Muscular Diseases; Pain; Rosiglitazone; Thiazolidinediones | 2007 |
Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones.
Topics: Aged; Cromakalim; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Mammary Arteries; Middle Aged; Nitroprusside; Phenylephrine; Pioglitazone; Potassium Channel Blockers; Potassium Chloride; Rosiglitazone; Thiazolidinediones; Vasoconstriction | 2006 |
The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Topics: Animals; Aorta; Diabetes Mellitus, Type 2; Down-Regulation; Hypoglycemic Agents; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; PPAR gamma; Receptors, Cell Surface; Receptors, Leptin; RNA, Messenger; Rosiglitazone; Superoxides; Thiazolidinediones | 2007 |
Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
[The pharmacological prevention and treatment of diabetes mellitus; significance of 2 recent, large studies for the use of rosiglitazone].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; Disease Models, Animal; Encephalitis; Hypertension; Intercellular Adhesion Molecule-1; Ischemic Attack, Transient; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neuroprotective Agents; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Superoxide Dismutase-1; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones | 2007 |
Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2007 |
Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy.
Topics: Atrial Fibrillation; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2008 |
Glycemic durability of monotherapy for diabetes.
Topics: Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Rosiglitazone; Thiazolidinediones | 2007 |
Metabolic syndrome: a work in progress, but a useful construct.
Topics: Abdominal Fat; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Models, Biological; Obesity; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Topics: Adipocytes; Adipose Tissue; Animals; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin-Secreting Cells; JNK Mitogen-Activated Protein Kinases; Liver; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone | 2007 |
Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Body Weight; Carrier Proteins; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Intra-Abdominal Fat; Male; Mice; Perilipin-1; Phosphoproteins; Random Allocation; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; RNA; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Triglycerides | 2007 |
Fluid retention with thiazolidinediones: does the mechanism influence the outcome?
Topics: Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Rosiglitazone; Systole; Thiazolidinediones; Ventricular Function, Left; Water-Electrolyte Balance | 2007 |
Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Gene Expression Profiling; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic | 2007 |
Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Male; Pioglitazone; Rats; Rats, Long-Evans; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A | 2007 |
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Rosiglitazone; Thiazolidinediones | 2007 |
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?
Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone: seeking a balanced perspective.
Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Myocardial Infarction; Periodicals as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes.
Topics: Adiponectin; Adiposity; Adult; Anthropometry; Asian People; China; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone--continued uncertainty about safety.
Topics: Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiotoxicity--weighing the evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
The record on rosiglitazone and the risk of myocardial infarction.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Drug Labeling; Hospitalization; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Research Design; Rosiglitazone; Thiazolidinediones; United States | 2007 |
Coronary heart disease outcomes in patients receiving antidiabetic agents.
Topics: Adolescent; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; United States | 2007 |
[The pharmacological prevention and treatment of diabetes mellitus; significance of 2 recent, large studies for the use of rosiglitazone].
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Rosiglitazone; Thiazolidinediones | 2007 |
Clinical research observations with use of exubera in patients with type 1 and 2 diabetes.
Topics: Administration, Inhalation; Administration, Oral; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Equipment Design; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Nebulizers and Vaporizers; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and implications for pharmacovigilance.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Cardiovascular safety of rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
The anti-diabetic effects of ethanol extract from two variants of Artemisia princeps Pampanini in C57BL/KsJ-db/db mice.
Topics: Animals; Artemisia; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet; Eating; Ethanol; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Liver; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Organ Size; Plant Extracts; Rosiglitazone; Solvents; Spectrophotometry, Ultraviolet; Thiazolidinediones | 2007 |
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.
Topics: Age Distribution; Causality; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; New Hampshire; New York; Pioglitazone; Prevalence; Rosiglitazone; Sex Distribution; Thiazolidinediones; Vermont | 2007 |
Faster publication isn't always better.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Publishing; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Thiazolidinediones; Time Factors | 2007 |
Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Topics: Aged; Animals; Blood Pressure; Carotid Arteries; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Endothelium, Vascular; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Nitric Oxide; Oxidative Stress; PPAR gamma; Reference Values; Rosiglitazone; Stem Cells; Superoxides; Thiazolidinediones; Vasodilator Agents | 2007 |
Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
[ADOPT study. Glitazone controls diabetes progression].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
[New rank order of antidiabetic drugs. Using glitazone before sulfonylurea drugs? (interview by Dr. Dirk Einecke)].
Topics: Diabetes Mellitus, Type 2; Disease Progression; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
[Doubts as to the cardiovascular safety of rosiglitazone].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
Thiazolidinediones and fluid retention.
Topics: Aged; Blood Volume; Diabetes Mellitus, Type 2; Edema; Female; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
Topics: Biomarkers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Topics: Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment.
Topics: Abdominal Fat; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones; Ultrasonography | 2007 |
[ADOPT study: Reevaluation of antidiabetic drugs. Control of diabetes].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
[Consulting Prof. Dr. Stephan Matthaei. Quakenbrück diabetes center. Prescription relevant conclusions].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
Topics: Acute Disease; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2007 |
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; PPAR gamma; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Approval; Drug Evaluation; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
[Rosiglitazone--under fire].
Topics: Clinical Trials as Topic; Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice.
Topics: Animals; Blood Glucose; Catalase; Cholesterol; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Hypoglycemic Agents; Insulin; Kidney; Lipid Peroxidation; Male; Mice; Myocardium; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Thyroxine; Triglycerides; Triiodothyronine | 2007 |
Options sought after drug study. Patients who take rosiglitazone might consider pioglitazone instead.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
Topics: Arteries; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Elasticity; Female; Follow-Up Studies; Humans; Hyperinsulinism; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time; Treatment Outcome; Vascular Resistance | 2007 |
Rosiglitazone and the FDA.
Topics: Advisory Committees; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Odds Ratio; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone: failure of oversight or demons imagined?
Topics: Clinical Trials as Topic; Counseling; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Myocardial Infarction; Physician-Patient Relations; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Topics: Diabetes Mellitus, Type 2; Health Care Costs; Humans; Hypoglycemic Agents; Models, Economic; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Practice Patterns, Physicians'; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Bayes Theorem; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Essential role of mitochondrial function in adiponectin synthesis in adipocytes.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Endoplasmic Reticulum; Epididymis; Fatty Acids, Nonesterified; Gene Expression Regulation; Male; Mice; Mice, Obese; Mitochondria; Obesity; Oxygen Consumption; RNA, Messenger; Rosiglitazone; Stress, Physiological; Thiazolidinediones | 2007 |
[Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular risk and the thiazolidinediones: déjà vu all over again?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2008 |
Simultaneously quantitative measurement of comprehensive profiles of esterified and non-esterified fatty acid in plasma of type 2 diabetic patients.
Topics: Adult; Aged; Calibration; Chromatography, Thin Layer; Diabetes Mellitus, Type 2; Esters; Fatty Acids; Female; Gas Chromatography-Mass Spectrometry; Humans; Male; Methylation; Middle Aged; Multivariate Analysis; Oleic Acid; Reproducibility of Results; Rosiglitazone; Thiazolidinediones; Time Factors | 2007 |
Thiazolidinediones, deadly sins, surrogates, and elephants.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
The rosiglitazone controversy: the Indian perspective.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; India; Meta-Analysis as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Topics: Animals; Blood Glucose; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Energy Metabolism; Hypoglycemic Agents; Mice; Mice, Obese; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone: a thunderstorm from scarce and fragile data.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Rosiglitazone; Thiazolidinediones | 2007 |
Avandia update. Committee urges caution on heart risks.
Topics: Advisory Committees; Cardiac Output, Low; Contraindications; Diabetes Mellitus, Type 2; Humans; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States | 2007 |
[Rosiglitazone--statistics for benefits and problems].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
[Glitazones--again].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Topics: Adipose Tissue; Blood Glucose; Body Composition; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Oxidation-Reduction; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
[Stop selling rosiglitazone].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and the FDA.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
[Doubts as to the cardiovascular safety of rosiglitazone].
Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety; Thiazolidinediones; Time Factors | 2007 |
Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Count; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Nicotine; Nicotinic Agonists; Pregnancy; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2008 |
The Avandia debacle: methodology and practical importance of the findings.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Effects of the ethanol extract of the roots of Brassica rapa on glucose and lipid metabolism in C57BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Brassica rapa; Diabetes Mellitus, Type 2; Ethanol; Glucokinase; Glucose-6-Phosphatase; Glycated Hemoglobin; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Plant Extracts; Random Allocation; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinedione-induced edema in patients with heart failure.
Topics: Diabetes Mellitus, Type 2; Edema; Heart Failure; Humans; Hypoglycemic Agents; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Databases, Factual; Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Health Care Costs; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Medication Adherence; Middle Aged; Multivariate Analysis; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; United States | 2007 |
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Rosiglitazone; Syndrome; Thiazolidinediones | 2007 |
Studies of diabetes, thiazolidinediones, and coronary heart disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation.
Topics: Anthraquinones; Diabetes Mellitus, Type 2; Humans; Hydrocarbons, Chlorinated; Inhibitory Concentration 50; Luciferases; Molecular Structure; PPAR gamma; Rosiglitazone; Streptomyces; Thiazolidinediones | 2007 |
Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Health Care Surveys; Health Services; Hospitalization; Humans; Hypoglycemic Agents; Linear Models; Male; Medicaid; Middle Aged; Multivariate Analysis; North Carolina; Patient Compliance; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2007 |
[Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; PPAR gamma; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2007 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Topics: Adolescent; Adult; Capillary Permeability; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Microcirculation; Microscopic Angioscopy; Obesity; Plethysmography; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2007 |
Supplementation of a novel microbial biopolymer, PGB1, from new Enterobacter sp. BL-2 delays the deterioration of type 2 diabetic mice.
Topics: Animals; Biopolymers; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Enterobacter; Glucosamine; Glucose Tolerance Test; Hypoglycemic Agents; Immunohistochemistry; Insulin; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Pancreas; Random Allocation; Rosiglitazone; Thiazolidinediones | 2007 |
Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Formularies as Topic; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Male; Medical Records Systems, Computerized; Middle Aged; Pioglitazone; Quebec; Retrospective Studies; Risk Factors; Rosiglitazone; Socioeconomic Factors; Thiazolidinediones; Thiazolidines | 2008 |
Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.
Topics: Adult; Aged; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Body Mass Index; Diabetes Mellitus, Type 2; DNA; Female; Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio | 2008 |
[Glitazone - mailing no 4. In response to DMW 49/2007].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2008 |
Choosing first-line therapy for management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones | 2008 |
[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Publishing; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Topics: Adipocytes; Adipogenesis; Animals; Benzothiazoles; Binding Sites; Cells, Cultured; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Ligands; Mice; Models, Molecular; PPAR gamma; Rosiglitazone; Sulfonamides; Thiazolidinediones; Weight Gain | 2008 |
The rosigliazone meta-analysis: lessons for the future.
Topics: Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors.
Topics: Diabetes Mellitus, Type 2; Diet; Folic Acid; Humans; Hyperhomocysteinemia; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2008 |
Letter by Thum et al regarding article, "Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist
Topics: Biopterins; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Humans; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; PPAR gamma; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents | 2008 |
Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Hypoglycemic Agents; Male; PPAR alpha; PPAR delta; PPAR gamma; Rats; Rats, Wistar; Retina; Rosiglitazone; Thiazolidinediones | 2007 |
A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Topics: 3T3-L1 Cells; Acetates; Adipose Tissue, White; Animals; Cardiomegaly; Cardiovascular Diseases; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Gene Expression Profiling; Gene Expression Regulation; Hemodilution; Humans; Hypoglycemic Agents; Indoles; Insulin Resistance; Male; Mice; Mice, Inbred Strains; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Protein Binding; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Transfection; Water-Electrolyte Balance | 2008 |
[The effectiveness in type 2 diabetes prevention: a forced landing to reality].
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Life Style; Metformin; Patient Education as Topic; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Controversy over the cardiovascular effects of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Survival Rate; Thiazolidinediones | 2008 |
Skeletal toxicity of thiazolidinediones.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Outcome Assessment, Health Care; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
Topics: Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Incidence; Male; Markov Chains; Metformin; Middle Aged; Registries; Rosiglitazone; Sulfonylurea Compounds; Thailand; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leptin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio | 2008 |
Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma.
Topics: Diabetes Mellitus, Type 2; Hodgkin Disease; Humans; Liver Failure, Acute; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
[The decline of rosiglitazone].
Topics: Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Re: "Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome", Sinha SK et al., JPEM 2007; 20: 1045-1052.
Topics: Child; Deafness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Nystagmus, Congenital; Obesity; Retinitis Pigmentosa; Rosiglitazone; Syndrome; Thiazolidinediones | 2008 |
Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Color Perception Tests; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fundus Oculi; Humans; Hypoglycemic Agents; Macular Edema; Male; Middle Aged; Retina; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Vision Tests; Visual Acuity | 2008 |
The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients.
Topics: Adiponectin; Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones | 2008 |
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
Topics: Amputation, Surgical; Blindness; Cardiovascular Diseases; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Biological; Prognosis; Renal Insufficiency; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2008 |
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Leptin; Male; Middle Aged; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2008 |
The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Rosiglitazone; Thiazolidinediones | 2008 |
The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Topics: Adipokines; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2008 |
Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Topics: Adipocytes; Adipose Tissue; Affinity Labels; Animals; Azides; Blood Glucose; Cell Membrane; Cholesterol; Diabetes Mellitus, Type 2; Diet; Disaccharides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Epididymis; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Glucose Transporter Type 4; Glycosides; Hypoglycemic Agents; Insulin; Kinetics; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Propylamines; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1995 |
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
Topics: Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C3H; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 1995 |
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1997 |
Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine.
Topics: Administration, Oral; Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycosuria; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Protons; Rosiglitazone; Thiazoles; Thiazolidinediones | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
From the Food and Drug Administration.
Topics: Diabetes Mellitus, Type 2; Endotoxemia; Gentamicins; Humans; Hypoglycemic Agents; Joint Prosthesis; Pioglitazone; Rosiglitazone; Temporomandibular Joint; Temporomandibular Joint Disorders; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
[Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Rosiglitazone for type 2 diabetes mellitus.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 1999 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil | 2000 |
Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Male; Middle Aged; Monitoring, Physiologic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone approved for treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Hypothalamus; Insulin; Intracellular Signaling Peptides and Proteins; Leptin; Neuropeptides; Obesity; Orexins; Protein Precursors; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription, Genetic | 2000 |
[New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; User-Computer Interface | 2000 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
[Tackling insulin resistance. Control of etiology in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
Topics: Alitretinoin; Amino Acid Sequence; Binding Sites; Crystallography; Diabetes Mellitus, Type 2; Dimerization; Drug Design; Histone Acetyltransferases; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Nuclear Proteins; Nuclear Receptor Coactivator 1; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Sequence Homology, Amino Acid; Surface Properties; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2000 |
Oral antidiabetic agents safe with renal disease?
Topics: Aged; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Type 2 diabetes. A new kind of insulin sensitizer at the door].
Topics: Diabetes Mellitus, Type 2; Drugs, Investigational; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone has a reducing effect on thromboxane production.
Topics: Arachidonic Acid; Blood Platelets; Chromans; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Gas Chromatography-Mass Spectrometry; Humans; Leukemia, Erythroblastic, Acute; Rosiglitazone; Thiazoles; Thiazolidinediones; Thromboxane A2; Troglitazone; Tumor Cells, Cultured; Vitamin E | 2000 |
[Thiazolidinediones in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Food-Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
Topics: Diabetes Mellitus, Type 2; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Unraveling the mechanism of action of thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Diabetes. Type-righting lessons.
Topics: Cost of Illness; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypoglycemic Agents; Rosiglitazone; State Medicine; Thiazoles; Thiazolidinediones; United Kingdom | 2000 |
[New prospects for the type 2 diabetic patient. Delaying disease progression].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Prognosis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Pulmonary edema associated with rosiglitazone and troglitazone.
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Humans; Male; Pulmonary Edema; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2001 |
Anticipated US approval for rosiglitazone and pioglitazone.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Rosiglitazone; Technology Assessment, Biomedical; Thiazoles; Thiazolidinediones; United Kingdom | 2001 |
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Topics: Aging; Animals; Cataract; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Pancreas; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Thirst; Time Factors | 2000 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats.
Topics: Adipocytes; Animals; Blotting, Western; Diabetes Mellitus, Type 2; Enzyme Activators; Fasting; Hypoglycemic Agents; Insulin; Isoenzymes; Mice; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Guidance on rosiglitazone for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; England; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
What caused this patient's sudden liver dysfunction?
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Topics: Aging; Animals; Blood Glucose; Body Weight; Cell Death; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Rosiglitazone and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Topics: Chromans; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice.
Topics: Adiponectin; Adrenergic beta-Agonists; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Mice; Mice, Obese; Nerve Growth Factor; Phenethylamines; Protein Biosynthesis; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Resistin; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
[ACE inhibitor plus glitazone. Insulin sensitizer, preventing diabetes?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Glitazones--a new therapeutic principle in diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Infarct prevention for diabetics. To lower blood sugar is not enough].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2001 |
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
Topics: Adipocytes; Adipose Tissue; Blood Glucose; Body Composition; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Fatty Acids; Glucose Clamp Technique; Glycated Hemoglobin; Glycerol; Humans; Hyperinsulinism; Insulin; Kinetics; Lipids; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Microdialysis; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
[A case report. Rosiglitazone treatment was highly effective yet had to be terminated].
Topics: Administration, Oral; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Type 2 diabetes. How can the infarction risk be reduced?].
Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents | 2002 |
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sample Size; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Topics: Animals; Cardiotonic Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lactic Acid; Male; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone monotherapy and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Pregnancy; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |